Production of polyketides and other natural products

ABSTRACT

The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).

FIELD OF THE INVENTION

The present invention relates to production of polyketides and othernatural products and to libraries of compounds and individual novelcompounds. One important area is the isolation and potential use ofnovel FKBP-ligand analogues and host cells that produce these compounds.The invention is particularly concerned with methods for the efficienttransformation of strains that produce FKBP analogues and recombinantcells in which cloned genes or gene cassettes are expressed to generatenovel compounds such as polyketide (especially rapamycin) FKBP-ligandanalogues, and to processes for their preparation, and to means employedtherein (e.g. nucleic acids, vectors, gene cassettes and geneticallymodified strains).

BACKGROUND OF THE INVENTION

Rapamycin (sirolimus) (FIG. 1) is a lipophilic macrolide produced byStreptomyces hygroscopicus NRRL 5491 (Sehgal et al., 1975; Vézina etal., 1975; U.S. Pat. No. 3,929,992; U.S. Pat. No. 3,993,749) with a1,2,3-tricarbonyl moiety linked to a pipecolic acid lactone (Paiva etal., 1991). Other related macrolides (FIG. 2) include FK506 (tacrolimus)(Schreiber and Crabtree, 1992), FK520 (ascomycin or immunomycin) (Wu etal., 2000), FK525 (Hatanaka H, et al., 1989, FK523 (Hatanaka, H., etal., 1988), antascomicins (Fehr, T., et al., 1996) and meridamycin(Salituro et al., 1995). For the purpose of this invention rapamycin isdescribed by the numbering convention of McAlpine et al. (1991) inpreference to the numbering conventions of Findlay et al. (1980) orChemical Abstracts (11^(th) Cumulative Index, 1982-1986 p60719CS).

The versatile mode of action of rapamycin demonstrates thepharmacological value of the compound and emphasizes the necessity toisolate novel derivatives of the drug. Rapamycin shows moderateantifungal activity, mainly against Candida species but also againstfilamentous fungi (Baker et al., 1978; Sehgal et al., 1975; Vézina etal., 1975; U.S. Pat. No. 3,929,992; U.S. Pat. No. 3,993,749). Rapamycininhibits cell proliferation by targeting signal transduction pathways ina variety of cell types, e.g. by inhibiting signalling pathways thatallow progression from the G₁ to the S-phase of the cell cycle (Kuo etal., 1992). In T cells rapamycin inhibits signalling from the IL-2receptor and subsequent autoproliferation of the T cells resulting inimmunosuppression. The inhibitory effects of rapamycin are not limitedto T cells, since rapamycin inhibits the proliferation of many mammaliancell types (Brunn et al., 1996). Rapamycin is, therefore, a potentimmunosuppressant with established or predicted therapeutic applicationsin the prevention of organ allograft rejection and in the treatment ofautoimmune diseases (Kahan et al., 1991). It appears to cause fewer sideeffects than the standard anti-rejection treatments (Navia, 1996).40-O-(2-hydroxyl)ethyl-rapamycin (SDZ RAD, Certican, Everolimus) is asemi-synthetic analogue of rapamycin that shows immunosuppressivepharmacological effects (Sedrani, R. et al., 1998; U.S. Pat. No.5,665,772). The clinical efficacy of the drug is presently underinvestigation in Phase III clinical trials (Kirchner at al., 2000). Therapamycin ester CCI-779 (Wyeth-Ayerst) inhibits Cell growth in vitro andinhibits tumour growth in vivo (Yu et al., 2001). The drug is currentlyin Phase III clinical trials. The value of rapamycin in the treatment ofchronic plaque psoriasis (Kirby and Griffiths, 2001), the potential useof effects such as the stimulation of neurite outgrowth in PC12 cells(Lyons et al., 1994), the block of the proliferative responses tocytokines by vascular and smooth muscle cells after mechanical injury(Gregory et al., 1993) and its role in prevention of allograft fibrosis(Waller and Nicholson, 2001) are areas of intense research (Kahan andCamardo, 2001). Recent reports reveal that rapamycin is associated withlower incidence of cancer in organ allograft patients on long-termimmunosuppressive therapy than those on other immunosuppressive regimes,and that this reduced cancer incidence is due to inhibition ofangiogenesis (Guba at al., 2002). It has been reported that theneurotrophic activities of immunophilin ligands are independent of theirimmunosuppressive activity (Steiner et al., 1997) and that nerve growthstimulation is promoted by disruption of the mature steroid receptorcomplex as outlined in the patent application WO01/03692. Side effectssuch as hyperlipidemia and thrombocytopenia as well as potentialteratogenic effects have been reported (Hentges et al., 2001; Kahan andCamardo, 2001).

The polyketide backbone of rapamycin is synthesised by head-to-tailcondensation of a total of seven propionate and seven acetate units to ashikimate derived cyclohexane carboxylic acid starter unit (Paiva etal., 1991). The L-lysine derived imino acid, pipecolic acid, iscondensed via an amide linkage onto the last acetate of the polyketidebackbone (Paiva et al., 1993) and is followed by lactonisation to formthe macrocycle. A 107 kb genomic region containing the biosynthetic genecluster has been sequenced (Schwecke et al., 1995). Analysis of the openreading frames revealed three large genes encoding the modularpolyketide synthase (PKS) (Aparicio et al., 1996; Schwecke et al.,1995). Embedded between the PKS genes lies the rapP gene encoding aprotein with sequence similarity to activation domains of nonribosomalpeptide synthetases and it is thought to act analogously (Konig et al.,1997). The region encoding the PKS genes is flanked on both sides by 24additional open reading frames encoding enzymes believed to be requiredfor the biosynthesis of rapamycin (Molnar et al., 1996). These includethe following post-polyketide modification enzymes: two cytochrome P-450monooxygenases, designated as RapJ and RapN, an associated ferredoxinRapO, and three potential SAM-dependent O-methyltransferases RapI, RapMand RapQ. Other adjacent genes have putative roles in the regulation andthe export of rapamycin (Molnar et al., 1996). The cluster also containsthe gene rapt whose product RapL is proposed to catalyse the formationof the rapamycin precursor L-pipecolic acid through the cyclodeaminationof L-lysine (Khaw et al., 1998; Paiva et al., 1993). The introduction ofa frameshift mutation into rapL gave rise to a mutant unable to producesignificant amounts of rapamycin and feeding of L-pipecolic acid to thegrowth medium restored wild-type levels of rapamycin production (Khaw etal., 1998). The biosynthetic precursors to the cyclohexane ring ofrapamycin originate from the shikimic acid pathway (Lowden et al., 1996;Lowden et al., 2001). Other closely-related macrolides such as FK506(tacrolimus) (Schreiber and Crabtree, 1992), FK520 (ascomycin orimmunomycin) (Wu et al., 2000), antascomicin (Fehr, T., et al., 1996)and meridamycin (Salituro et al., 1995) share a common pharmacophorethat interacts with FK506-binding proteins (FKBPs) (FIG. 2). Thusrapamycin and related compounds for example, but without limitation,FK506, FK520, ‘hyg’, FK523, meridamycin, antascomicin, FK525 andtsukubamycin can be considered “FKBP-ligands”. The partial sequence ofthe FK506 gene cluster (Motamedi et al., 1996; Motamedi et al., 1997;Motamedi and Shafiee, 1998), the ‘hyg’ cluster (Ruan et al., 1997) andthe complete sequence of the FK520 gene cluster have been published (Wuet al., 2000; U.S. Pat. No. 6,150,513). There is significant homologybetween genes within these clusters and the rapamycin biosynthetic genecluster and similarity in enzyme function (Motamedi et al., 1996).

The pharmacologic actions of rapamycin characterised to date arebelieved to be mediated by the interaction with cytosolic receptorstermed FKBPs or immunophilins. Immunophilins (this term is used todenote immunosuppressant binding proteins) catalyse the isomerisation ofcis and trans peptidyl-proline bonds and belong to a highly conservedfamily of enzymes found in a wide variety of organisms (Rosen andSchreiber, 1992). Two large groups of enzymes belonging to the family ofimmunophilins are represented by FKBPs and cyclophilins (Schreiber andCrabtree, 1992). The major intracellular rapamycin receptor ineukaryotic T-cells is FKBP12 (DiLella and Craig, 1991) and the resultingcomplex interacts specifically with target proteins to inhibit thesignal transduction cascade of the cell. FK506, an immunosuppressiveagent structurally related to rapamycin, also specifically binds toFKBP12 but it effects immunosuppression through a different mechanism(Chang et al., 1991; Sigal and Dumont, 1992). Rapamycin and FK506compete for the same binding site, thus FK506 can have an antagonisticeffect with rapamycin when the two drugs are used together (Cao et al.,1995). Analysis of the crystal structure of the FKBP12-rapamycin complexhas identified a rapamycin-binding pharmacophore termed the ‘bindingdomain’ (Van Duyne et al., 1993) (see FIG. 1). The ‘binding domain’ isrequired for the interaction with the immunophilin and consists, forboth FK506 and rapamycin, of the C-1 to C-14 region including the esterlinkage, the pipecolinyl ring, the dicarbonyl and the hemiketal ring(see FIG. 2). The interaction is characterised by many hydrophobiccontacts and some hydrogen bonds including one to the hydroxyl group onthe cyclohexane ring. The pipecolinyl ring (C2 to N7) makes the deepestpenetration into the protein where it is surrounded by highly conservedaromatic amino acid residues lining the hydrophobic binding cavity. Boththe C1 and the C8 carbonyl groups are involved in hydrogen bonding andthe C9 carbonyl group protrudes into a pocket formed by three completelyconserved aromatic amino acid residues (one tyrosine and twophenylalanine acid residues) in FKBP12. The domain of theimmunophilin-ligand complex interacting with the target protein projectsaway from FKBP.

The target of the rapamycin-FKBP12 complex has been identified in yeastas TOR (target of rapamycin) (Alarcon et al., 1999) and the mammalianprotein is known as FRAP (FKBP-rapamycin associated protein) or mTOR(mammalian target of rapamycin) (Brown et al., 1994). These proteinsshow significant similarity to the phosphotransferase domains ofphosphatidylinositol 3-kinases and the observation that a point mutationin the FKBP12-rapamycin binding domain (FRB) of mTOR abolishes mTORkinase activity provides evidence for the involvement of FRB in thefunction of the kinase domain (Vilella-Bach at al., 1999). The crystalstructure of FKBP12-rapamycin with a truncated form of mTOR containingthe FRB domain (Chen et al., 1995) has been obtained thus defining the‘effector’ domain of rapamycin (Choi et al., 1996; Liang et al., 1999).The analysis of the crystal structure revealed that protein-proteincontacts are relatively limited compared to the interaction betweenrapamycin and each protein. No hydrogen bonds between rapamycin and FRBwere identified. Interaction is concentrated in a series of hydrophobiccontacts between the triene region of rapamycin and mainly aromaticresidues of FRB (Liang et al., 1999). The most deeply buried atom ofrapamycin is the methyl attached to C23 (see FIG. 2). The C23 to C34region and the cyclohexyl ring of rapamycin make superficial hydrophobiccontacts with FRB. A small conformational change in rapamycin wasevident between the binary and the ternary complexes (Liang et al.,1999).

Divergences between the biological effects of C16 methoxy grouprapamycin analogues and their ability to bind FKBP12 were detected andthe location of the C16 substituents at the interfacial space betweenFKBP12 and mTOR was postulated (Luengo at al., 1995). The analysis ofthe crystal structure of FKBP12 with the non-immunosuppressive28-O-methyl rapamycin revealed a significant difference in theorientation of the cyclohexyl ring which may result in disruption ofmTOR binding (Kallen at al., 1996).

Rapamycin impacts signalling cascades within the cell through theinhibition of the p70^(S6k) kinase, a serine/threonine kinase in highereukaryotes which phosphorylates the ribosomal protein S6 (Ferrari ofal., 1993; Kuo at al., 1992). The S6 protein is located in the ribosomal40S subunit and it is believed to be an important functional siteinvolved in tRNA and mRNA binding. A regulatory function for mRNAtranslation through S6 phosphorylation by p70^(S6k) has been postulated(Kawasome of al., 1998). Rapamycin inhibits protein synthesis throughits effect on other growth related events, including the activity ofcyclin-dependent kinases, phosphorylation of cAMP-responsive elementmodulator (CREM) and phosphorylation of the elongation factor bindingprotein 4E-BP1 (PHAS1) (Hung at al., 1998). The drug induces theaccumulation of the dephosphorylated species of 4E-BP1 that binds to thetranslation initiation factor eIF-4E, thus, suppressing translationinitiation of cap-dependent mRNAs (Nara et al., 1997; Raught et al.,2001).

A link between mTOR signalling and localized protein synthesis inneurons; the effect on the phosphorylation state of proteins involved intranslational control; the abundance of components of the translationmachinery at the transcriptional and translational levels; control ofamino acid permease activity and the coordination of the transcriptionof many enzymes involved in metabolic pathways have been described(Raught et al., 2001). Rapamycin sensitive signalling pathways alsoappear to play an important role in embryonic brain development,learning and memory formation (Tang et al., 2002). Research on TORproteins in yeast also revealed their roles in modulatingnutrient-sensitive signalling pathways (Hardwick et al., 1999).Similarly, mTOR has been identified as a direct target for the action ofprotein kinase B and of having a key role in insulin signalling(Shepherd et al., 1998; Nave et al., 1999). Mammalian TOR has also beenimplicated in the polarization of the actin cytoskeleton and theregulation of translational initiation (Alarcon et al., 1999).Phophatidylinositol 3-kinases, such as mTOR, are functional in severalaspects of the pathogenesis of tumours such as cell-cycle progression,adhesion, cell survival and angiogenesis (Roymans and Slegers, 2001).

Most immunophilins do not appear to be directly involved inimmunosuppressive activities and relatively little is known concerningtheir natural ligands although candidates for natural ligands of theFKBPs termed FKBP-associated proteins (FAP) such as FAP48 and FAP1 havebeen reported. The specific interaction of FAPs with FKBPs during theformation of complexes was prevented by rapamycin in a dose-dependentmanner (Chambraud et al., 1996; Kunz of al., 2000). Immunophilins appearto function in a wide range of cellular activities such as proteinfolding; assembly and trafficking of proteins; co-regulation ofmolecular complexes including heat shock proteins; steroid receptors;ion channels; cell-to-cell interactions and transcription andtranslation of genes (Galat 2000; Hamilton and Steiner 1998). Allimmunophilins possess the protein folding property of peptidyl-prolylcis-trans isomerisation and several immunophilins are found located inthe endoplasmic reticulum, a principal site of protein synthesis in thecell. In addition to FKBP12 (U.S. Pat. No. 5,109,112) otherimmunophilins include FKBP12.6 (U.S. Pat. No. 5,457,182), FKBP13(Hendrickson et al., 1993; U.S. Pat. No. 5,498,597), FKBP25 (Hung andSchreiber, 1992; Jin of al., 1992), FKBP14.6 (U.S. Pat. No. 5,354,845),FKBP52 (U.S. Pat. No. 5,763,590), FKBP60 (Yem et al., 1992) and FKBP65(Patterson et al., 2000).

The multitude of the FKBP's which are present in different cell typesalso underline the utility of isolating novel FKBP-ligand analogues withpotentially changed binding and/or effector domains.

Pharmacokinetic studies of rapamycin and rapamycin analogues havedemonstrated the need for the development of novel rapamycin compoundsthat may be more stable in solution, more resistant to metabolic attackand have improved bio-availability. Modification using chemicallyavailable positions on the molecule has been addressed, however, thisapproach has limited utility as the sites available for chemicalmodification are limited and there is less ability to selectively modifya particular position. Biological approaches to producing novelrapamycin analogues have been less successful due to the difficultiesencountered in working with the organism (Lomovskaya et al., 1997;Kieser et al., 2000) despite the availability of the sequence of thebiosynthetic gene cluster of rapamycin from S. hygroscopicus (Schweckeat al., 1995).

A range of synthesised rapamycin analogues using the chemicallyavailable sites of the molecule has been reported. The description ofthe following compounds was adapted to the numbering system of therapamycin molecule described in FIG. 1. Chemically available sites onthe molecule for derivatisation or replacement include C40 and C28hydroxyl groups (e.g. U.S. Pat. No. 5,665,772; U.S. Pat. No. 5,362,718),C39 and C16 methoxy groups (e.g. WO96/41807; U.S. Pat. No. 5,728,710),C32, C26 and C9 keto groups (e.g. U.S. Pat. No. 5,378,836; U.S. Pat. No.5,138,051; U.S. Pat. No. 5,665,772). Hydrogenation at C17, C19 and/orC21, targeting the triene, resulted in retention of antifungal activitybut loss of immunosuppression (e.g. U.S. Pat. No. 5,391,730; U.S. Pat.No. 5,023,262). Significant improvements in the stability of themolecule (e.g. formation of oximes at C32, C40 and/or C28, U.S. Pat. No.5,563,145, U.S. Pat. No. 5,446,048), resistance to metabolic attack(e.g. U.S. Pat. No. 5,912,253), bioavailability (e.g. U.S. Pat. No.5,221,670; U.S. Pat. No. 5,955,457; WO98/04279) and the production ofprodrugs (e.g. U.S. Pat. No. 6,015,815; U.S. Pat. No. 5,432,183) havebeen achieved through derivatisation. However, chemical modificationrequires significant quantities of rapamycin template and, as a base andacid labile compound, it is difficult to work with. Where chemicalderivatisation can be group selective, it is often difficult to be siteselective. Consequently, chemical modification invariably requiresmultiple protective and deprotecive steps and produces mixed products invariable yields.

the isolation of rapamycin analogues using biological methods such asbiotransformation and phage-based genetic modification has also beendescribed. Isolation of minor metabolites from both mutant strains andrapamycin producing strains has provided small quantities of a number ofrapamycin analogues. These strains are often low yielding and producemixtures of rapamycin analogues. The isolation of27-O-desmethylrapamycin and 27-desmethoxyrapamycin was reported from theculture supernatant of S. hygroscopicus NCIMB 40319 (Box et al., 1995).The antifungal activity of 27-O-desmethylrapamycin was lower than thatof rapamycin but the inhibition of FKBP12 PPlase activity seemed to beincreased. The inhibition of ConA-stimulated proliferation of murinesplenic T cells and the inhibition of LPS-stimulated proliferation ofmurine splenic B cells was decreased when compared to rapamycin (Box atal., 1995). Similarly, antifungal activities of the rapamycinderivatives prolylrapamycin, 27-O-desmethylrapamycin and27-desmethoxyrapamycin were lower than that of rapamycin′ (Wong et al.,1998). Rapamycin analogues (16-O-desmethylrapamycin,27-O-desmethylrapamycin, 39-O-desmethylrapamycin,16,27-O-bisdesmethylrapamycin, prolylrapamycin,26-O-desmethylprolylrapamycin, 9-deoxorapamycin, 27-desmethoxyrapamycin,27-desmethoxy-39-O-desmethylrapamycin, 9-deoxo-27-desmethoxyrapamycin,28-dehydrorapamycin, 9-deoxo-27-desmethoxy-39-O-desmethylrapamycin) werealso isolated from Actinoplanes sp N902-109 after the addition ofcytochrome P450 inhibitors and/or precursor feeding to the culture orafter biotransformation of isolated rapamycin (Nishida et al., 1995).The use of such inhibitors, however, only allows the targeting of aparticular enzyme function and is not site selective. Rationalproduction of a single selected analogue is not possible via thismethod. The resulting production of mixtures of rapamycin analoguesrather than a single desired product also impacts yield. The mixedlymphocyte reaction (MLR) inhibitory activity of the compounds wasassessed and little effect on the activity was detected after the lossof the methyl group at C27 or/and C16. In addition, 9-deoxorapamycinshowed a more significant decrease in activity and the loss of themethoxy group at C27, the hydroxy group at C28 and the substitution of apipecolinyl group for a prolyl group resulted in a reduction in potency(Nishida of al., 1995). Similarly, biotransformation of rapamycin andthe isolation of 16,39-O-bisdesmethylrapamycin have been reported (WO94/09010). The retention of inhibitory activity in cell proliferationassays with compounds modified in the cyclohexyl ring, e.g.39-O-desmethylrapamycin and C40 modifications such as SDZ RAD, identifythis region of the molecule as a target for the generation of novelrapamycin analogues. Novel rapamycin analogues were reported afterfeeding cyclohexanecarboxylic acid, cycloheptanecarboxylic acid,cyclohex-1-enecarboxylic acid, 3-methylcyclohexanecarboxylic acid,cyclohex-3-enecarboxylic acid, 3-hydroxycyclohex-4-enecarboxylic acidand cyclohept-1-enecarboxylic acid to cultures of S. hygroscopicus thusdemonstrating the flexibility in the loading module of the rapamycinpolyketide synthase (P. A. S. Lowden, PhD dissertation, University ofCambridge, 1997). These novel rapamycin analogues were produced incompetition with the natural starter,4,5-dihydroxycyclohex-1-enecarboxylic acid, resulting in reduced yieldsand mixed products.

The isolation of recombinant S. hygroscopicus strains producing variousrapamycin analogues, using biological methods mediated by phagetechnology (Lomovskaya et al., 1997), has been reported. In the presenceof added proline derivatives, a S. hygroscopicus rapL deletion mutantsynthesized the novel rapamycin analogues prolylrapamycin,4-hydroxyprolylrapamycin and 4-hydroxyprolyl-26-desmethoxy-rapamycin(Khaw et al., 1998). Similarly, the novel rapamycins3-hydroxy-prolyl-rapamycin, 3-hydroxy-prolyl-26-desmethoxy-rapamycin,and trans-3-aza-bicyclo[3,1,0]hexane-2-carboxylic acid rapamycin havebeen identified as described in WO98/54308. The activity ofprolylrapamycin and 4-hydroxyprolyl-26-desmethoxy-rapamycin was assessedin proliferation assays and the inhibitory activity of the lattercompound was significantly less than that of rapamycin (Khaw et al.,1998). The deletion of five contiguous genes, rapQONML (responsible forpost-polyketide modifications at C16, C27 and production of L-pipecolicacid) and their replacement with a neomycin resistance marker in S.hygroscopicus ATCC29253 using phage-based methology resulted in theproduction of 16-O-desmethyl-27-desmethoxyrapamycin when fed withpipecolic acid (Chung at al., 2001). No complementation of this deletionmutant has been demonstrated using this technology. Furthermore, thesite-specific functionality of rapM and rapQ remains unclear; therefore,rational design of rapamycin analogues requiring methylation at C16-OHor 027-OH has not been enabled. The phage-based methodology suffers froma number of drawbacks as described in more detail below. It offers adifficult and protracted process of obtaining engineered strains and hasa reduced versatility in comparison to the methodology disclosed withinthis current patent.

Conventional approaches to manipulate rapamycin modifying genes usingbiological methods comprise the mutation or deletion of individual genesin the chromosome of a host strain or/and the insertion of individualgenes as extra copies of homologous or heterologous genes eitherindividually or as gene cassettes (WO01/79520, WO 03/048375). However,the isolation of novel rapamycin analogues using such biological methodshas been limited due to the difficulties in transforming therapamycin-producing organism S. hygroscopicus. It has been reported thatthe commonly used methods of transformation with plasmid DNA or conjugaltransfer were unsuccessful with the rapamycin producing strain(Lomovskya et al., 1997, Schweke et al., 1995, Kieser at al., 2000). Thecurrent state of the art uses the methodology of Lomovskya at al.(1997), a work intensive phage based method that is severely limited bythe size of the cloned DNA fragments transferred into S. hygroscopicus(Kieser et al., 2000). This technology is limited to the transfer of amaximum of 6.4 kb of cloned DNA. Thus, when complementing a deletionmutant using this technology the artisan is limited to the inclusion of˜2 functional genes in addition to desired promoter, regions of homologyand resistance marker. The genetic information for the rapamycinbiosynthetic gene cluster has been available since 1995 (Schwecke etal., 1995), however, limited progress in this area has been made (Khawet al., 1998; Chung at al., 2001; WO01/34816).

SUMMARY OF THE INVENTION

The present invention provides recombinant methods for the efficienttransformation of strains that contain a biosynthetic cluster encodingan FKBP ligand, for example but without limitation Streptomyceshygroscopicus subsp. hygroscopicus NRRL 5491, Actinoplanes sp. N902-109FERM BP-3832, Streptomyces sp. AA6554, Streptomyces hygroscopicus var.ascomyceticus MA 6475 ATCC 14891, Streptomyces hygroscopicus var.ascomyceticus MA 6678 ATCC 55087, Streptomyces hygroscopicus var.ascomyceticus MA 6674, Streptomyces hygroscopicus var. ascomyceticusATCC 55276, Streptomyces tsukubaensis No. 9993 FERM BP-927, Streptomyceshygroscopicus subsp. yakushimaensis, Streptomyces sp. DSM 4137,Streptomyces sp. DSM 7348, Micromonospora n.sp. A92-306401 DSM 8429,Steptomyces sp. MA 6858 ATCC 55098, Steptomyces sp. MA 6848, saidmethods comprising:

-   -   (a) constructing a conjugative deletion plasmid in an E. coli        strain that is dam⁻, dcm⁻ or dam⁻ and dcm⁻.    -   (b) generation of spores from said strain suitable for        conjugation wherein said strain is grown at a humidity of        between 10% and 40% and the spores are harvested at between 5        and 30 days;    -   (c) conjugating the E. coli strain of step (a) with the spores        from step (b) on a medium that comprises per litre:        -   i) 0.5 g to 5 g corn steep powder,        -   ii) 0.1 g to 5 g Yeast extract,        -   iii) 0.1 g to 10 g calcium carbonate; and        -   iv) 0.01 g to 0.5 g iron sulphate;    -   said media additionally containing BACTO-agar and starch and        having been dried to result in 1-20% weight loss; and    -   (d) optionally culturing the strain under conditions suitable        for polyketide production.

In a preferred embodiment the methods are used for the transformation ofStreptomyces hygroscopicus subsp. hygroscopicus (e.g. NRRL 5491),Actinoplanes sp. N902-109 (e.g. FERM BP-3832), Streptomyces sp. AA6554,Streptomyces hygroscopicus var. ascomyceticus (e.g. MA 6475 ATCC 14891),Streptomyces hygroscopicus var. ascomyceticus (e.g. MA 6678 ATCC 55087),Streptomyces hygroscopicus var. ascomyceticus (e.g. MA 6674),Streptomyces hygroscopicus var. ascomyceticus (e.g. ATCC 55276),Streptomyces tsukubaensis No. 9993 (e.g. FERM BP-927), Streptomyceshygroscopicus subsp. yakushimaensis, Streptomyces sp. (e.g. DSM 4137),Streptomyces sp. (e.g. DSM 7348), Micromonospora n.sp. A92-306401 (e.g.DSM 8429) or Streptomyces sp. (e.g. MA 6858 ATCC 55098). In a morepreferred embodiment the methods are used for the transformation of: S.hygroscopicus subsp. hygroscopicus (e.g. NRRL 5491) or S. hygroscopicusvar. ascomyceticus (e.g. ATCC 14891). In a still more highly preferredembodiment the methods are used for the transformation of the rapamycinproducer S. hygroscopicus subsp. hygroscopicus (e.g. NRRL 5491).

Therefore the present invention also provides a recombinant strain thatcontains biosynthetic clusters that encode FKBP-ligands where one ormore auxiliary genes have been deleted or inactivated using the methodsas described herein.

In a further aspect, the present invention provides recombinant methodsand materials for expressing combinations of polyketide modificationenzymes so as to produce novel polyketide analogues. In a specificembodiment, the present invention provides recombinant methods andmaterials for expressing the combinations of enzymes responsible forpost-PKS modification and/or precursor supply from biosynthetic clustersthat encode FKBP-ligands for example but without limitation rapamycin,FK506, FK520, FK523, FK525, antascomicin, meridamycin, tsukubamycin andanalogues thereof and methods for the production of analogues inrecombinant host cells. In a preferred embodiment the recombinantmethods and materials are used for expressing the combinations ofenzymes responsible for post-PKS modification and/or precursor supply inthe biosynthesis of rapamycin, FK520, FK506 and ‘hyg’ and methods forthe production of rapamycin, FK520, FK506 and ‘hyg’ analogues inrecombinant host cells. In a more highly preferred embodiment therecombinant methods and materials are used for expressing thecombinations of enzymes responsible for post-PKS modification and/orprecursor supply in the biosynthesis of rapamycin and methods for theproduction of rapamycin analogues in recombinant host cells.

Broadly, the present invention is concerned with the alteration of agene system which has a core portion responsible for the production of abasic product, and a multiplicity of modifying genes responsible foreffecting relatively small modifications to the basic product—e.g.effecting glycosylation, oxidation, reduction, alkylation, dealkylation,acylation or cyclisation of the basic product, and a multiplicity ofprecursor supply genes which are involved in the production ofparticular precursor compounds (e.g. pipecolate; 4,5dihydroxycyclohex-1-ene carboxylic acid). Thus the basic product may bea modular polyketide and the modifying genes may be concerned withglycosylation and/or other modifications of a polyketide chain, and theprecursor supply genes may be involved in the production and/orincorporation of natural or non-natural precursors (e.g. pipecolateand/or 4,5 dihydroxycyclohex-1-ene carboxylic acid in the rapamycinsystem).

The core portion may not function properly or even at all in the absenceof a precursor supply gene (unless a natural or unnatural precursorcompound is supplied or is otherwise available).

In one aspect the invention provides methods for the alteration of agene system with a core portion that cannot function due to a deletionor inactivation of a precursor supply gene. Suitable gene systemsinclude, but are not limited to, the rapamycin, antascomicin, FK520,FK506, ‘hyg’, FK523, meridamycin, FK525 and tsukubamycin biosyntheticclusters. In this aspect of the invention, the precursor supply genelacking is preferably rapK or a homologue of rapK (e.g. fkbO in theFK506 or FK520 gene clusters). The gene system is preferably therapamycin cluster. The precursor supply gene lacking is more preferablyrapK. This aspect of the invention provides methods for the efficientproduction of a multiplicity of basic products through the incorporationof natural or non-natural precursors (e.g. 4,5-dihydroxycyclohex-1-enecarboxylic acid). Methods may also embody further aspects as set outbelow.

Another type of system is a non-ribosomal peptide (“NRP”) system wherethe basic product is a peptide and the modifying genes are genesresponsible for modifications to a peptide (glycosylation, reductionetc), and the precursor supply genes are genes involved in theproduction of unusual amino acid residues to be incorporated in thepeptide. Systems can also be of mixed type, e.g. having a polyketidepart and a part with a different biosynthetic origin, e.g. NRP. Indeed,rapamycin can be regarded as an example of this since the pipecolateresidue is an amino acid residue added by an enzyme similar to onesfound in NRP systems.

These modifying genes and precursor supply genes may be regarded as“auxiliary genes” for polyketide synthesis and the term “auxiliarygenes” as used herein may refer to modifying genes, precursor supplygenes or both.

The alteration of the gene system involves the creation of a functioningaltered system in which the set of auxiliary genes has been altered.Thus one or more auxiliary genes (and preferably two or more, three ormore, four or more, five or more, six or more or seven or more) may havebeen deleted (or rendered non-functional) and/or replaced by differentgenes.

This may involve a “deletion system” comprising nucleic acid encoding agene system lacking a multiplicity of functional auxiliary genes. Thisdeletion system can then be complemented with one or more functionalauxiliary genes (which may be the same as or different from the genesthey replace). This can be carried out combinatorially, a deletionsystem being complemented by a multiplicity of different genes and setsof genes.

An altered system which differs from the natural system in lacking oneor more modifying functions could be produced (a) by producing adeletion system and restoring by complementation less than all of thedeleted genes; or (b) by selectively deleting or inactivating genes ofan existing system. In an altered system produced according to (b) genesmay be inactivated by site-directed mutagenesis of an active siteimportant in the protein function (active site point mutation), bytruncation of the gene through a frameshift mutation, by an in-framedeletion of a section of the gene important to its function, such as anactive site; partial deletion or inactivation by point mutation. Thesecould all be carried out by double recombination and selecting for themutant genotype, or by single recombination. In a preferred embodimentthe altered system is produced by method (a). Such methods could also beused in producing a deletion system. The “complementation” approach (a)is preferably homologous, in that the “restored” genes are from the samegene cluster, however, heterologous complementation, wherein the“restored” genes are selected from a different biosynthetic cluster thatencodes FKBP-ligands, is also contemplated by the present invention. Ina preferred embodiment the “restored” genes are essentially the same asthe deleted genes, or are variants thereof, which perform similarfunctions.

In a further aspect of the invention, an altered system with a deleted(or non-functional) precursor supply gene can be fed with alternativeprecursors so that it produces variant products.

As applied to a polyketide synthase (“PKS”) system, one preferred typeof embodiment is a method for producing polyketides comprising: (a)providing a strain of an organism which contains one or more PKS genesexpressible to produce a functioning PKS which can generate a polyketidein the organism, for example PKS genes that encode a FKBP-ligand, theorganism lacking one or more (and preferably a plurality) of functionalauxiliary genes naturally associated with said PKS genes which encodegene products capable of effecting respective modifications of thepolyketide; and (b) effecting complementation by causing said organismto express one or more auxiliary genes, the expressed modifying genesconstituting an incomplete set of auxiliary genes naturally associatedwith said PKS genes and/or comprising one or more variant auxiliarygenes; and (c) culturing said strain and optionally isolating thepolyketide analogues produced.

The step of providing a strain of an organism containing one or more PKSgenes may include a step of providing nucleic acid encoding a genecluster comprising said one or more PKS genes and lacking said one ormore auxiliary genes; and introducing said nucleic acid into theorganism.

The PKS genes are preferably rapamycin genes. The auxiliary genes whichare lacking are preferably one or more of rapK, rapI, rapQ, rapM, thecontiguous genes rapN and O (herein designated as rapN/O), rapL andrapJ. In specific embodiments contemplated by the present invention:

-   -   i) one auxiliary gene is lacking, for example rapK; rapt rapQ;        rapM; rapL, rapN/O or rapJ is lacking; preferably where one        auxiliary gene is lacking it is selected from the group        consisting of rapK; rapt; rapQ; rapM; rapN/O and rapJ;    -   ii) two auxiliary genes are lacking for example: rapKrapI;        rapKrapQ; rapKrapM; rapKrapN/O; rapKrapL; rapKrapJ; rapkIrapQ;        rapIrapM; rapIrapN/O; rapIrapL; rapIrapJ; rapQrapM; rapQrapN/O;        rapQrapL; rapQrapJ; rapMrapN/O; rapMrapL; rapMrapJ; rapN/OrapL;        rapN/OrapJ or rapLrapJ are lacking;    -   iii) three auxiliary genes are lacking for example:        rapKrapIrapQ; rapKrapIrapM; rapKrapIrapN/O; rapKrapIrapL;        rapKrapIrapJ; rapKrapQrapM; rapKrapQRapN/O; rapKrapQrapL;        rapKrapQrapJ; rapKrapMrapN/O; rapKrapMrapL; rapKrapMrapJ;        rapKrapN/OrapL; rapKrapN/OrapJ; rapKrapLrapJ; rapIrapQrapM;        rapIrapQrapN/O; rapIrapQrapL; rapIrapQrapJ; rapIrapMrapN/O;        rapIrapMrapL; rapI rapMrapJ; rapIrapN/OrapL; rapIrapN/OrapJ;        rapIrapLrapJ; rapQrapMrapN/O; rapQrapMrapL; rapQrapMrapJ;        rapQrapN/OrapL; rapQrapN/OrapJ; rapQrapLrapJ; rapMrapN/OrapL;        rapMrapN/OrapJ; rapMrapLrap or rapN/OrapLrapJ are lacking    -   iv) four auxiliary genes are lacking, for example:        rapKrapIrapQrapM; rapKrapIrapQrapN/O; rapKrapIrapQrapL;        rapKrapIrapQrapJ; rapKrapIrapMrapN/O; rapKrapIrapMrapL;        rapKrapIrapQrapJ; rapKrapIrapN/OrapL; rapKrapIrapN/OrapJ;        rapKrapIrapLrapJ; rapKrapQrapMrapN/O; rapKrapQrapMrapL;        rapKrapQrapMrapJ; rapKrapQrapN/OrapL; rapK, rapQ, rapN/O, rapJ;        rapKrapQrapLrapJ; rapKrapMrapN/OrapL; rapKrapMrapN/OrapJ;        rapKrapMrapLrapJ; rapKrapN/OrapLrapJ; rapIrapQrapMrapN/O;        rapIrapQrapMrapL; rapI rapQrapMrapJ; rapIrapQrapN/OrapL;        rapIrapQrapN/OrapJ; rapIrapQrapLrapJ; rapIrapMrapN/OrapL;        rapIrapMrapN/OrapJ; rap/rapMrapLrapJ; rapIrapN/OrapLrapJ;        rapQrapMrapN/OrapL; rapQrapMrapN/OrapJ; rapQrapMrapLrapJ;        rapQrapN/OrapLrapJ or rapMrapN/OrapLrapJ are lacking;    -   v) five auxiliary genes are lacking; for example:        rapKrapIrapQrapMrapN/O; rapKrapIrapQrapMrapL;        rapKrapIrapQrapMrapJ; rapKrapIrapQrapN/OrapL; rapKrapIrapQrap        N/OrapJ; rapKrapIrapQrapLrapJ; rapKrapIrapMrapN/OrapL;        rapKrapIrapMrapN/OrapJ; rapKrapIrapMrapLrapJ;        rapKrapIrapN/OrapLrapJ; rapKrapQrapMrapN/OrapL;        rapKrapQrapMrapN/OrapJ; rapKrapQrapMrapLrapJ;        rapKrapQrapN/OrapLrapJ; rapKrapMrapN/OrapLrapJ;        rapIrapQrapMrapN/OrapL; rapIrapQrapMrapN/OrapJ;        rapIrapQrapN/OrapLrapJ; rapIrapMrapN/OrapLrapJ;        rapQrapMrapN/OrapLrapJ or rapIrapQrapMrapLrapJ are lacking;    -   vi) six auxiliary genes are lacking for example:        rapKrapIrapQrapMrapN/OrapL; rapKrapIrapQrapMrapN/OrapJ;        rapKrapIrapQrapMrapLrapJ; rapKrapIrapQrapN/OrapLrapJ;        rapKrapIrapMrapN/OrapLrapJ; rapKrapQrapMrapN/OrapLrapJ or        rapIrapQrapMrapN/OrapLrapJ are lacking; or    -   vii) seven auxiliary genes are lacking, e.g.        rapKrapIrapQrapMrapN/OrapLrapJ are lacking.

The expression “lacking one or more functional auxiliary genes” coversboth the lack of a gene and the presence of a gene but in anon-functioning state, e.g. because it has been specifically disabled.

In one aspect, the invention provides a novel and expeditious route tothe efficient incorporation of natural or non-natural precursors intoFKBP-ligands. These include, but are not limited to, the rapamycin,antascomicin, FK520, FK506, hyg′, FK523, meridamycin, FK525 andtsukubamycin polyketide synthase/non-ribosomal peptide synthase systems,the invention thus provides novel analogues of their respective naturalproducts. In specific aspect, the invention provides a novel andexpeditious route to the efficient incorporation of natural ornon-natural precursors providing novel rapamycin analogues.

Therefore in one aspect the present invention provides a method ofgenerating analogues of FKBP-ligands which incorporate a non-naturalstarter unit, said method comprising:

-   -   (a) generating a recombinant strain in which at least the rapK        homologue has been deleted or inactivated; and    -   (b) feeding a non-natural starter unit to said strain

In a preferred embodiment the recombinant strain is generated using themethods of the present invention.

In further aspects the invention provides libraries of compounds andindividual compounds available using such systems. Thus a typicalcompound is a variant of a compound naturally produced by a gene systemwhich has a core portion responsible for the production of a basicproduct, and a multiplicity of auxiliary genes responsible for effectingrelatively small modifications to the basic product, the variant beingproducible by a system altered so that one or more of the auxiliarygenes are absent, non-functional, or replaced by functional variants. Apreferred class of compounds is rapamycin analogues corresponding toproducts of a rapamycin system wherein one or more of the genes selectedfrom the group consisting of rapK, rapI, rapQ, rapM, rapN, rapO, rapLand rapI genes are absent, non-functional or variant.

In a further aspect, the present invention provides novelFKBP-analogues, in a preferred embodiment the present invention providesnovel rapamycin analogues. Such compounds may have one or more usefulproperties, for example but without limitation, utility asimmunosuppressants, antifungal agents, anticancer agents,neuroregenerative agents, or agents for the treatment of psoriasis,rheumatoid arthritis, fibrosis and other hyperproliferative diseases.

DEFINITIONS

As used herein the term “modifying gene(s)” includes the genes requiredfor post-polyketide synthase modifications of the polyketide, forexample but without limitation cytochrome P-450 monooxygenases,ferredoxins and SAM-dependent O-methyltransferases. In the rapamycinsystem these modifying genes include rapN/O, rapM, rapI, rapQ, and rapJbut a person of skill in the art will appreciate that PKS systemsrelated to rapamycin (for example but without limitation: FK506, FK520,antascomicin, ‘hyg’, FK523, meridamycin, FK525 and tsukubamycin) willhave homologues of at least a subset of these genes, some of which arediscussed further below.

As used herein the term “precursor supply gene(s)” includes the genesrequired for the supply of the natural or non-natural precursors, thegenes required for the synthesis of any naturally or non-naturallyincorporated precursors and the genes required for the incorporation ofany naturally or non-naturally incorporated precursors. For example butwithout limitation in the rapamycin system these genes include rapL,rapK and rapP but a person of skill in the art will appreciate that PKSsystems related to rapamycin (for example but without limitation: FK506,FK520, antascomicin, ‘hyg’, FK523, meridamycin, FK525 and tsukubamycin)will have homologues of these genes, some of which are discussed furtherbelow.

As used herein, the term “auxiliary gene(s)” includes references tomodifying genes, precursor supply genes or both modifying genes andprecursor supply genes.

As used herein, the term “precursor” includes the natural starter units(i.e. 4,5-dihydroxycyclohex-1-ene carboxylic acid), non-natural starterunits, and naturally incorporated amino acids (i.e. pipecolic acid) andnon-naturally incorporated amino acids

As used herein the term “non-natural starter unit” refers to anycompounds which can be incorporated as a starter unit in polyketidesynthesis that are not the starter unit usually chosen by that PKS.

As used herein, the term “FKBP-ligands” refers to compounds that bind tothe immunophilin FKBP, such compounds preferentially contains an α,β-diketo amide where the β-keto is masked as an hemi-acetal. Suchcompounds include, without limitation, rapamycin, FK520, FK506,antascomicin, hyg′, FK523, meridamycin, FK525 and tsukubamycin,

As used herein, the term “biosynthetic clusters that encodeFKBP-ligands” includes but is not limited to the gene clusters whichdirect the synthesis of rapamycin, FK506, FK520, ‘hyg’, FK523,antascomicin, meridamycin, FK525 and tsukubamycin.

As used herein the term “strains that contain biosynthetic clusters thatencode FKBP-ligands” includes but is not limited to: Streptomyceshygroscopicus subsp. hygroscopicus (e.g. NRRL 5491), Actinoplanes sp.N902-109 (e.g. FERM BP-3832), Streptomyces sp. AA6554, Streptomyceshygroscopicus var. ascomyceticus MA 6475 (e.g. ATCC 14891), Streptomyceshygroscopicus var. ascomyceticus MA 6678 (e.g. ATCC 55087), Streptomyceshygroscopicus var. ascomyceticus MA 6674, Streptomyces hygroscopicusvar. ascomyceticus (e.g. ATCC 55276), Streptomyces tsukubaensis No. 9993(e.g. FERM BP-927), Streptomyces hygroscopicus subsp. yakushimaensis,Streptomyces sp. (e.g. DSM 4137), Streptomyces sp. (e.g. DSM 7348),Micromonospora n.sp. A92-306401 (e.g. DSM 8429) or Streptomyces sp. MA6858 (e.g. ATCC 55098).

As used herein, the term “rapK homologue” refers to homologues of therapamycin gene rapK from other biosynthetic clusters that encodeFKBP-ligands, for example but without limitation: the fkbO gene from theFK520 cluster, the fkbO gene from the FK506 cluster and the Orf5 in the‘hyg’ cluster. Such rapK homologues perform the same function as rapK inthe synthesis of these related FKBP-ligands, namely they are essentialfor the supply of the natural starter unit. Preferably; such rapKhomologues have at least 40% sequence identity, preferably at least 60%,at least 70%, at least 80%, at least 90% or at least 95% sequenceidentity to the sequence of rapK as shown in FIG. 27 (SEQ ID NO: 13).

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present invention provides a novel and expeditiousmethod for the transformation of S. hygroscopicus. The use of phagetechnology for the isolation of genetically modified strains of S.hygroscopicus has previously been described (Khaw et al., 1998;Lomovskaya et al., 1997). However, no method other than transfection hasever been reported for the introduction of DNA into the rapamycinproducing strain S. hygroscopicus. Indeed, it has been stated previouslythat the commonly used methods of transformation with plasmid DNA orconjugal transfer were unsuccessful with the rapamycin-producing strain(Lomovskaya et al., 1997, Kieser et al., 2000; Schweke at al., 1995).

In the present invention, surprisingly a conjugation protocol tosuccessfully transform S. hygroscopicus was established as described inExample 1. The methodology was exemplified by the isolation of thedeletion mutant in S. hygroscopicus MG2-10 (Example 2) and by theexpression of genes and gene combinations as described in Examples 3, 5and 15.

Therefore, in one aspect the present invention provides a method forproducing a recombinant strain that contains biosynthetic clusters thatencode FKBP-ligands where one or more auxiliary genes have been deletedor inactivated said method comprising:

-   -   (a) construction of a conjugative plasmid in an E. coli strain        that is dam, dcm⁻ or dam⁻ and dcm⁻;    -   (b) generation of spores from said strain suitable for        conjugation wherein said strain is grown at a humidity of        between 10% and 40% and the spores are harvested at between 5        and 30 days;    -   (c) conjugating the E. coli strain of step (a) with the spores        from step (b) in a medium that comprises per litre:        -   i) 0.5 g to 5 g corn steep powder,        -   ii) 0.1 g to 5 g Yeast extract,        -   iii) 0.1 g to 10 g calcium carbonate; and        -   iv) 0.01 g to 0.5 g iron sulphate;    -   said media additionally containing BACTO-agar and starch and        having been dried to result in 1-20% weight loss; and    -   (d) optionally culturing the strain under conditions suitable        for polyketide production.

Preferably the E. coli strain of step (a) is dam⁻ and dm⁻.

Preferably, in step (b) the spores are harvested at between 10 and 25days or at between 14 and 21 days. In another embodiment, in step (b)the strain is grown at a humidity of between 10 and 20%.

In a specific embodiment the starch in the media in step (c) used iswheat starch.

In preferred embodiments the media used in step (c) comprises 1 g to 4 gcorn steep powder, 1 g to 4 g Yeast extract, 1 g to 5 g calciumcarbonate; and 0.2 g to 0.4 g iron sulphate per litre. In a morepreferred embodiment the media comprises per litre: 2.5 g corn steeppowder, 3 g Yeast extract, 3 g calcium carbonate; and 0.3 g ironsulphate;

The complementation strategy disclosed in this invention provides anexpeditious method to assess and identify the function of each auxiliarygene i.e. rapK, rapQ, rapN/O, rapM, rapL, rapJ and/or rapI in rapamycinbiosynthesis. The gene product RapK has previously been identified as aninteresting candidate for a pteridine-dependent dioxygenase that couldalso catalyse an oxidative step in the biosynthesis of rapamycin (Molnaret at, 1996). The homologous gene fkbO was identified in thebiosynthetic gene cluster of FK506 and due to the structural similarityof rapamycin and FK506 a role for rapK in the oxidation of the C9 OHgroup was postulated (Motamedi et al., 1996). The findings in Examples3, 4 and 6, describing the rapK-dependent production of pre-rapamycin byS. hygroscopicus MG2-10 [pSGsetrapK] suggests that RapK has at least anadditional function in rapamycin biosynthesis.

In another aspect, therefore, the methods of the present invention ledto the elucidation of the function of RapK, namely that the expressionof the rapK gene is essential for the accumulation of any cyclisedmacrolide product. In a further aspect, the present invention describesthe complementation of S. hygroscopicus MG2-10 with fkbO, the homologueof rapK from the FK520 cluster, with the surprising observation of fkbOdependent production of pre-rapamycin by S. hygroscopicusMG2-10[pMG169-1] (Example 11). It can be seen by one skilled in the artthat fkbO fulfils a similar function in the production of FK520 as rapKand fkbO in the production of pre-rapamycin. Further, one skilled in theart will appreciate that other homologues of rapK, including but notlimited to, fkbO in the FK506 cluster, fkbO in the FK520 cluster andOrf5 in the ‘hyg’ cluster also fulfil the same function. In a furtheraspect of the invention, homologues of rapK in biosynthetic clustersthat encode FKBP-ligands, including, but not limited to, FK506, FK520,FK525, antascomicin, FK523, tsukubamycin, and ‘hyg’ can be deleted orinactivated, providing strains unable to make their respective knownnatural products. Similarly, the complementation strategy outlined aboveprovides an expeditious method to investigate the function, specificityand order for the expressed products of auxiliary genes in thebiosynthesis of other polyketides or non-ribosomal peptides.

In a preferred class of embodiment, the present invention provides amethod for the production of a recombinant host strain capable ofproducing rapamycin analogues, further involving the construction ofgenomic deletions, including but not limited to rapQONMLKJI introducedinto S. hygroscopicus and complementation or partial complementation byexpressing single genes or combinations of genes, including but notlimited to rapK, rapI, rapQ, rapM, the contiguous genes rapN and O(herein designated as rapN/O), rapL and rapJ, in gene cassettes.Further, the invention provides a method of producing said rapamycinanalogues by culturing said recombinant host strain, and optionallyisolating the rapamycin analogues produced. Thus, the recombinant strainMG2-10[pSGsetrapK], produced by complementation of the genomic deletionstrain S. hygroscopicus MG2-10, with rapK, was cultured to produce9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin).

In a further aspect of this class of the invention, the strategyinvolves the integration of a vector comprising a sub-set of genesincluding, but not limited to, rapK, rapI, rapQ, rapM, rapN, rapO, rapLand rapJ into the S. hygroscopicus deletion mutant above. Suchintegration may be performed using a variety of available integrationfunctions including but not limited to: ΦC31-based vectors, vectorsbased on pSAM2 integrase (e.g. in pPM927 (Smovkina et al., 1990)), R4integrase (e.g. in pAT98 (Matsuura et al., 1996)), ΦVWB integrase (e.g.in pKT02 (Van Mellaert et al., 1998)), ΦBT1 integrase ((e.g. pRT801)Gregory et a, in press) and L5 integrase (e.g. Lee et a, 1991). In somecases this may need alteration of the host strain by addition of thespecific attB site for the integrase to enable high efficiencyintegration. Replicating vectors could also be used, either asreplacements to, or in addition to φC31-based vectors. These include,but are not limited to, vectors based on pIJ101 (e.g. pIJ487, Kieser etal., 2000), pSG5 (e.g. pKC1139, Bierman et al., 1992) and SCP2* (e.g.pIJ698, Kieser et al., 2000). This methodology has been exemplifiedherein by the use of the φBT1 and φC31 site-specific integrationfunctions.

Although the introduction of gene cassettes into S. hygroscopicus hasbeen exemplified in the present invention using the φBT1 and the φC31site-specific integration functions, those skilled in the art willappreciate that there are a number of different strategies described inthe literature, including those mentioned above that could also be usedto introduce such gene cassettes into prokaryotic, or more preferablyactinomycete, host strains. These include the use of alternativesite-specific integration vectors as described above and in thefollowing articles (Kieser et al., 2000; Van Mellaert et al., 1998; Leeet al., 1991; Smovkina et al., 1990; Matsuura et al., 1996).Alternatively, plasmids containing the gene cassettes may be integratedinto a neutral site on the chromosome using homologous recombinationsites. Further, for a number of actinomycete host strains, including S.hygroscopicus, the gene cassettes may be introduced on self-replicatingplasmids (Kieser et al., 2000; WO98/01571).

In a further aspect of this class, the invention provides gene cassettesfor the complementation of the recombinant S. hygroscopicus deletionstrains. Methods of constructing gene cassettes and their heterologoususe to produce hybrid glycosylated macrolides have been previouslydescribed (Gaisser et al., 2002; WO01/79520, WO 03/048375). The cloningmethod used to isolate the gene cassettes of the present inventiondiffers significantly from the approach previously described in that thegene cassette is assembled directly in an expression vector rather thanpre-assembling the genes in pUC18/19-plasmids, thus providing a morerapid cloning procedure. The approach is exemplified as described inExample 3, 4, 5, 9 and 15. As described herein, a suitable vector (forexample but without limitation pSGLit1) can be constructed for use inthe construction of said gene cassettes, where a suitable restrictionsite (for example but without limitation XbaI), sensitive to dammethylation is inserted 5′ to the gene(s) of interest and a secondrestriction site (for example XbaI) can be inserted 3′ to the genes ofinterest. The skilled artisan will appreciate that other restrictionsites may be used as an alternative to XbaI and that the methylationsensitive site may be 5′ or 3′ of the gene(s) of interest.

The use of gene cassettes enables the rapid and parallel generation ofmultiple recombinant strains deleted in any combination of modifyinggenes from a single S. hygroscopicus deletion strain. The cloningstrategy facilitates the assembly of a library of gene cassettes ineither a directed or random manner, and is therefore a powerful tool forthe combinatorial production of novel rapamycin analogues including butnot exclusively limited to9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin),9-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin,16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin,16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-27-O-desmethyl-39-O-desmethyl-rapamycin;9-deoxo-16-O-desmethyl-27-O-desmethyl-rapamycin,27-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-rapamycin, 9-deoxo-39-O-desmethyl-rapamycin,8-deoxo-15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin(pre-prolylrapamycin),8-deoxo-15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamycin,15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin,8-deoxo-26-desmethoxy-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-26-desmethoxy-prolylrapamycin,15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-26-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-26-O-desmethyl-prolylrapamycin,15-O-desmethyl-38-O-desmethyl-prolylrapamycin,15-O-desmethyl-26-O-desmethyl-prolylrapamycin,15-O-desmethyl-26-desmethoxy-prolylrapamycin,26-desmethoxy-38-O-desmethyl-prolylrapamycin,26-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-prolylrapamycin,8-deoxo-26-O-desmethyl-prolylrapamycin,8-deoxo-38-O-desmethyl-prolylrapamycin, 15-O-desmethyl-prolylrapamycin,38-O-desmethyl-prolylrapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin,16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin,9-deoxo-27-desmethoxy-39-desmethoxy-rapamycin,9-deoxo-16-O-desmethyl-39-desmethoxy-rapamycin,16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin,9-deoxo-27-O-desmethyl-39-desmethoxy-rapamycin,16-O-desmethyl-39-desmethoxy-rapamycin,27-desmethoxy-39-desmethoxy-rapamycin,27-O-desmethyl-39-desmethoxy-rapamycin, 9-deoxo-39-desmethoxy-rapamycin,8-deoxo-15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin,8-deoxo-15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamycin,15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin,8-deoxo-26-desmethoxy-38-desmethoxy-prolylrapamycin,8-deoxo-15-O-desmethyl-38-desmethoxy-prolylrapamycin,15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamycin,8-deoxo-26-O-desmethyl-38-desmethoxy-prolylrapamycin,15-O-desmethyl-38-desmethoxy-prolylrapamycin,26-desmethoxy-38-desmethoxy-prolylrapamycin,26-O-desmethyl-38-desmethoxy-prolylrapamycin,8-deoxo-38-desmethoxy-prolylrapamycin, 38-desmethoxy-prolylrapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(dihydroxycyclohexyl) rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-methyl-4-hydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methylhydroxycyclohexyl) rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-fluoro-4-hydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-fluorocyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-chloro-4-hydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-chlorocyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-cis-4-cis-dihydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-trans-4-trans-dihydroxycyclohexyl)rapamycin, 9-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethylrapamycin, 9-deoxo-16-O-desmethyl-27O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl)rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl)rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methylhydroxycyclohexyl) rapamycin.

In a further aspect of this class, the present invention provides asystem for the combinatorial production of recombinant host strainscapable of producing rapamycin analogues, involving construction of agenomic deletion rapQONMLKJI introduced into S. hygroscopicus and itspartial complementation by a combinatorial library of gene cassettescomprising one or a plurality of the deleted auxiliary genes rapQ,rapN/O, rapM, rapL, rapK, rapJ, and rapI.

The approach outlined comprises as a part the cloning strategy tocombine genes including but not exclusively limited to rapK, rapI, rapQ,rapM, rapN/O, rapL and rapJ, and I or genes with similar gene functions,in any possible gene combination and gene order.

Another aspect of the invention allows the enhancement of geneexpression by changing the order of genes in a gene cassette. As appliedto the preferred class, the genes may comprise one or more of rapK,rapI, rapQ, rapM, rapN/O, rapL and rapJ and/or genes with similarfunctions, allowing the arrangement of the genes in a multitude ofpermutations as outlined in Example 5.

The cloning strategy outlined in this invention also allows theintroduction of a histidine tag in combination with a terminatorsequence 3′ of the gene cassette to enhance gene expression. Thoseskilled in the art will appreciate other terminator sequences could beused.

Another aspect of the invention describes the multiple uses of promotorsequences in the assembled gene cassette to optimise gene expression.

It will now be obvious to one skilled in the art that S. hygroscopicusdeletion strains, the deletion comprising, but not limited to, a gene ora sub-set of the genes rapQ, rapN/O, rapM, rapL, rapK, rapJ and rapIcould be constructed. In this case, gene cassettes for complementationor partial complementation would generally comprise single genes or aplurality of genes selected from the sub-set of the genes deleted.

It is well known to those skilled in the art that there are homologuesto several of the rapamycin modifying and precursor supply genes in thegene clusters of closely related systems including FK506 (Motamedi etal, 1996; Motamedi et al, 1997; Motamedi & Shafiee, 1998) and FK520 (Wuet al, 2000). These include the following as described in Table I below:

TABLE I FK520 Rapamycin gene FK506 homologue homologue ‘hyg’ rapI (AccNo fkbM (Acc No fkbM (Acc No CAA60470) AAC44360) AAF86398) rapJ (Acc NofkbD (Acc No fkbD (Acc No CAA60469) AAC44359) AAF86397) rapK (Acc NofkbO (Acc No fkbO (Acc No Orf5 (Acc No CAA60468) AAC68817) AAF86394)AAC38060) rapL (Acc No fkbL (Motamedi & fkbL (Acc No CAA60467) Shafiee,1998) AAF86391)

Although the gene clusters of other closely related systems, includingbut not limited to those for the biosynthesis of FK523, meridamycin,FK525, antascomicin and tsukubamycin have not yet been sequenced, it canbe anticipated that these will be shown to bear a close resemblance tothose whose sequences have been determined, and, in particular, thatthese gene clusters will contain close homologues of several of therapamycin modifying and precursor supply genes. Therefore, in a furtheraspect of the invention, genes from heterologous gene clusters from suchclosely related systems, including but not limited to FK506, FK520,FK523, antascomicin, meridamycin, FK525, ‘hyg’ and tsukubamycin can beincluded in gene cassettes in place of or in addition to their rapamycinhomologues for complementation and/or partial complementation of arapamycin producer strain containing a gene deletion or deletionsincluding but not limited to the genes rapK, rapI, rapQ, rapM, rapNIO,rapL and rapJ.

It is well known to those skilled in the art that polyketide geneclusters may be expressed in heterologous hosts (Pfeifer and Khosla,2001). Accordingly, the present invention includes the transfer of therapamycin biosynthetic gene cluster with or without resistance andregulatory genes, either complete or containing deletions, forcomplementation in heterologous hosts. Methods and vectors for thetransfer as defined above of such large pieces of DNA are well known inthe art (Rawlings, 2001; Staunton and Weissman, 2001) or are providedherein in the methods disclosed. In this context a preferred host cellstrain is a prokaryote, more preferably an actinomycete or Escherichiacoli, still more preferably include, but are not limited to S.hygroscopicus, S. hygroscopicus sp., S. hygroscopicus var.ascomyceticus, Streptomyces tsukubaensis, Streptomyces coelicolor,Streptomyces lividans, Saccharopolyspora erythraea, Streptomycesfradiae, Streptomyces avermitilis, Streptomyces cinnamonensis,Streptomyces rimosus, Streptomyces albus, Streptomyces griseofuscus,Streptomyces longisporoflavus, Streptomyces venezuelae, Micromonosporagriseorubida, Amycolatopsis mediterranei or Actinoplanes sp. N902-109.

In another aspect, the rapamycin analogues of the invention may beobtained by a process comprising the steps of:

-   -   a) constructing a deletion strain, by the methods of the        invention, the deletion including, but not limited to, the genes        rapK, rapQ, rapN/O, rapM, rapL, rapJ and rapI, or a sub-set        thereof;    -   b) culturing the strain under conditions suitable for polyketide        production;    -   c) optionally, isolating the rapamycin analogue intermediate        produced;    -   d) constructing a biotransformation strain containing a gene        cassette comprising all or a sub-set of the genes deleted;    -   e) feeding the rapamycin analogue intermediate in culture        supernatant or isolated as in step c) to a culture of the        biotransformation strain under suitable biotransformation        conditions    -   f) optionally isolating the rapamycin analogue produced.

Suitable host strains for the construction of the biotransformationstrain include the native host strain in which the rapamycinbiosynthetic gene cluster has been deleted, or substantially deleted orinactivated, so as to abolish polyketide synthesis, or a heterologoushost strain. Methods for the expressing of gene cassettes comprising oneor a plurality of modifying or precursor supply genes in heterologoushosts are described in WO 01/79520. In this context heterologous hostssuitable for biotransformation of the said FKBP-ligand analogueintermediates include, but are not limited to, S. hygroscopicus, S.hygroscopicus sp., S. hygroscopicus var. ascomyceticus, Streptomycestsukubaensis, Streptomyces coelicolor, Streptomyces lividans,Saccharopolyspora erythraea, Streptomyces fradiae, Streptomycesavermitilis, Streptomyces cinnamonensis, Streptomyces rimosus,Streptomyces albus, Streptomyces griseofuscus, Streptomyceslongisporoflavus, Streptomyces venezuelae, Micromonospora griseorubida,Amycolatopsis mediterranei, Escherichia coli and Actinoplanes sp.N902-109.

The close structural relationship between rapamycin and FK506, FK520,FK523, ‘hyg’, meridamycin, antascomicin, FK525 and tsukubamycin, amongothers, and the established homologies between genes involved in thebiosynthesis of rapamycin and FK506 and FK520 (vide supra), rendersobvious the application of the methods of the present invention to theseclosely related systems. In a further aspect, therefore, the inventionincludes the construction of deletion strains of the producer strains ofclosely related compounds, including but not limited to FK506, FK520,FK523, ‘hyg’, antascomicin, meridamycin, FK525 and tsukubamycincontaining a gene deletion or deletions of modifying and/or precursorsupply genes, and more particularly including but not limited to geneswith similar functions as rapK, rapI, rapQ, rapM, rapN/O, rapL and rapJ,and their complementation or partial complementation with a gene or genecassettes comprising all or a sub-set of the deleted homologous genes,or their functional homologues from heterologous gene clusters,including but not limited to rapK, rapI, rapQ, rapM, rapN/O, rapL andrapJ to produce recombinant strains capable of producing polyketideanalogues varying from the parent polyketide in the incorporation ofalternative precursors and/or the extent of post-PKS modification.Further, the invention provides a method of producing said polyketideanalogues by culturing said recombinant host strains, and optionallyisolating the polyketide analogues produced.

In a further aspect, the invention provides a method for the productionof recombinant host strains capable of producing polyketide FKBP-ligandanalogues (other than rapamycin) varying from the parent polyketide inthe incorporation of alternative precursors and/or the extent ofpost-PKS modification, comprising the construction of a genomic deletionstrain from which all or a portion of the auxiliary genes have beenremoved, and its partial complementation by a gene cassette comprisingone or a plurality of the deleted genes and/or their homologues, andfurther a method of producing said polyketide analogues by culturingsaid recombinant host strain, and optionally isolating the polyketideanalogues produced. It is well known in the art that in most cases thatauxiliary genes are co-located with polyketide synthase genes in a genecluster (Hopwood, 1997; Motamedi and Shafiee, 1998; Wu et al., 2000)thus facilitating creation of the deletion strain. The auxiliary genesto be deleted may or may not naturally form a contiguous sequence,however, once the deletion strain has been created the partialcomplementation by gene cassettes provides an expeditious approach tothe production of recombinant strains in which one or a plurality of thesaid genes have been deleted. Therefore, in a further aspect, theinvention provides a method for the combinatorial production ofrecombinant host strains capable of producing polyketide FKBP-ligandanalogues (other than rapamycin) varying from the parent polyketide inthe incorporation of alternative precursors and/or the extent ofpost-PKS modification, comprising the partial complementation of thesaid genomic deletion strain by a combinatorial library of genecassettes comprising one or a plurality of the deleted genes, andfurther a method of producing said polyketide analogues by culturingsaid recombinant host strains under conditions suitable for polyketideproduction, and optionally isolating the polyketide analogues produced.In this context a preferred recombinant host cell strain is aprokaryote, more preferably an actinomycete, still more preferably astrain selected from S. hygroscopicus, S. hygroscopicus sp., S.hygroscopicus var. ascomyceticus, Streptomyces tsukubaensis,Streptomyces coelicolor, Streptomyces lividans, Saccharopolysporaerythraea, Streptomyces fradiae, Streptomyces avermitilis, Streptomycescinnamonensis, Streptomyces rimosus, Streptomyces albus, Streptomycesgriseofuscus, Streptomyces longisporoflavus, Streptomyces venezuelae,Micromonospora griseorubida, Amycolatopsis mediterranei or Actinoplanessp. N902-109.

Those skilled in the art will appreciate that the methods of the presentinvention could be applied to recombinant host strains in which thepolyketide synthase (PKS) has been altered by genetic engineering toexpress a modified rapamycin or other polyketide analogue. The prior artdescribes several methods for the production of novel polyketides by thedeletion or inactivation of individual domains (WO93/13663, WO97/92358),construction of hybrid polyketide synthases (WO98/01546, WO00/00618,WO00/01827) or alteration of domain specificity by site-directedmutagenesis (WO02/14482).

It is well known in the art that non-ribosomal peptides arebiosynthesised by Non-Ribosomal Peptide Synthases (NRPSs) via thestepwise condensation of successive amino acid building blocks, in aprocess analogous to that of polyketide biosynthesis (for review seeMarahiel et al., 1997; Schwarzer and Marahiel, 2001). It is well knownthat several non-ribosomal peptides include unusual amino-acid residues(modified, proteinogenic amino acids and/or non-proteinogenic aminoacids) and carboxy acids, the biosynthetic genes for which areco-located with the non-ribosomal peptide synthase genes in thenon-ribosomal peptide gene cluster (Marahiel et al., 1997; Konz andMarahiel, 1999; Blanc et al., 1997). In several cases, the non-ribosomalpeptide product initially released from the NRPS is further modified bya set of enzymes, including but not limited to glycosyl transferases,reductases, acylation or heterocyclic ring formation (Konz and Marahiel,1999; Blanc et al., 1995). These include the antibioticschioroeremomycin, pristinamycin, vancomycin and bleomycin (Konz andMarahiel, 1999; Du et al., 2000). The genes for these post-NRPS enzymesare also typically co-located in the biosynthetic gene cluster (Marahielet al., 1997; Schwarzer and Marahiel, 2001). Therefore, in a furtheraspect, the invention includes a method for the production ofnon-ribosomal peptide analogues, varying from the parent non-ribosomalpeptide in the incorporation of alternative precursor amino-acids and/orthe extent of post-NRPS modification, comprising the construction of agenomic deletion strain from Which all or a portion of the gentsencoding the native amino-acid precursor synthesis and/or post-NRPSenzyme's have been removed, and its partial complementation by a genecassette comprising one or a plurality of the deleted genes and/or theirhomologues, and further a method of producing said non-ribosomal peptideanalogues by culturing said recombinant host strain, and optionallyisolating the non-ribosomal peptide analogues produced. The post-NRPSand precursor biosynthesis genes to be deleted may or may not naturallyform a contiguous sequence, however, once the deletion strain has beencreated the partial complementation by gene cassettes provides anexpeditious approach to the production of recombinant strains in whichone or a plurality of the said genes have been deleted. Therefore, in afurther aspect, the invention provides a method for the combinatorialproduction of recombinant host strains capable of producingnon-ribosomal peptide analogues varying from the parent non-ribosomalpeptide in the incorporation of alternative precursors and/or the extentof post-NRPS modification, comprising the partial complementation of thesaid genomic deletion strain by a combinatorial library of genecassettes comprising one or a plurality of the deleted genes, andfurther a method of producing said non-ribosomal peptide analogues byculturing said recombinant host strains under conditions suitable fornon-ribosomal peptide production, and optionally isolating thenon-ribosomal peptide analogues produced.

In this context a preferred recombinant host cell strain is aprokaryote, more preferably an actinomycete, still more preferably astrain selected from S. hygroscopicus, S. hygroscopicus sp., S.hygroscopicus var. ascomyceticus, Streptomyces tsukubaensis,Streptomyces coelicolor, Streptomyces lividans, Saccharopolysporaetythraea, Streptomyces fradiae, Streptomyces avermitilis, Streptomycescinnamonensis, Streptomyces rimosus, Streptomyces albus, Streptomycesgriseofuscus, Streptomyces longisporoflavus, Streptomyces venezuelae,Micromonospora griseorubida, Amycolatopsis mediterranei or Actinoplanessp. N902-109.

It is well known that many actinomycetes contain multiple biosyntheticgene clusters for different secondary metabolites, including polyketidesand non-ribosomally synthesised peptides. Specifically, it has beendemonstrated that strains of S. hygroscopicus produce a variety ofpolyketides and non-ribosomally synthesised peptides in addition torapamycin, FK506, FK520, FK523, meridamycin, FK525, antascomicin andtsukubamycin. These include, but are not limited to, elaiophylin,bialaphos, hygromycin, augustmycin, endomycin (A, B), glebomycin,hygroscopin, ossamycin and nigericin. These additional biosynthetic geneclusters represent a competing requirement for biosynthetic precursorsand an additional metabolic demand on the host strain. In order toenhance production of the desired rapamycin, or other polyketide,analogues, it may therefore be advantageous to delete or inactivate anyother biosynthetic gene clusters present in the host strain. Methods forthe deletion or inactivation of biosynthetic gene clusters are wellknown in the art.

In a further aspect of this class, the invention provides amutasynthesis methodology for the complementation of recombinantdeletion strains

In a further aspect, S. hygroscopicus strains of the present inventioncontaining a deletion of rapL may be fed with analogues of the naturallyincorporated amino acid, L-pipecolic acid, to produce new analogues ofrapamycin in which the pipecolyl residue is replaced. Prior artdescribes that a rapL mutant can be complemented by the addition ofL-pipecolic acid to the culture (Khaw et al., 1998). Similarly, it wasdemonstrated that rapamycin analogues were isolated after the feedingand incorporation of L-pipecolic acid analogues, L-proline,L-trans-4-hydroxyproline, L-cis-4-hydroxyproline,L-cis-3-hydroxyproline, trans-3-aza-bicyclo[3,1,0]hexane-2-carboxylicacid (WO98/54308). Using S. hygroscopicus MG2-10 as strain background toexpress genes or gene cassettes encoding for post-PKS modifying stepsnot including rapL or rapL homologues, a library of S. hygroscopicusstrains is generated, capable of producing a plurality of modifiedproducts on feeding with L-pipecolic acid analogues. SuitableL-pipecolic acid analogues include alkyl-, halo-, hydroxy-, andamino-substituted pipecolic acids and prolines, and more particularlyL-proline, L-trans-4-hydroxyproline, L-cis-4-hydroxyproline,L-cis-3-hydroxyproline, trans-3-aza-bicyclo[3,1,0]hexane-2-carboxylicacid and L-pipecolic acid analogues demonstrated to catalyse PP-ATPexchange measured by a modification of Lipmann's method (Nielsen et al.,1991) including L-4-hydroxyproline, 1-hydroxyproline, 2-hydroxyproline,3-hydroxyproline, trans-3-methyl-L-proline, cis-3-methylproline,cis-3-methyl-DL-proline, cis, trans-4-methylproline,cis-4-methyl-DL-proline, trans-4-methyl-DL-proline,trans-4-aminoproline, cis-4-chloro-L-proline, 5-iminoprolinehydrochloride, cis-5-methyl-DL-proline, (+)-piperazic acid,5-chloropipecolic acid, 5-hydroxypipecolic acid,cis-4-hydroxy-L-pipecolic acid, trans-4-hydroxy-D-pipecolic acid,4-hydroxyallopipecolic acid, thiazolidine-4-carboxylic acid (Nielsen etal., 1991). This approach is exemplified in Example 7.

The production of a limited number of novel rapamycin-analogues afterfeeding-t lose structural analogues of the natural4,5-dihydroxycyclohex-1-enecarboxylic acid starter unit to cultures ofS. hygroscopicus has previously been described, thus demonstrating thatthe loading module of the rapamycin polyketide synthase has someflexibility with respect to the starter acid (P. A. S. Lowden, PhDdissertation, University of Cambridge, 1997). However, these methods ledto the production of a mixture of products. In a further aspect, thepresent invention allows for the production of rapamycin and relatedFKBP-ligand analogues by feeding strains of the present invention withanalogues of the naturally incorporated4,5-dihydroxycyclohex-1-enecarboxylic acid starter unit to producerapamycin analogues incorporating alternative starter units including,but not limited to, cyclohexane carboxylic acid,3-cis,4-trans-dihydroxycyclohexane carboxylic acid, 1-cyclohexenecarboxylic acid, 3-cyclohexene carboxylic acid, cycloheptane carboxylicacid, 2-norbornane carboxylic acid, 3-hydroxycyclohexane carboxylicacid, 4-hydroxycyclohexane carboxylic acid, 3-methylcyclohexanecarboxylic acid, 4-methylcyclohexane carboxylic acid,3-(cis/trans)methoxycyclohexane carboxylic acid,4-(cis/trans)methoxycyclohexane carboxylic acid, 4-oxo cyclohexanecarboxylic acid, 3-fluoro-4-hydroxycarboxylic acid and4-fluoro-3-hydroxycarboxylic acid, 3-cyclohexane oxide carboxylic acid,3,4-cis-dihydroxycyclohexane carboxylic acid,3-chloro-4-hydroxycarboxylic acid and 4-chloro-3-hydroxycarboxylic acid(and the pair of opposite diastereomers), cyclohexylpropionic acid,4-tert-Butylcyclohexane carboxylic acid and simple esters and saltsthereof. This approach is exemplified in Examples 8, 19 and 20.

Additionally, structural analogues of biosynthetic precursors of the4,5-dihydroxycyclohex-1-enecarboxylic acid starter unit may be fed(Lowden et al., 2001), leading to production of novel rapamycinanalogues incorporating alternative starter units.

However, these methods can lead to the production of mixed groups ofproducts; therefore, the present invention additionally provides amethod for removing the competition between the endogenously producedstarter unit and the alternative starter acid analogues that are fed inorder to improve the efficiency of production of novel rapamycinanalogues.

In order to remove the competition between the endogenously producednatural starter unit and the alternative starter acid analogues fed, itis preferable to disrupt the biosynthesis of the natural4,5-dihydroxycyclohex-1-enecarboxylic acid starter unit. This may beachieved by deletion or inactivation of one or more of the genesinvolved in the biosynthesis of the natural4,5-dihydroxycyclohex-1-enecarboxylic acid starter unit from shikimicacid (Lowden et al., 2001) or the biosynthesis of shikimic acid itself.In the latter case, it may be necessary to supplement cultures witharomatic amino acids (phenyl alanine, tyrosine, tryptophan).Alternatively, endogenous production of the natural4,5-dihydroxycyclohex-1-ene carboxylic acid starter unit may besuppressed by the addition of a chemical inhibitor of shikimic acidbiosynthesis. Such inhibitors are well known in the literature.

In a further aspect, the invention makes use of the surprising discoverythat rapK is involved in the supply of the biosynthetic precursor(s),e.g. 4,5-dihydroxycyclohex-1-ene carboxylic acid starter unit ofrapamycin and therefore that deletion or inactivation of rapK or a rapKhomologue provides a strain lacking in competition between the naturalstarter unit and fed non-natural starter units. In another aspect, theinvention provides a method for the efficient incorporation of fed acidsincluding, but not limited to those described below.

Therefore in one aspect of the invention the method comprises feedingstarter units of the formula

where X=bond or CH₂ and R₁, R₂, R₃, R₄, R₅ and R₆ may be the same ordifferent and may independently be Cl, F, OH, SH, H, alkyl, CN, Br, R₇,OR⁷, C(O)R₇ or HNR₇ where R₇ is a C1-C4 alkyl; R₁ and R₃, R₂ and R₄, R₃and R₅, R₄ and R₅, R₁ and R₅, or R₂ and R₆ may be joined as either asubstituted or unsubstituted methylene link, an ether link, a thia linkor an amino link, R₁ and R₂, R₃ and R₄ or R₅ and R₆ may be takentogether as a ketone; provided that no more than 4 of R₁, R₂, R₃, R₄, R₅or R₆ may be Cl; no more than 2 of R₁, R₂, R₃, R₄, R₅ or R₆ may be HNR₇;no more than 2 of R₁, R₂, R₃, R₄, R₅ or R₆ may be SH and both R groupsfrom one carbon on the ring are not OH.

In a preferred embodiment the starter unit is not selected from thegroup consisting of: cyclohexane carboxylic acid,3-cis,4-trans-dihydroxycyclohexane carboxylic acid, cycloheptanecarboxylic acid and 3-(cis/trans)-methylcyclohexane carboxylic acid

In preferred embodiments: where R₁, R₂, R₃, R₄, R₅ or R₆ are acombination of F and OH substitution no more than 3 of R₁₋₆ aresubstituted and the remainder are H. Where R₁, R₂, R₃, R₄, R₅ or R₆ area combination of Cl and OH substitution no more than 3 of R₁₋₆ aresubstituted and the remainder are H. Where any two of R₁, R₂, R₃, R₄, R₅or R₆ are OH and any two remaining R groups are F on one carbon theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl, notoriginating from the same carbon, and a further R is OH the remainderare H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is alkyl and the remainderare H; the alkyl group shall have a linear length of no greater than 3carbons. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is NHR₇ the remainder areH.

In more highly preferred embodiments: where two of R₁, R₂, R₃, R₄, R₅ orR₆ are OH and a third R group is F, the remainder are H. Where two ofR₁, R₂, R₃, R₄, R₅ or R₆ are F the remainder are H. Where two of R₁, R₂,R₃, R₄, R₅ or R₆ are OH the remainder are H. Where two of R₁, R₂, R₃,R₄, R₅ or R₆ are OH and a third R group is Cl the remainder are H. Wheretwo of R₁, R₂, R₃, R₄, R₅ or R₆ are F, and a third R group is OH theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is SH theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is SH and asecond R group is OH (not originating from the same carbon) theremainder are H.

In still more highly preferred embodiments: where one of R₁, R₂, R₃, R₄,R₅ or R₆ is F the remainder are H. Where of R₁, R₂, R₃, R₄, R₅ or R₆ areCl the remainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆, are F anda second R group is OH (not originating from the same carbon) theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Cl and asecond R group is OH (not originating from the same carbon) theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is alkyl and theremainder are H; the alkyl group shall contain no more than 4 carbonsand have a linear length of no greater than 3 carbons. Where one of R₁,R₂, R₃, R₄, R₅ or R₆ is alkyl and a second R group is OH (notoriginating from the same carbon) and remainder are H; the alkyl groupshall contain no more than 4 carbons and have a linear length of nogreater than 3 carbons.

A further aspect of the invention comprises feeding starter units of theformula

where X=bond or CH₂ and R₁, R₂, R₃, R₄, R₅ and R₆ may be the same ordifferent and may independently be Cl, F, OH, SH, H, alkyl, CN, Br, R₇,OR⁷, C(O)R₇ or HNR₇ where R₇ is a C1-C4 alkyl; R₁ and R₃, R₂ and R₄, R₃and R₅, R₄ and R₆, R₁ and R₅, or R₂ and R₆ may be joined as either asubstituted or unsubstituted methylene link, an ether link, a thia linkor an amino link, R₁ and R₂, R₃ and R₄ or R₅ and R₆ may be takentogether as a ketone; provided that no more than 4 of R₁, R₂, R₃, R₄, R₅or R₆ may be Cl; no more than 2 of R₁, R₂, R₃, R₄, R₅ or R₆ may be HNR₇;no more than 2 of R₁, R₂, R₃, R₄, R₅ or R₆ may be SH and both R groupsfrom one carbon on the ring are not OH.

In a preferred embodiment the starter unit is not selected from thegroup consisting of: 1-cyclohexene carboxylic acid and 1-cycloheptenecarboxylic acid

In preferred embodiments, where R₁, R₂, R₃, R₄, R₅ or R₆ are acombination of F and OH substitution no more than 3 of R₁₋₆ aresubstituted and the remainder are H. Where R₁, R₂, R₃, R₄, R₅ or R₆ area combination of Cl and OH substitution no more than 3 of R₁₄ aresubstituted and the remainder are H. Where any two of R₁, R₂, R₃, R₄, R₅or R₆ are OH and two of the remaining R groups are F on the same carbonthe remainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl, notoriginating from the same carbon, and a further R group is OH theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is alkyl and theremainder are H; the alkyl group shall have a linear length of nogreater than 3 carbons. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is NHR₇the remainder are H.

In more highly preferred embodiments: where two of R₁, R₂, R₃, R₄, R₅ orR₆ are OH and a third R group is F, the remainder are H. Where two ofR₁, R₂, R₃, R₄, R₅ or R₆ are F the remainder are H. Where two of R₁, R₂,R₃, R₄, R₅ or R₆ are OH the remainder are H. Where two of R₁, R₂, R₃,R₄, R₅ or R₆ are OH and a third R group is to Cl the remainder are H.Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are F, and a third R group is OHthe remainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is SH theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is SH and asecond R group is OH (not originating from the same carbon) theremainder are H.

In still more highly preferred embodiments: where one of R₁, R₂, R₃, R₄,R₅ or R₆ is F the remainder are H. Where of R₁, R₂, R₃, R₄, R₅ or R₆ areCl the remainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆, are F anda second R group is OH (not originating from the same carbon) theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Cl, a second Rgroup is OH (not originating from the same carbon) the remainder are H.Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is alkyl and the remainder are H;the alkyl group shall contain no more than 4 carbons and have a linearlength of no greater than 3 carbons. Where one of R₁, R₂, R₃, R₄, R₅ orR₆ is alkyl and a second R group is OH (not originating from the samecarbon) the remainder are H; and the alkyl group shall contain no morethan 4 carbons and have a linear length of no greater than 3 carbons.

A further aspect of the invention comprises feeding starter units of theformula:

where X=bond or CH₂, R₁ and R₂, may be the same or different and mayindependently be F, Cl, OH, SH, H, CN, OR₇, C(O)R₇, or NHR₇ wherein R₇is a C1-C4 alkyl, R₁ and R₂ may also be taken together to form a ketone,a spirocyclopropyl group or with —OCH₂—, —CH₂O—, —SCH₂— or —CH₂S—;furthermore R₃, and R₄ may be the same or different and mayindependently be F, Cl, Br, OR₇, H or CN; provided that both R groupsfrom one carbon on the ring are not OH.

In a preferred embodiment the starter unit shall not be5-cis-hydroxyl-3-cyclohexene carboxylic acid.

In preferred embodiments: Where two of R₁, R₂, R₃, or R₄ are F theremainder are H. Where one of R₁, R₂, R₃, or R₄ is Cl the remainder areH. Where one of R₃, or R₄ is F and one of R1 or R2 is OH the remainderare H. Where one of R₃ or R₄ is Cl and one of R₁ or R₂ is OH theremainder are H. Where one of R₁ or R₂ is SH the remainder are H. Whereone of R₁, R₂, R₃, or R₄ is alkyl and the remainder are H; the alkylgroup shall contain no more than 4 carbons and have a linear length ofno greater than 3 carbons. Where one of R₃ or R₄ is alkyl and R₁ or R₂is OH the remainder are H; and the alkyl group shall contain no morethan 4 carbons and have a linear length of no greater than 3 carbons.

In more highly preferred embodiment where one of R₁, R₂, R₃, or R₄ is Fthe remainder are H. Where one of R₁, R₂, R₃, or R₄ is Cl the remainderare H

A further aspect of the invention comprises feeding starter units of theformula

where R₁, R₂, R₃, R₄, R₅ or R₆ may be the same or different and mayindependently be Cl, F, OH, SH, H, alkyl, CN, Br, R₇, OR⁷, C(O)R₇ orHNR₇ where R₇ is a C1-C4 alkyl; R₁ and R₃, R₂ and R₄, R₃ and R₅, R₄ andR₆, R₁ and R₅, or R₂ and R₆ may be joined as either a substituted orunsubstituted methylene link, an ether link, a thia link or an aminolink, R₃ and R₄ or R₅ and R₆ may be taken together as a ketone; providedthat both R groups from one carbon on the ring are not OH.

In preferred embodiments: Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Fthe remainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₈ are OH, theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are OH, and athird R group is F the remainder are H. Where two of R₁, R₂, R₃, R₄, R₅or R₆ are OH, and a third R group is Cl the remainder are H. Where twoof R₁, R₂, R₃, R₄, R₅ or R₆ are F and a third R group is OH theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Br theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Br and asecond R group is OH the remainder are H

In more preferred embodiments: Where one of R₁, R₂, R₃, R₄, R₅ or R₆ isF the remainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is F and a secondR group is OH (not originating from the same carbon) the remainder areH. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Cl and a second R group isOH (not originating from the same carbon) the remainder are H. Where oneof R₁, R₂, R₃, R₄, R₅ or R₆ is SH the remainder are H. Where one R₁, R₂,R₃, R₄, R₅ or R₆ is SH and a second R group is OH (not originating fromthe same carbon) the remainder are H. Where one of R₁, R₂, R₃, R₄, R₅ orR₆ is alkyl and the remainder are H; the alkyl group shall contain nomore than 4 carbons and have a linear length of no greater than 3carbons. Where one of R₁, R₂, R₃, R₅ or R₆ alkyl and a second R group isOH (not originating from the same carbon) the remainder are H; and thealkyl group shall contain no more than 4 carbons and have a linearlength of no greater than 3 carbons

A further aspect of the invention comprises feeding starter units of theformula

where R₁, R₂, R₃, R₄, R₅ or R₆ may be the same or different and mayindependently be Cl, F, OH, SH, H, alkyl, CN; Br, R₇, OR⁷, C(O)R₇ orHNR₇ where R₇ is a C1-C4 alkyl; R₁ and R₃, R₂ and R₄, R₃ and R₅, R₄ andR₆, R₁ and R₅, or R₂ and R₆ may be joined as either a substituted orunsubstituted methylene link, an ether link, a thia link or an aminolink, R₃ and R₄ or R₅ and R₆ may be taken together as a ketone; providedthat both R groups from one carbon on the ring are not OH.

In preferred embodiments: where R₁, R₂, R₃, R₄, R₅ or R₆ are acombination of F and OH substitution no more than 3 of R₁₋₆ aresubstituted and the remainder are H. Where R₁, R₂, R₃, R₄, R₅ or R₆ area combination of Cl and OH substitution no more than 3 of R₁₋₆ aresubstituted and the remainder are H. Where two of R₁, R₂, R₃, R₄, R₅ orR₆ are OH and two of the remaining R groups are F on one carbon theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are Cl (notoriginating from the same carbon) and a third R group is OH, theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is alkyl and theremainder are H; the alkyl group shall have a linear length of nogreater than 3 carbons. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are SH theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is HNR₇ theremainder are H.

In more preferred embodiments: Where two of R₁, R₂, R₃, R₄, R₅ or R₆ areF the remainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are OH theremainder are H. Where two of R₁, R₂, R₃, R₄, R₅ or R₆ are OH and athird R group is F, the remainder are H. Where two of R₁, R₂, R₃, R₄, R₅or R₆ are OH and a third R group is Cl the remainder are H. Where two ofR₁, R₂, R₃, R₄, R₅ or R₆ are F, and a third R groups is OH the remainderare H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Br the remainder are H.Where one R₁, R₂, R₃, R₄, R₅ or R₆ is Br and a second R group is OH (notoriginating from the same carbon) the remainder are H. Where one of R₁,R₂, R₃, R₄, R₅ or R₆ is SH the remainder are H. Where one of R₁, R₂, R₃,R₄, R₅ or R₆ is SH and a second R groups is OH (not originating from thesame carbon) the remainder are H.

In more preferred embodiments: Where one of R₁, R₂, R₃, R₄, R₅ or R₆ isF the remainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is Cl theremainder are H. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ is F and a secondR group is OH (not originating from the same carbon) the remainder areH. Where one of R₁, R₂, R₃, R₄, R₅ or R₈ is Cl and a second R group isOH (not originating from the same carbon) the remainder are H. Where oneof R₁, R₂, R₃, R₄, R₅ or R₆ is alkyl and the remainder are H; the alkylgroup shall contain no more than 4 carbons and have a linear length ofno greater than 3 carbons. Where one of R₁, R₂, R₃, R₄, R₅ or R₆ isalkyl and a second R group is OH (not originating from the same carbon)the remainder are H; and the alkyl group shall contain no more than 4carbons and have a linear length of no greater than 3 carbons.

A further aspect of the invention comprises feeding starter units of theformula

where R₁ and R₂, may be the same or different and may independently beF, Cl, OH, SH, H, CN, OR₇, C(O)R₇, or NHR₇ wherein R₇ is a C1-C4 alkyl,R₁ and R₂ may also be taken together to form a ketone, aspirocyclopropyl group or with —OCH₂—, —CH₂O—, —SCH₂— or —CH₂S—;furthermore R₃, and R₄ may be the same or different and mayindependently be F, Cl, Br, OR₇, H or CN; provided that both R groupsfrom one carbon on the ring are not OH.

In preferred embodiments: Where one of R₁, R₂, R₃ and R₄ is F theremainder are H. Where one of R₁, R₂, R₃ and R₄ is Cl the remainder areH. Where one of R₁, R₂, R₃ and R4 is F and a second R groups is OH (notoriginating from the same carbon) the remainder are H. Where one of R₁,R₂, R₃ and R₄ is Cl and a second R group is OH (not originating from thesame carbon) the remainder are H. Where one of R₁, R₂, R₃ and R₄ is SHthe remainder are H. Where one of R₁, R₂, R₃ and R₄ is alkyl theremainder are H; and the alkyl group shall contain no more than 4carbons and have a linear length of no greater than 3 carbons. Where oneof R₁, R₂, R₃ and R₄ is alkyl and a second R groups is OH (notoriginating from the same carbon) the remainder are H; and the alkylgroup shall contain no more than 4 carbons and have a linear length ofno greater than 3 carbons. Where two of R₁, R₂, R₃ and R₄ are F theremainder are H.

An additional aspect of the invention comprises feeding starter units ofthe formula

where X=bond or CH₂; and R₁, R₂, R₃, R₄ or R₅ may be the same ordifferent and may independently be Cl, F, OH, SH, H, alkyl, CN, Br, R₇,OR⁷, C(O)R₇ or HNR₇ where R₇ is a C1-C4 alkyl, R₁ and R₃, R₂ and R₄, maybe taken together as a ketone or linked as either a substituted orunsubstituted methylene link, an ether link, a thia link or an aminolink where R₁ and R₂ or R₃ and R₄ are linked as a spiro-cyclopropylgroup or with —OCH₂— or —CH₂O— or —SCH₂— or —CH₂S—, R5 may be F, CL,OR₇, H or CN; provided that no more than two of R₁, R₂, R₃, R₄ or R₅ areSH and that both R groups attached to one carbon are not OH.

In preferred embodiments: where R₁, R₂, R₃, R₄ or R₅ are a combinationof F and OH no more than 3 of R₁, R₂, R₃, R₄ or R₅ are substituted andthe remainder are H. Where R₁, R₂, R₃, R₄ or R₅ are a combination of Cland OH no more than 3 of R₁₋₅ are substituted and the remainder are H.Where R₁, R₂, R₃, R₄ or R₅ are a combination of two are OH (not on thesame carbon) and two are F on one carbon the remainder are H. Where twoof R₁, R₂, R₃, R₄ or R₅ are Cl the remainder are H. Where two of R₁, R₂,R₃, R₄ or R₅ are Cl (not originating from the same carbon) and a third Rgroup is OH the remainder are H. Where one of R₁, R₂, R₃, R₄ or R₅ isalkyl the remainder are H; and the alkyl group shall have a linearlength of no greater than 3 carbons. Where two of R₁, R₂, R₃, R₄ or R₅are SH the remainder are H. Where one of R₁, R₂, R₃, R₄ or R₅ is NHR₇the remainder are H. Where one of R₁, R₂, R₃, R₄ or R₅ is SH theremainder are H.

In more highly preferred embodiments: where one of R₁, R₂, R₃, R₄ or R5is OH the remainder are H. Where one of R₁, R₂, R₃, R₄ or R₅ is F theremainder are H. Where one of R₁, R₂, R₃, R₄ or R₅ is Cl the remainderare H. Where one of R₁, R₂, R₃, R₄ or R₅ is F and a second R group is OH(not originating from the same carbon) the remainder are H. Where one ofR₁, R₂, R₃, R₄ or R₅ is Cl and a second R groups is OH (not originatingfrom the same carbon) the remainder are H. Where one of R₁, R₂, R₃, R₄or R₅ is SH and a second R group is OH (not originating from the samecarbon) the remainder are H. Where one of R₁, R₂, R₃, R₄ or R₅ is alkylthe remainder are H; and the alkyl group shall contain no more than 4carbons and have a linear length of no greater than 3 carbons. Where oneof R₁, R₂, R₃, R₄ or R₅ is alkyl and a second R group is OH (notoriginating from the same carbon) the remainder are H; and the alkylgroup shall contain no more than 4 carbons and have a linear length ofno greater than 3 carbons. Where two of R₁, R₂, R₃, R₄ or R₅ are F theremainder are H. Where two of R₁, R₂, R₃, R₄ or R₅ are OH the remainderare H. Where two of R₁, R₂, R₃, R₄ or R₅ are OH and a third R group is Fthe remainder are H. Where two of R₁, R₂, R₃, R₄ or R₅ are OH and athird R groups is Cl the remainder are H. Where two of R₁, R₂, R₃, R₄ orR₅ are F and a third R group is OH the remainder are H.

An additional aspect of the invention comprises feeding starter units ofthe formula

where R₁, R₂, R₃ and R₄ may be the same or different and mayindependently be Cl, F, OH, SH, H, alkyl, CN, Br, R₇, OR⁷, C(O)R₇ orHNR₇ where R₇ is a C1-C4 alkyl, R₁ and R₂ or R₃ and R₄ may be takentogether to form a ketone, provided that two R groups attached to thesame carbon are not both OH.

In preferred embodiments: Where one of R₁, R₂, R₃ or R₄ is F theremainder are H. Where one of R₁, R₂, R₃ or R₄ is Cl the remainder areH. Where one of R₁, R₂, R₃ or R₄ is Br the remainder are H. Where one ofR₁, R₂, R₃ or R₄ is OH the remainder are H. Where one of R₁, R₂, R₃ orR₄ is F and a second R group is OH (not originating from the samecarbon) the remainder are H. Where one of R₁, R₂, R₃ or R₄ is Cl and asecond R groups is OH (not originating from the same carbon) theremainder are H. Where one of R₁, R₂, R₃ or R₄ is SH the remainder areH. Where one of R₁, R₂, R₃ or R₄ is SH and a second R groups is OH (notoriginating from the same carbon) the remainder are H. Where one of R₁,R₂, R₃ or R₄ is alkyl the remainder are H; and the alkyl group shallcontain no more than 4 carbons and have a linear length of no greaterthan 3 carbons. Where one of R₁, R₂, R₃ or R₄ is alkyl and a second Rgroups is OH (not originating from the same carbon) the remainder are H;and the alkyl group shall contain no more than 4 carbons and have alinear length of no greater than 3 carbons. Where two of R₁, R₂, R₃ orR₄ are F the remainder are H. Where two of R₁, R₂, R₃ or R₄ are OH theremainder are H. Where two of R₁, R₂, R₃ or R₄ are OH and a third Rgroup is F the remainder are H. Where two of R₁, R₂, R₃ or R₄ are OH anda third R group is Cl the remainder are H. Where two of R₁, R₂, R₃ or R₄are F and a third R group is OH the remainder are H.

In a preferred embodiment the present invention provides a method forthe efficient incorporation of: 2-norbomane carboxylic acid;2-(cis/trans)-hydroxycyclohexane carboxylic acid;3-(cis/trans)-hydroxycyclohexane carboxylic acid;4-(cis/trans)-hydroxycyclohexane carboxylic acid;2-(cis/trans)-methylcyclohexane carboxylic acid;4-(cis/trans)-methylcyclohexane carboxylic acid;3-(cis/trans)-methoxycyclohexane carboxylic acid;4-(cis/trans)-methoxycyclohexane carboxylic acid; 4-oxocyclohexanecarboxylic acid; ethyl 2-oxocyclohexane carboxylic acid;4-trans-n-pentylcyclohexane carboxylic acid; 2-trans-aminocyclohexanecarboxylic acid; 4-cis-aminocyclohexane carboxylic acid;4-(cis/trans)-aminomethylcyclohexane carboxylic acid; cyclopentanecarboxylic acid; cyclobutane carboxylic acid; 1-methylcyclohexanecarboxylic acid; 3-trans-hydroxy-4-cis-fluorocyclohexane carboxylic acidand 4-trans-hydroxy-3-cis-fluorocyclohexane carboxylic acid;3-cis-hydroxy-4-trans-fluorocyclohexane carboxylic acid and4-cis-hydroxy-3-trans-fluorocyclohexane carboxylic acid;3-cis-hydroxy-4-trans-chlorocyclohexane carboxylic acid and4-cis-hydroxy-3-trans-chlorocyclohexane carboxylic acid;3-trans-hydroxy-4-cis-chlorocyclohexane carboxylic acid and4-trans-hydroxy-3-cis-chlorocyclohexane carboxylic acid;3-trans-cyclohexeneoxide carboxylic acid; 3-cis-cyclohexeneoxidecarboxylic acid; 3,4-cis-dihydroxycyclohexane carboxylic acid and3,4-trans-dihydroxycyclohexane carboxylic acid; cyclohexaneacetic acid;cyclohexanepropionic acid or 4-cis/trans-tert-butylcyclohexanecarboxylic acid or simple esters or salts thereof into FKBP-ligandanalogues by a strain with rapK or a rapK homologue deleted orinactivated. In a more preferred embodiment the present inventionprovides a method for the efficient incorporation of:3-(cis/trans)-hydroxycyclohexane carboxylic acid;4-(cis/trans)-hydroxycyclohexane carboxylic acid;3-(cis/trans)-methoxycyclohexane carboxylic acid;4-(cis/trans)-methoxycyclohexane carboxylic acid; 4-oxo cyclohexanecarboxylic acid; cyclobutane carboxylic acid;3-trans-hydroxy-4-cis-fluorocyclohexane carboxylic acid and4-trans-hydroxy-3-cis-fluorocyclohexane carboxylic acid;3-cis-hydroxy-4-trans-fluorocyclohexane carboxylic acid and4-cis-hydroxy-3-trans-fluorocyclohexane carboxylic acid;3-cis-hydroxy-4-trans-chlorocyclohexane carboxylic acid and4-cis-hydroxy-3-trans-chlorocyclohexane carboxylic acid;3-trans-hydroxy-4-cis-chlorocyclohexane carboxylic acid and4-trans-hydroxy-3-cis-chlorocyclohexane carboxylic acid;3-trans-cyclohexeneoxide carboxylic acid; 3-cis-cyclohexeneoxidecarboxylic acid; 3,4-cis-dihydroxycyclohexane carboxylic acid and3,4-trans-dihydroxycyclohexane carboxylic acid; cyclohexanepropionicacid; 4-cis/trans-tert-butylcyclohexane carboxylic acid or simple estersor salts thereof into FKBP-ligand analogues by a strain with rapK or arapK homologue deleted or inactivated.

In a specific embodiment of the present invention the fed starter unitsare not: cyclohexane carboxylic acid, 3-cis,4-trans-dihydroxycyclohexanecarboxylic acid, 1-cyclohexene carboxylic acid, 3-cyclohexene carboxylicacid, cycloheptane carboxylic acid, 3-(cis/trans)-methylcyclohexanecarboxylic acid, 4-(cis/trans)-methylcyclohexane carboxylic acid,1-cycloheptene carboxylic acid or 5-cis-hydroxyl-3-cyclohexenecarboxylic acid.

The strains for use in the embodiments described above are selected fromthe group comprising: Streptomyces hygroscopicus subsp. hygroscopicusNRRL 5491, Actinoplanes sp. N902-109 FERM BP-3832, Streptomyces sp.AA6554, Streptomyces hygroscopicus var. ascomyceticus MA 6475 ATCC14891, Streptomyces hygroscopicus var. ascomyceticus MA 6678 ATCC 55087,Streptomyces hygroscopicus var. ascomyceticus MA 6674, Streptomyceshygroscopicus var. ascomyceticus ATCC 55276, Streptomyces hygroscopicussubsp. ascomyceticus ATCC 14891, Streptomyces tsukubaensis No. 9993 FERMBP-927, Streptomyces hygroscopicus subsp. yakushimaensis, Streptomycessp. DSM 4137, Streptomyces sp. DSM 7348, Micromonospora n.sp. A92-306401DSM 8429, Steptomyces sp. MA 6858 ATCC 55098, Steptomyces sp. MA 6848.In a preferred embodiment said strain is selected from the groupconsisting et Streptomyces hygroscopicus subsp. hygroscopicus NRRL 5491,Actinoplanes sp. N902-109 FERM BP-3832, Streptomyces sp. AA6554,Streptomyces hygroscopicus var. ascomyceticus MA 6475 ATCC 14891,Streptomyces hygroscopicus var. ascomyceticus MA 6678 ATCC 55087,Streptomyces hygroscopicus var.

ascomyceticus MA 6674, Streptomyces hygroscopicus var. ascomyceticusATCC 55276, Streptomyces hygroscopicus subsp. ascomyceticus ATCC 14891,Streptomyces tsukubaensis No. 9993 FERM BP-927, Streptomyceshygroscopicus subsp. yakushimaensis, Streptomyces sp. DSM 4137,Streptomyces sp. DSM 7348, Micromonospora n.sp. A92-306401 DSM 8429 orStreptomyces sp. MA 6858 ATCC 55098. In a more highly preferredembodiment the strain is the rapamycin producer S. hygroscopicus subsp.hygroscopicus.

In the methods for the efficient incorporation of fed carboxylic acidsdescribed above the compounds produced are analogues of the FKBP-ligardsas described herein, for example but without limitation: rapamycin,FK506, FK520, FK523, FK525, antascomicin, meridamycin and tsukubamycin.In a preferred embodiment the compounds produced are analogues ofrapamycin, FK506 or FK520. In a more highly preferred embodiment thecompounds produced are analogues of rapamycin; these compoundscorrespond to Formula II or Formula III as described below.

Additionally, the methods described above may be used to generate novelFK506 and FK520 analogues which correspond to Formula I below:

-   -   R1=

-   -   -   R₈=OH        -   R₉=H, OH, halo, thiol, alkyl            R₂=H, alkyl, halo, hydroxyl, thiol            R₃=H, alkyl, halo, hydroxyl, thiol            R₄=H, alkyl, halo, hydroxyl, thiol

R₅=OMe, Me or H R₆=OMe, Me or H R₇=CH₂CH₃ or CH₂CH═CH₂

Z=keto or CH₂X=X=bond; X=bond and X′=CH₂, S, O or X=CH₂, S, O, fused cyclopropyl unitandX′=bondIn a preferred embodiment, R₁=

where R₈=OH and R₉=H, OH, halo, alkyl or thiol.In a further preferred embodiment R₁=

where R₈=OH and R₉=halo.

FK520=

where R₈=4-trans-OH, R₉=3-cis-OCH₃, and R₂=R₃=R₄=H, X=CH₂, X′=bond,Z=keto, R₅=R₅=OCH₃ and R₇=CH₂CH₃

FK506=

where R₈=4-trans-OH, R₉=3-cis-OCH₃, and R₂=R₃=R₄=H, X=CH₂, X′=bond,Z=keto, R₅=R₆=OCH₃ and R₇=CH₂CH═CH₂

Thus, for example, the recombinant strain S. hygroscopicus MG2-10 can becultured in the presence of cyclohexane carboxylic acid to produce9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin (Example12). It can be seen by one skilled in the art that homologues to rapK inother biosynthetic clusters that i encode FKBP-ligands, including, butnot limited to, FK506, FK520, FK523, FK525, meridamycin, tsukubamycin,antascomicin and ‘hyg’ can also be deleted or inactivated allowingefficient feeding of starter unit carboxylic acids leading to theproduction of novel analogues.

In another aspect, S. hygroscopicus strains of the invention (includingrapL or rapL homologues or not including rapL or rapL homologues and/orincluding rapK or rapK homologues or not including rapK or rapKhomologues) may be fed with analogues of L-pipecolic acid, as describedabove, in combination with analogues of the natural4,5-dihydroxycyclohex-1-enecarboxylic acid starter unit, as describedabove, to produce rapamycin analogues in which both the starter unit andthe pipecolyl residue have been replaced. This approach is exemplifiedin Examples 10, 11 and 12.

The present invention provides a process for producing FKBP-ligandanalogues varying in the extent of post-PKS modification and/or in whichthe pipecolic acid residue has been replaced, and optionally the starter4,5-dihydroxycyclohex-1-enecarboxylic acid residue has been replaced.This process comprises the step of deleting or inactivating one or moregenes in the microorganism host cell involved in the production of theprecursor compound, L-pipecolic acid and/or 4,5-dihydroxycyclohex-1-enecarboxylic acid, required for biosynthesis of the rapamycinpolyketide/NRPS template and/or in its subsequent post-PKS modification,thereby to suppress the production of the natural product. The processfurther comprises transforming the microorganism host cells with nucleicacid encoding polyketide-modifying genes to restore polyketideproduction, culturing the transformed host cells under conditionssuitable for polyketide production and optionally isolating therapamycin analogues produced.

The present invention provides a process for the production ofFKBP-ligand analogues including, but not limited to FK506, FK520, FK523,FK525, tsukubamycin, antascomicin, meridamycin and ‘hyg’, varying in theextent of post-PKS modification and/or in which the amino acid residuehas been replaced, and optionally the starter unit has been replaced.This process comprises the step of deleting or inactivating one or moregenes in the microorganism host cell involved in the production of theprecursor amino acid residue and/or starter unit, required for thebiosynthesis of the polyketide/NRPS template and/or in its subsequentpost-PKS modification, thereby to suppress the production of the naturalproduct. The process further comprises transforming the microorganismhost cells with nucleic acid encoding polyketide-modifying genes torestore polyketide production, culturing the transformed host cellsunder conditions suitable for polyketide production and optionallyisolating polyketide analogues produced.

The present invention provides novel FKBP-ligand analogues.

In a further aspect the present invention provides the following FK520analogues: 31-desmethoxy-FK520,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK520,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK520,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK520,31-O-desmethyl-32-dehydroxy-FK520, 31-O-desmethyl-FK520,31-desmethoxy-31-methyl-FK520,31-O-desmethyl-32-dehydroxy-32-methyl-FK520,31-O-desmethyl-32-dehydroxy-32-fluoro-FK520,31-desmethoxy-31-fluoro-FK520,31-O-desmethyl-32-dehydroxy-32-chloro-FK520,31-desmethoxy-31-chloro-FK520,31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK520,9-deoxo-31-desmethoxy-FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK520,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-FK520, 9-deoxo-31-O-desmethyl-FK520,9-deoxo-31-desmethoxy-31-methyl-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-FK520,9-deoxo-31-desmethoxy-31-fluoro-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-FK520,9-deoxo-31-desmethoxy-31-chloro-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK520,30-desmethoxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-prolyl-FK520, 30-O-desmethyl-prolyl-FK520,30-desmethoxy-30-methyl-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-prolyl-FK520,30-desmethoxy-30-fluoro-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-prolyl-FK520,30-desmethoxy-30-chloro-prolyl-FK520,30-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-FK520,8-deoxo-30-desmethoxy-31-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-prolyl-FK520,30-desmethoxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK520,30-O-desmethyl-3-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK520,30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK520,30-desmethoxy-30-chloro-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-31-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydro-31-tert-butyl-3-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK520,30-desmethoxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK520,30-O-desmethyl-4-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK520,30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK520,30-desmethoxy-30-chloro-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-31-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK520,31-desmethoxy-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0.]FK520,31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0]FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0]FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0]FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK520,

In a preferred embodiment, the present invention provides the followingFK520 analogues: 31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK520,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK520,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK520,31-desmethoxy-31-methyl-FK520, 31-desmethoxy-31-fluoro-FK520,31-desmethoxy-31-chloro-FK520,31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK520,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK520,9-deoxo-31-desmethoxy-31-methyl-FK520,9-deoxo-31-desmethoxy-31-fluoro-FK520,9-deoxo-31-desmethoxy-31-chloro-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-prolyl-FK520,30-desmethoxy-30-fluoro-prolyl-FK520,30-desmethoxy-30-chloro-prolyl-FK520,30-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-FK520,8-deoxo-30-desmethoxy-31-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-prolyl-FK520,30-desmethoxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK520,30-O-desmethyl-3-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK520,30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK520,30-desmethoxy-30-chloro-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-31-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK520,30-desmethoxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK520,30-O-desmethyl-4-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK520,30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK520,30-desmethoxy-30-chloro-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-31-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK520,31-desmethoxy-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0.]FK520,31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0]FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK520,In a more highly preferred embodiment, the present invention providesthe following novel FK520 analogues: 31-desmethoxy-31-methyl-FK520,31-desmethoxy-31-fluoro-FK520, 31-desmethoxy-31-chloro-FK520,31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK520,9-deoxo-31-desmethoxy-31-methyl-FK520,9-deoxo-31-desmethoxy-31-fluoro-FK520,9-deoxo-31-desmethoxy-31-chloro-FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK520,30-desmethoxy-30-methyl-prolyl-FK520,30-desmethoxy-30-fluoro-prolyl-FK520,30-desmethoxy-30-chloro-prolyl-FK520,30-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-FK520,8-deoxo-30-desmethoxy-31-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-prolyl-FK520,30-desmethoxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK520,30-O-desmethyl-3-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK520,30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK520,30-desmethoxy-30-chloro-3-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-31-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-3-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK520,30-desmethoxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK520,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK520,30-O-desmethyl-4-hydroxy-prolyl-FK520,30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK520,30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK520,30-desmethoxy-30-chloro-4-hydroxy-prolyl-FK520,30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK520,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-31-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK520,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-4-hydroxy-prolyl-FK520,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK520,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK520,31-desmethoxy-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK520,31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0.]FK520,31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0.]FK520,31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0.]FK520,31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK520,31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0.]FK520,31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0]FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK520,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK520,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0]FK520,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0]FK520.

In a further aspect the present invention provides the following FK506analogues: 31-desmethoxy-FK506,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK506,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK506,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK506,31-O-desmethyl-32-dehydroxy-FK506, 31-O-desmethyl-FK506,31-desmethoxy-31-methyl-FK506,31-O-desmethyl-32-dehydroxy-32-methyl-FK506,31-O-desmethyl-32-dehydroxy-32-fluoro-FK506,31-desmethoxy-31-fluoro-FK506,31-O-desmethyl-32-dehydroxy-32-chloro-FK506,31-desmethoxy-31-chloro-FK506,31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK506,9-deoxo-31-desmethoxy-FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK506,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-FK506, 9-deoxo-31-O-desmethyl-FK506,9-deoxo-31-desmethoxy-31-methyl-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-FK506,9-deoxo-31-desmethoxy-31-fluoro-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-FK506,9-deoxo-31-desmethoxy-31-chloro-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-ten-butyl-FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK506,30-desmethoxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-prolyl-FK506, 30-O-desmethyl-prolyl-FK506,30-desmethoxy-30-methyl-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-prolyl-FK506,30-desmethoxy-30-fluoro-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-prolyl-FK506,30-desmethoxy-30-chloro-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-FK506,8-deoxo-30-desmethoxy-31-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-prolyl-FK506,30-desmethoxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK506,30-O-desmethyl-3-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK506,30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-S-hydroxy-prolyl-FK506,30-desmethoxy-30-chloro-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-31-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK506,30-desmethoxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK506,30-O-desmethyl-4-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK506,30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK506,30-desmethoxy-30-chloro-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-31-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK506,31-desmethoxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0.]FK506,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK506,31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK506,

In a preferred embodiment, the present invention provides the followingFK506 analogues: 31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK506,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK506,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK506,31-desmethoxy-31-methyl-FK506,31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-FK506,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-FK506,9-deoxo-31-desmethoxy-31-methyl-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-prolyl-FK506,30-desmethoxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK506,30-O-desmethyl-3-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK506,30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK506,30-desmethoxy-30-chloro-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-31-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK506,30-desmethoxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK506,30-O-desmethyl-4-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK506,30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK506,30-desmethoxy-30-chloro-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-31-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK506,31-desmethoxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK506,31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0.]FK506,31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0]FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0]FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK506.

In a more highly preferred embodiment, the present invention providesthe following FK506 analogues: 31-desmethoxy-31-methyl-FK506,31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK506,9-deoxo-31-desmethoxy-31-methyl-FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-FK506,30-desmethoxy-30-methyl-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-FK506,8-deoxo-30-desmethoxy-30-methyl-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-prolyl-FK506,30-desmethoxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK506,30-O-desmethyl-3-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK506,30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK506,30-desmethoxy-30-chloro-3-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-31-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-3-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-3-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-3-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-3-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-3-hydroxy-prolyl-FK506,30-desmethoxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK506,30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK506,30-O-desmethyl-4-hydroxy-prolyl-FK506,30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK506,30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK506,30-desmethoxy-30-chloro-4-hydroxy-prolyl-FK506,30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK506,28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-31-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-cis-hydroxy-31-cis-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-trans-hydroxy-31-trans-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-methyl-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-methyl-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-fluoro-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-fluoro-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-chloro-4-hydroxy-prolyl-FK506,8-deoxo-30-desmethoxy-30-chloro-3-hydroxy-4-hydroxy-prolyl-FK506,8-deoxo-30-O-desmethyl-31-dehydroxy-31-tert-butyl-4-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-cycloheptyl)-4-hydroxy-prolyl-FK506,8-deoxo-28-de(3-methoxy-4-hydroxy-cyclohexyl)-28-(hydroxy-norbornyl)-4-hydroxy-prolyl-FK506,31-desmethoxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0.]FK506,31-O-desmethyl-trans-3-bicyclo[3.1.0]FK506,31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0.]FK506,31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0.]FK506,31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK506,31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0.]FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0]FK506,29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-cis-hydroxy-32-cis-hydroxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-desmethoxy-31-trans-hydroxy-32-trans-hydroxy-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-methyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-methyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-fluoro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-fluoro-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-chloro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-desmethoxy-31-chloro-trans-3-bicyclo[3.1.0]FK506,9-deoxo-31-O-desmethyl-32-dehydroxy-32-tert-butyl-trans-3-bicyclo[3.1.0]FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-cycloheptyl)-trans-3-bicyclo[3.1.0.]FK506,9-deoxo-29-de(3-methoxy-4-hydroxy-cyclohexyl)-29-(hydroxy-norbornyl)-trans-3-bicyclo[3.1.0.]FK506.

In further aspects the invention provides:

A: Compounds of the Formula:

where:x=bond or CHR₁₁, or —CHR₆-x-CHR₅— is

R15=

R1=OH, OCH₃ R2=H, OH, OCH₃ R3=H, OH, CH₃, F, Cl, OCH₃ R4=H, OH, CH₃, F,Cl R5=H, OH R6=H, OH R7=H

R8=H, ketoR9=H, keto

R10=H R11=H R13=H R14=H R16=OH, OCH₃ R17=H, OH, Cl, F and

y=bond, CH₂with the proviso that the compounds do not include the following:

-   -   i) where R₁=OCH₃ in combination with R₂=H, R₁₅=C, R₁₈=cis-3-OH,        R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈=H, R₅=H, R₁₀=H, R₁₁=H,        x=CHR₁₁;    -   ii) where R₁=OH in combination with R₂=OCH₃, R₁₅=C,        R₁₅=cis-3-OH, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto,        R₁₀=H R₁₁=H, x=CHR₁₁;    -   iii) where R₁=OH in combination with R₂=OH, R₁₅=C,        R16=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, Re, R₉=keto,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   iv) where R₁=OH in combination with R₂=H, R₁₅=C, R₁₆=cis-3-OCH₃,        R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto, R₁₀=H, R₁₁=H,        x=CHR₁₁;    -   v) where R₁=OCH₃ in combination with R₂=H, R₁₅=C, R₁₆=cis-3-OH,        R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto, R₁₀=H, R₁₁=H,        x=CHR₁₁;    -   vi) where R₁=OCH₃ in combination with R₂=H, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈=H, R₉=H,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   vii) except where R₁=OCH₃ in combination with R₂=OH, R₁₆=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈=H, R₉=H,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   viii) where R₁=OCH₃ in combination with R₂=OCH₃, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈=H, R₉=H,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   ix) where R₁=OH in combination with R₂=OCH₃, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₅, R₆=keto,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   x) where R₁=OCH₃ in combination with R₂=OH, R₁₅=C;        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   xi) where R₁=OCH₃ in combination with R₂=H, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   xii) where R₁=OCH₃ in combination with R₂=OCH₃, R₁₅=C,        R₁₆=cis-3-OH, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto,        R₁₀=H, R₁₁=H, x=CHR₁₁;    -   xiii) where R₁=OCH₃ in combination with R₂=H, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈=H, R₉=H,        R₁₀=H, x=bond;    -   xiv) where R₁=OCH₃ in combination with R₂=OCH₃, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈=H, R₉=H,        R₁₀=H, x=bond;    -   xv) where R₁=OCH₃ in combination with R₂=OH, R₁₅=C,        R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₈=H, R₇=H, R₈, R₉=keto,        R₁₀=H, x=bond;    -   xvi) where R₁=OCH₃ in combination with R₂=H, R₁₅=C,        R₁₃=cis-3-OCH₃, R₁₇=trans-4-OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto,        R₁₀=H, x=bond;    -   xvii) where R₁=OCH₃ in combination with R₂=OCH₃, R₁₅=C, R₁₆=H,        R₁₇=OH, R₅=H, R₆=H, R₇=H, R₈, R₉=keto, R₁₀=H, R₁₁=H, x=CHR₁₁;    -   xviii) where —CHR₈-x-CHR₈— is

and R₁₁=H, R₁₃=H, R₁₄=H, in combination with R₁=OCH₃, R₂=OCH₃, R₁₅=C,R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, R₇=H, R₈, R₉=keto, R₁₀=H;

-   -   xix) where R₁₅=G, R₁₆=cis-3-OCH₃, R₁₇=trans-4-OH, y=bond, in        combination with R₁=OCH₃, R₂=H, R₅=H, R₆=OH, R₇=H, R₁₁=H,        x=bond, R₈, R₉=keto, R₁₀=H    -   xx) where R₁₅=G, R₃=H, R₄=trans-OH, y=bond, in combination with        R₁=OCH₃, R₂=OCH₃, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈, R₉=keto,        R₁₀=H    -   xxi) where R₁₅=G, R₃=H, R₄=OH, y=CH₂ in combination with        R₁=OCH₃, R₂=OCH₃; R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈, R₉=keto,        R₁₀=H    -   xxii) where R₁₅=G, R₃=cis-OH, R₄=H, y=bond, in combination with        R₁=OCH₃, R₂=OCH₃, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈, R₉=keto,        R₁₀=H    -   xxiii) where R₁₅=G, R₃=CH₃, R₄=OH, y=bond, in combination with        R₁=OCH₃, R₂=OCH₃, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈, R₉=keto,        R₁₀=H    -   xxiv) where R₁₅=G, R₃=H, R₄=OH, y=CH₂, in combination with        R₁=OH, R₂=OH, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈=R₉=H, R₁₀=H    -   xxvii) where R₁₅=G, R₃=H, R₄=OH, y=CH₂, in combination with        R₁=OCH₃, R₂=OCH₃, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈=R₉=H,        R₁₀=H    -   xxvi) where R₁₅=G, R₃=H, R₄=OH, y=CH₂, in combination with        R₁=OH, R₂=OCH₃, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈=R₉=H, R₁₀=H    -   xxvii) where R₁₅=G, R₃=H, R₄=OH, y=CH₂, in combination with        R₁=OH, R₂=H, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈=R₉=H, R₁₀=H;    -   xxviii) where R₁₅=G, R₃=H, R₄=OH, y=CH₂, in combination with        R₁=OH, R₂=OCH₃, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈, R₉=keto,        R₁₀=H    -   xxix) where R₁₅=G, R₃=H, R₄=OH, y=CH₂, in combination with        R₁=OCH₃, R₂=H, R₅=H, R₆=H, R₇=H, R₁₁=H, x=CHR₁₁, R₈, R₉=keto,        R₁₀=H

B. Compounds according to the formula below

where

R₁=OH, OCH₃ R₂=H, OH, OCH₃ R₃=H, OH, CH₃, OCH₃ R₄=H, OH R₉=H R₆=H, OHR₇=H

R₈=H, ketoR₉=H, keto

R₁₀=H

x=bond, CH₂ or CHR₆-x-CHR₃— is

R₁₁=H R₁₃= R₁₄=H

y=bond, CH₂with the proviso that the compounds do not include the following:

-   -   i) where R₃=H, R₄=trans-OH, y=bond, in combination with R₁=OCH₃,        R₂=OCH₃, R₅=H, R₈=H, R₇=H, x=CH₂, R₈, R₉=keto, H    -   ii) where R₃=H, R₄=OH, y=CH₂ in combination with R₁=OCH₃,        R₂=OCH₃, R₅=H, R₆=H, R₇=H, x=CH₂, R₈, R₉=keto, R₁₀=H    -   iii) where R₃=cis-OH, R₄=H, y=bond, in combination with R₁=OCH₃,        R₂=OCH₃, R₅=H, R₆=H, R₇=H, x=CH₂, R₈, R₉=keto, R₁₀=H    -   iv) where R₃=CH₃, R₄=OH, y=bond, in combination with R₁=OCH₃,        R₂=OCH₃, R₅=H, R₆=H, R₇=H, x=CH₂, R₈, R₉=keto, R₁₀=H    -   v) where R₃=H, R₄=OH, y=CH₂, in combination with R₁=OH, R₂=OH,        R₅=H, R₆=H, R₇=H, x=CH₂, R₈=R₉=H, R₁₀=H    -   vi) where R₃=H, R₄=OH, y=CH₂, in combination with R₁=OCH₃,        R₂=OCH₃, R₅=H, R₆=H, R₇=H, x=CH₂, R₈=R₉=H, R₁₀=H    -   vii) where R₃=H, R₄=OH, y=CH₂, in combination with R₁=OH,        R₂=OCH₃, R₅=H, R₈=H, R₇=H, x=CH₂, R₈=R₉=H, R₁₀=H    -   viii) where R₃=H, R₄=OH, y=CH₂, in combination with R₁=OH, R₂=H,        R₅=H, R₆=H, R₇=H, x=CH₂, R₈=R₉=H, R₁₀=H;    -   ix) where R₃=H, R₄=OH, y=CH₂, in combination with R₁=OH,        R₂=OCH₃, R₅=H, R₈=H, R₇=H, x=CH₂, R₈, R₉=keto, R₁₀=H    -   x) where R₃=H, R₄=OH, y=CH₂, in combination with R₁=OCH₃, R₂=H,        R₅=H, R₅=H, R₇=H, x=CH₂, R₈, R₉=keto, R₁₀=H    -   xi) where R₃=OCH₃, R₄=OH, y=bond, in combination with R₁=OCH₃,        R₂=H, R₅=H, R₆=OH, R₇=H, x=bond, R₈, R₉=keto, R₁₀=H    -   xii) where —CHR₈-x-CHR₅— is

-   -   and R₁₁=H, R₁₃=H, R₁₄=H, in combination with R₁=OCH₃, R₂=OCH₃,        R₃=OCH₃, R₄=OH, R₇=H, R₈, R₉=keto, R₁₀=H    -   xiii) where R₁=OCH₃ in combination with R₂=H, R₃=OCH₃, R₄=OH,        R₅=H, R₆=H, R₇=H, R₈=H, R₉=H, R₁₀=H, x=bond, y=bond    -   xiv) where R₁=OCH₃ in combination with R₂=OCH₃, R₃=OCH₃, R₄=OH,        R₅=H, R₆=H, R₇=H, R₈=H, R₉=H, R₁₀=H, x=bond, y=bond    -   xv) where R₁=OCH₃ in combination with R₂=OH, R₃=OCH₃, R₄=OH,        R₅=H, R₈=H, R₇=H, R₈, R₉=keto, R₁₀=H, x=bond, y=bond    -   xvi) where R₁=OCH₃ in combination with R₂=H, R₃=OCH₃, R₄=OH,        R₅=H, R₆=H, R₇=H, R₈, R₉=keto, R₁₀=H, x=bond, y=bond    -   xvii) where R₁=OCH₃, R₂=H, R₃=OH, R₄=OH, R₆=H, R₉=H    -   xviii) where R₁=OCH₃, R₂=H, R₃=OCH₃, R₄=OH, R₈=H, R₉=H    -   xix) where R₁=OCH₃, R₂=H, R₃=OH, R₄=OH, R₈, R₉=keto    -   xx) where R₁=OH, R₂=OH, R₃=OCH₃, R₄=OH, R₈, R₉=keto    -   xxi) where R₁=OCH₃, R₂=OCH₃, R₃=OH, R₄=OH, R₈, R₉=keto    -   xxii) where R₁=OCH₃, R₂=OH, R₃=OCH₃, R₄=OH, R₈, R₉=keto    -   xxiii) where R₁=OCH₃, R₂=OCH₃, R₃=OCH₃, R₄=OH, R₈=H, R₉=H

C. A compound selected from the group consisting of:9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin),9-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin,16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin,16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-27-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-rapamycin,27-O-desmethyl-39-O-desmethyl-rapamycin,9-deoxo-16-O-desmethyl-rapamycin, 9-deoxo-39-O-desmethyl-rapamycin,8-deoxo-15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin(pre-prolylrapamycin),8-deoxo-15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamycin,15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin,8-deoxo-26-desmethoxy-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-26-desmethoxy-prolylrapamycin,15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-26-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-26-O-desmethyl-prolylrapamycin,15-O-desmethyl-38-O-desmethyl-prolylrapamycin,15-O-desmethyl-26-O-desmethyl-prolylrapamycin,15-O-desmethyl-26-desmethoxy-prolylrapamycin,26-desmethoxy-38-O-desmethyl-prolylrapamycin,26-O-desmethyl-38-O-desmethyl-prolylrapamycin,8-deoxo-15-O-desmethyl-prolylrapamycin,8-deoxo-26-O-desmethyl-prolylrapamycin8-deoxo-38-O-desmethyl-prolylrapamycin, 15-O-desmethyl-prolylrapamycin,38-O-desmethyl-prolylrapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin,16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin,9-deoxo-27-desmethoxy-39-desmethoxy-rapamycin,9-deoxo-16-O-desmethyl-39-desmethoxy-rapamycin,16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin,9-deoxo-27-O-desmethyl-39-desmethoxy-rapamycin,16-O-desmethyl-39-desmethoxy-rapamycin,27-desmethoxy-39-desmethoxy-rapamycin,27-O-desmethyl-39-desmethoxy-rapamycin, 9-deoxo-39-desmethoxy-rapamycin,8-deoxo-15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin,8-deoxo-15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamycin,15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin,8-deoxo-26-desmethoxy-38-desmethoxy-prolylrapamycin,8-deoxo-15-O-desmethyl-38-desmethoxy-prolylrapamycin,15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamycin,8-deoxo-26-O-desmethyl-38-desmethoxy-prolylrapamycin,15-O-desmethyl-38-desmethoxy-prolylrapamycin,26-desmethoxy-38-desmethoxy-prolylrapamycin,26-O-desmethyl-38-desmethoxy-prolylrapamycin,8-deoxo-38-desmethoxy-prolylrapamycin, 38-desmethoxy-prolylrapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(dihydroxycyclohexyl) rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-methyl-4-hydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methylhydroxycyclohexyl) rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-fluoro-4-hydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-fluorocyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-chloro-4-hydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-chlorocyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-cis-4-cis-dihydroxycyclohexyl)rapamycin,9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-trans-4-trans-dihydroxycyclohexyl)rapamycin, 9-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethylrapamycin, 9-deoxo-16-O-desmethyl-27O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl)rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl)rapamycin,9-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methylhydroxycyclohexyl) rapamycin.

In a specific embodiment the present invention describes methods toproduce and optionally isolate the following compounds (FIG. 10, FIG.11, FIG. 12, FIG. 13, and FIGS. 14, 15, 16 and FIG. 17):

TABLE II Compound no: Name: 1.9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin (pre

rapamycin) 2.9-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin 3.16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin 4.9-deoxo-27-desmethoxy-39-O-desmethyl-rapamycin 5.9-deoxo-16-O-desmethyl-39-O-desmethyl-rapamycin 6.9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin 7.16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin 8.9-deoxo-27-O-desmethyl-39-O-desmethyl-rapamycin 9.9-deoxo-16-O-desmethyl-27-O-desmethyl-rapamycin 10.16-O-desmethyl-39-O-desmethyl-rapamycin 11.16-O-desmethyl-27-O-desmethyl-rapamycin 12.16-O-desmethyl-27-desmethoxy-rapamycin 13.27-desmethoxy-39-O-desmethyl-rapamycin 14.27-O-desmethyl-39-O-desmethyl-rapamycin 15.9-deoxo-16-O-desmethyl-rapamycin 16. 9-deoxo-27-desmethoxy-rapamycin 17.9-deoxo-27-O-desmethyl-rapamycin 18. 9-deoxo-39-O-desmethyl-rapamycin19. 9-deoxo-rapamycin 20. 16-O-desmethyl-rapamycin 21.27-O-desmethyl-rapamycin 22. 27-desmethoxy-rapamycin 23.39-O-desmethyl-rapamycin 24.8-deoxo-15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamy

(pre-prolylrapamycin) 25.8-deoxo-15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamyci

26. 15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin 27.8-deoxo-26-desmethoxy-38-O-desmethyl-prolylrapamycin 28.8-deoxo-15-O-desmethyl-38-O-desmethyl-prolylrapamycin 29.8-deoxo-15-O-desmethyl-26-desmethoxy-prolylrapamycin 30.15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamycin 31.8-deoxo-26-O-desmethyl-38-O-desmethyl-prolylrapamycin 32.8-deoxo-15-O-desmethyl-26-O-desmethyl-prolylrapamycin 33.15-O-desmethyl-38-O-desmethyl-prolylrapamycin 34.15-O-desmethyl-26-O-desmethyl-prolylrapamycin 35.15-O-desmethyl-26-desmethoxy-prolylrapamycin 36.26-desmethoxy-38-O-desmethyl-prolylrapamycin 37.26-O-desmethyl-38-O-desmethyl-prolylrapamycin 38.8-deoxo-15-O-desmethyl-prolylrapamycin 39.8-deoxo-26-desmethoxy-prolylrapamycin 40.8-deoxo-26-O-desmethyl-prolylrapamycin 41.8-deoxo-38-O-desmethyl-prolylrapamycin 42. 8-deoxo-prolylrapamycin 43.15-O-desmethyl-prolylrapamycin 44. 26-O-desmethyl-prolylrapamycin 45.26-desmethoxy-prolylrapamycin 46. 38-O-desmethyl-prolylrapamycin 47.9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin 48.9-deoxo-16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin 49.16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin 50.9-deoxo-27-desmethoxy-39-desmethoxy-rapamycin 51.9-deoxo-16-O-desmethyl-39-desmethoxy-rapamycin 52.16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin 53.9-deoxo-27-O-desmethyl-39-desmethoxy-rapamycin 54.16-O-desmethyl-39-desmethoxy-rapamycin 55.27-desmethoxy-39-desmethoxy-rapamycin 56.27-O-desmethyl-39-desmethoxy-rapamycin 57.9-deoxo-39-desmethoxy-rapamycin 58. 39-O-desmethoxy-rapamycin 59.8-deoxo-15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin 60.8-deoxo-15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamyci

61. 15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin 62.8-deoxo-26-desmethoxy-38-desmethoxy-prolylrapamycin 63.8-deoxo-15-O-desmethyl-38-desmethoxy-prolylrapamycin 64.15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamycin 65.8-deoxo-26-O-desmethyl-38-desmethoxy-prolylrapamycin 66.15-O-desmethyl-38-desmethoxy-prolylrapamycin 67.26-desmethoxy-38-desmethoxy-prolylrapamycin 68.26-O-desmethyl-38-desmethoxy-prolylrapamycin 69.8-deoxo-38-desmethoxy-prolylrapamycin 70. 38-desmethoxy-prolylrapamycin71 9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl) rapamycin 729-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(dihydroxy cyclohexyl) rapamycin 739-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl) rapamycin 749-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-methyl-4-hydroxycyclohexyl) rapamycin 759-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methyl hydroxycyclohexyl) rapamycin 769-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-fluoro-4-hydroxycyclohexyl) rapamycin 779-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-fluorocyclohexyl) rapamycin 789-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-chloro-4-hydroxycyclohexyl) rapamycin 799-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-chlorocyclohexyl) rapamycin 809-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-cis-4-cis-dihydroxycyclohexyl) rapamycin 819-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-trans-4-trans-dihydroxycyclohexyl) rapamycin 829-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl rapamycin 839-deoxo-16-O-desmethyl-27O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl) rapamycin 849-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl) rapamycin 859-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methyl hydroxycyclohexyl) rapamycin 869-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycycloheptyl) rapamycin 879-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycycloheptyl) rapamycin

indicates data missing or illegible when filed

In a further aspect, the invention provides the following novelrapamycin analogues:

TABLE III Compound no: Name: 1.9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin) 2.9-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin 3.16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin 5.9-deoxo-16-O-desmethyl-39-O-desmethyl-rapamycin 6.9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin 7.16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin 8.9-deoxo-27-O-desmethyl-39-O-desmethyl-rapamycin 9.9-deoxo-16-O-desmethyl-27-O-desmethyl-rapamycin 14.27-O-desmethyl-39-O-desmethyl-rapamycin 15.9-deoxo-16-O-desmethyl-rapamycin 18. 9-deoxo-39-O-desmethyl-rapamycin24. 8-deoxo-15-O-desmethyl-26-desmethoxy-38-O-desmethyl- prolylrapamycin(pre-prolylrapamycin) 25.8-deoxo-15-O-desmethyl-26-O-desmethyl-38-O-desmethyl- prolylrapamycin26. 15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin 27.8-deoxo-26-desmethoxy-38-O-desmethyl-prolylrapamycin 28.8-deoxo-15-O-desmethyl-38-O-desmethyl-prolylrapamycin 29.8-deoxo-15-O-desmethyl-26-desmethoxy-prolylrapamycin 30.15-O-desmethyl-26-O-desmethyl-38-O-desmethyl-prolylrapamycin 31.8-deoxo-26-O-desmethyl-38-O-desmethyl-prolylrapamycin 32.8-deoxo-15-O-desmethyl-26-O-desmethyl-prolylrapamycin 33.15-O-desmethyl-38-O-desmethyl-prolylrapamycin 34.15-O-desmethyl-26-O-desmethyl-prolylrapamycin 35.15-O-desmethyl-26-desmethoxy-prolylrapamycin 36.26-desmethoxy-38-O-desmethyl-prolylrapamycin 37.26-O-desmethyl-38-O-desmethyl-prolylrapamycin 38.8-deoxo-15-O-desmethyl-prolylrapamycin 40.8-deoxo-26-O-desmethyl-prolylrapamycin 41.8-deoxo-38-O-desmethyl-prolylrapamycin 43.15-O-desmethyl-prolylrapamycin 46. 38-O-desmethyl-prolylrapamycin 47.9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin 48.9-deoxo-16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin 49.16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin 50.9-deoxo-27-desmethoxy-39-desmethoxy-rapamycin 51.9-deoxo-16-O-desmethyl-39-desmethoxy-rapamycin 52.16-O-desmethyl-27-O-desmethyl-39-desmethoxy-rapamycin 53.9-deoxo-27-O-desmethyl-39-desmethoxy-rapamycin 5416-O-desmethyl-39-desmethoxy-rapamycin 55.27-desmethoxy-39-desmethoxy-rapamycin 56.27-O-desmethyl-39-desmethoxy-rapamycin 57.9-deoxo-39-desmethoxy-rapamycin 59.8-deoxo-15-O-desmethyl-26-desmethoxy-38-desmethoxy- prolylrapamycin 60.8-deoxo-15-O-desmethyl-26-O-desmethyl-38-desmethoxy- prolylrapamycin 61.15-O-desmethyl-26-desmethoxy-38-desmethoxy-prolylrapamycin 62.8-deoxo-26-desmethoxy-38-desmethoxy-prolylrapamycin 63.8-deoxo-15-O-desmethyl-38-desmethoxy-prolylrapamycin 64.15-O-desmethyl-26-O-desmethyl-38-desmethoxy-prolylrapamycin 65.8-deoxo-26-O-desmethyl-38-desmethoxy-prolylrapamycin 66.15-O-desmethyl-38-desmethoxy-prolylrapamycin 67.26-desmethoxy-38-desmethoxy-prolylrapamycin 68.26-O-desmethyl-38-desmethoxy-prolylrapamycin 69.8-deoxo-38-desmethoxy-prolylrapamycin 70. 38-desmethoxy-prolylrapamycin71 9-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl) rapamycin 729-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(dihydroxy cyclohexyl) rapamycin 739-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl) rapamycin 749-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-methyl-4-hydroxycyclohexyl) rapamycin 759-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methyl hydroxycyclohexyl) rapamycin 769-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-fluoro-4-hydroxycyclohexyl) rapamycin 779-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-fluorocyclohexyl) rapamycin 789-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-chloro-4-hydroxycyclohexyl) rapamycin 799-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-hydroxy-4-chlorocyclohexyl) rapamycin 809-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-cis-4-cis-dihydroxycyclohexyl) rapamycin 819-deoxo-16-O-desmethyl-27-desmethoxy-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(3-trans-4-trans-dihydroxycyclohexyl) rapamycin 829-deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl rapamycin 839-deoxo-16-O-desmethyl-27O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxycyclohexenyl) rapamycin 849-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(hydroxynorbornyl) rapamycin 859-deoxo-16-O-desmethyl-27-O-desmethyl-36-de(3-cis-methoxy-4-trans-hydroxycyclohexyl)-36-(4-methyl hydroxycyclohexyl) rapamycin

In a further aspect, the invention provides novel rapamycin analogues ofFormula II:

wherex=bond or CHR₁₁, or —CHR₆-x-CHR₅— is

y=bond or CHR₁₂

R₁=OH, OCH₃ R₂=H, OH, OCH₃

R₃=H, OH, OCH₃, alkyl-, halo-, amino-, thiol-residueR₄=H, OH, OCH₃, alkyl-, halo-, amino-, thiol-residueR₅=H, alkyl-, halo-, hydroxy-residueR₆=H, alkyl-, halo-, hydroxy-residueR₇=H, alkyl-, halo-, hydroxy-residue

R₈, R₉=O or H, H

R₁₀=H, alkyl-, halo-, hydroxy-residueR₁₁=H, alkyl-, halo-, hydroxy-residueR₁₂=H, alkyl-, halo-, hydroxy-residueR₁₃=H, alkyl-, halo-, hydroxy-residueR₁₄=H, alkyl-, halo-, hydroxy-residueAdditionally, the present invention also provides novel rapamycinanalogues of Formula III:

where:x=bond or CHR₁₁, or —CHR₆-x-CHR₆— is

R₁=OH, OCH₃ R₂=H, OH, OCH₃

R₃=H, alkyl-, halo-, hydroxy-residueR₆=H, alkyl-, halo-, hydroxy-residueR₇=H, alkyl-, halo-, hydroxy-residue

R₈, R₉=O or H,H

R₁₀=H, alkyl-, halo-, hydroxy-residueR₁₁=H, alkyl-, halo-, hydroxy-residueR₁₂=H, alkyl-, halo-, hydroxy-residueR₁₃=H, alkyl-, halo-, hydroxy-residueR₁₄=H, alkyl-, halo-, hydroxy-residue

R₁₅=

R₁₆=OH

R₁₇=H, OH, halo-, thiol-, alkyl-

The novel rapamycin analogues are useful directly, and as templates forfurther semi-synthesis or bioconversion to produce compounds useful, asimmunosuppressants, antifungal agents, anticancer agents,neuroregenerative agents or agents for the treatment of psoriasis,rheumatoid arthritis, fibrosis and other hyperproliferative diseases.

Therefore in a further aspect, the present invention provides use of theFKBP-ligand analogues generated in the manufacture of a medicament forthe treatment of cancer, the treatment of fungal infections, thetreatment of autoimmune, inflammatory, proliferative andhyperproliferative diseases or the maintenance of immunosuppression.

One skilled in the art would be able by routine experimentation todetermine the ability of these compounds to inhibit fungal growth (e.g.Baker, H., et al., 1978; NCCLS Reference method for broth dilutionantifungal susceptibility testing for yeasts: Approved standard M27-A,17 (9). 1997), and for example but without limitation using the methodsdescribed in Example 19. Additionally, one skilled in the art would beable by routine experimentation to determine the ability of thesecompounds to inhibit tumour cell growth, for example but withoutlimitation using the methods described in Example 19, (also see Dudkin,L., et al., 2001; Yu et al. 2001). In a further aspect the compounds ofthis invention are useful for inducing immunosuppression and thereforerelate to methods of therapeutically or prophylactically inducing asuppression of a human's or an animal's immune system for the treatmentor prevention of rejection of transplanted organs or tissue, thetreatment of autoimmune, inflammatory, proliferative andhyperproliferative diseases (examples include but are not inclusivelylimited to autoimmune diseases, diabetes type I, acute or chronicrejection of an organ or tissue transplant, asthma, tumours orhyperprolific disorders, psoriasis, eczema, rheumatoid arthritis,fibrosis, allergies and food related allergies). Such assays are wellknown to those of skill in the art, for example but without limitation:Immunosuppressant activity—Warner, L. M., et al., 1992, Kahan et al.(1991) & Kahan & Camardo, 2001); Allografts—Fishbein, T. M., et al.,2002, Kirchner et al. 2000; Autoimmune/Inflammatory/Asthma—Carlson, R.P. et al., 1993, Powell, N. et al., 2001; Diabetes I—Rabinovitch, A. etal., 2002; Psoriasis—Reitamo, S. et al., 2001; Rheumatoidarthritis—Foey, A., et al., 2002; Fibrosis—Zhu, J. et al., 1999, Jain,S., et al., 2001, Gregory et al. 1993

The ability of the compounds of this invention to induceimmunosuppression may be demonstrated in standard tests used for thispurpose, for example but without limitation using the methods describedin example 19. In a further aspect the compounds of this invention areuseful in relation to antifibrotic, neuroregenerative andanti-angiogenic mechanisms, one skilled in the art would be able byroutine experimentation to determine the ability of these compounds toprevent angiogenesis (e.g. Guba, M., et al., 2002). One of skill in theart would be able by routine experimentation to determine the utility ofthese compounds in stents (e.g. Morice, M. C., et al., 2002).Additionally, one of skill in the art would be able by routineexperimentation to determine the neuroregenerative ability of thesecompounds (e.g. Myckatyn, T. M., et al., 2002, Steiner at al. 1997)

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 Structure of rapamycin, the sections to the left of the linerepresent the binding domain and those to the right indicate theeffector domain.

FIG. 2 Structure of rapamycin (A), FK-506 (B), FK-520 (C) andmeridamycin (D)

FIG. 3 Plasmid map of pMG55, a double recombination vector with RpsLpositive selection and oriT for conjugation.

FIG. 4 A flow chart demonstrating the cloning strategy for the isolationof to pMAG144-16 to create MG2-10.

FIG. 5 Overview over the gene cassettes

FIG. 6 Structure of 9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethylrapamycin

FIG. 7 Structure of 9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethylprolylrapamycin

FIG. 8 Structure of 9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxyrapamycin

FIG. 9 Structure of 16-O-desmethyl-27-desmethoxy rapamycin

FIG. 10 Structures of compounds 1, 2, 4, 5, 6, 8, 9, 15, 16, 17, 18 and19

FIG. 11 Structures of compounds 3, 7, 10, 11, 12, 13, 14, 20, 21, 22 and23

FIG. 12 Structures of compounds 24, 25, 27, 28, 29, 31, 32, 38, 39, 40,41 and 42

FIG. 13 Structures of compounds 26, 30, 33, 34, 35, 36, 37, 43, 44, 45,and 46

FIG. 14 Structures of compounds 47, 48, 50, 51, 53 and 57

FIG. 15 Structures of compounds 49, 52, 54, 55, 56, and 58

FIG. 16 Structure of compounds 61, 64, 66, 67, 68, and 70

FIG. 17 Structure of compounds 59, 60, 62, 63, 65, and 69

FIG. 18 Pre-rapamycin heteronuclear multiple bond coherence HMBC

FIG. 19 Pre-rapamycin heteronuclear multiple quantum coherence HMQC

FIG. 20 Pre-rapamycin correlation spectroscopy (COSY) indicated by solidarrows, Pre-rapamycin total correlation spectroscopy (TOCSY) indicatedby dotted arrows.

FIG. 21 Corrections in the DNA sequence of rapN, the corrected sequenceis shown on top (SEQ ID NO: 1) and the published sequence (acc no:X86780, nt 91764-92978) is shown underneath (SEQ ID NO: 2).

FIG. 22 Corrections in the amino acid sequence of RapN, the correctedsequence is shown on top (SEQ ID NO: 3) and the published sequence (accno: X86780) is shown underneath (SEQ ID NO: 4).

FIG. 23 Corrections in the DNA sequence of rapM, the corrected sequenceis shown on top (SEQ ID NO: 5) and the published sequence (acc no:X86780, nt 92992-93945 complement) is shown underneath (SEQ ID NO: 6).

FIG. 24 Corrections in the amino acid sequence of RapM, the correctedsequence is shown on top (SEQ ID NO: 7) and the published sequence (accno: X86780) is shown underneath (SEQ ID NO: 8).

FIG. 25 Corrections in the DNA sequence of rapL, the corrected sequenceis shown on top (SEQ ID NO: 9), the published sequence (acc no: X86780,nt 94047-95078 complement) is shown at the bottom (SEQ ID NO: 10).

FIG. 26 Corrections in the amino acid sequence of RapL, the correctedsequence is shown at the top (SEQ ID NO: 11) and the published sequence(acc no: X86780) is shown underneath (SEQ ID NO: 12)

FIG. 27 Corrections in the DNA sequence of rapK, the corrected sequenceis shown at the top (SEQ ID NO: 13) and the published sequence (acc no:X86780, nt 95430-96434) is shown at the bottom (SEQ ID NO: 14).

FIG. 28 Corrections in the amino acid sequence of RapK, the correctedsequence is shown at the top (SEQ ID NO: 15) and the published sequence(acc no: X86780) is shown underneath (SEQ ID NO: 16).

FIG. 29 Corrections in the DNA sequence of rapJ, the corrected sequenceis shown at the top (SEQ ID NO: 17) and the published sequence (acc no:X86780, nt 96465-97625) is shown at the bottom (SEQ ID NO: 18).

FIG. 30 Corrections in the amino acid sequence of RapJ, the correctedsequence is shown at the top (SEQ ID NO: 19) and the published sequence(acc no: X86780) is shown underneath (SEQ ID NO: 20).

FIG. 31 Corrections in the DNA sequence of rapI, the corrected sequenceis shown at the top (SEQ ID NO: 21) and the published sequence (acc no:X86780, nt 97622-98404) is shown at bottom (SEQ ID NO: 22).

FIG. 32 Corrections in the amino acid sequence of RapI, the correctedsequence is shown at the top (SEQ ID NO: 23) and the published sequence(acc no: X86780) is shown underneath (SEQ ID NO: 24).

FIG. 33 Corrections in the DNA sequence of rapQ, the corrected sequenceis shown at the top (SEQ ID NO: 25) and the published sequence (acc no:X86780, nt 90798-91433) is shown at the bottom (SEQ ID NO: 26).

FIG. 34 Corrections in the amino acid sequence of RapQ, the correctedsequence is shown at the top (SEQ ID NO: 27) and the published sequence(acc no: X86780) is shown underneath (SEQ ID NO: 28).

FIG. 35 A flow chart demonstrating the cloning strategy for theisolation of pMG278-1 to create MG3.

FIG. 36 A flow chart demonstrating the cloning strategy for theisolation of pMG267-1 to create MG4.

MATERIALS AND METHODS Materials

All molecular biology enzymes and reagents were from commercial sources.D/L pipecolic acid was obtained from Sigma.

Starter Materials

Table IV summarises the sources of the acids used in the feedingexperiments described in the Examples section. For those compounds thatwere purchased details of the source are given. A brief synthetic methodis given for those starter acids that were synthesised in house. Aperson of skill in the art will appreciate that variations on themethods described are routine and are within the scope of the presentinvention.

TABLE IV Stock Acid Company number synthesis cyclohexane carboxylic acidAldrich 10,183-4 3-cis,4-trans-dihydroxycyclohexane in house bycarboxylic acid method of Lowden PhD thesis 1-cyclohexene carboxylicacid Aldrich 32,836-7 3-cyclohexene carboxylic acid Aldrich 45,375-7cycloheptane carboxylic acid Aldrich C9,850-0 methyl-2-norbornanecarboxylate Aldrich S40,932-4 2-(cis/trans)-hydroxycyclohexane U.Nottingham Syn by Dr R Goss carboxylic acid3-(cis/trans)-hydroxycyclohexane U. Nottingham Syn by Dr R Gosscarboxylic acid 4-(cis/trans)-hydroxycyclohexane U. Nottingham Syn by DrR Goss carboxylic acid 2-(cis/trans)-methylcyclohexane Aldrich 33,060-4carboxylic acid 3-(cis/trans)-methylcyclohexane Aldrich 33,061-2carboxylic acid 4-(cis/trans)-methylcyclohexane Aldrich 33,062-0carboxylic acid 3-(cis/trans)-methoxycyclohexane Aldrich 33,283-6carboxylic acid 4-(cis/trans)-methoxycyclohexane Aldrich 33,284-4carboxylic acid ethyl 4-cyclohexanone carboxylate Aldrich 32,062-5 ethyl2-cyclohexanone carboxylate Aldrich 16,699-5 4-trans-n-pentylcyclohexaneAldrich 26,160-2 carboxylic acid 2-trans-aminocyclohexane Aldrich A7331carboxylic acid 4-cis-aminocyclohexane carboxylic Aldrich 40,485-3 acid4-(cis/trans)-(aminomethyl)- Aldrich S42,955-4 cyclohexane carboxylicacid Cyclopentane carboxylic acid Aldrich C11,200-3 Cyclobutanecarboxylic acid Aldrich C9,560-9 1-methylcyclohexane carboxylic acidAldrich 14,282-4 Mixture of 3-trans-hydroxy-4-cis- in house, Method Bfluorocyclohexane carboxylic acid and 4-trans-hydroxy-3-cis-fluorocyclohexane carboxylic acid OR mixture of 3-cis-hydroxy-4-trans-fluorocyclohexane carboxylic acid and 4-cis-hydroxy-3-trans-fluorocyclohexane carboxylic acid mixture of 3-cis-hydroxy-4-trans- inhouse, Method C chlorocyclohexane carboxylic acid and4-cis-hydroxy-3-trans- chlorocyclohexane carboxylic acid Mixture of3-trans-hydroxy-4-cis- in house, Method C chlorocyclohexane carboxylicacid and 4-trans-hydroxy-3-cis- chlorocyclohexane carboxylic acid3-trans-cyclohexeneoxide carboxylic in house, Method A acid3-cis-cyclohexeneoxide carboxylic in house, Method A acid Mixture of3,4-cis- in house, Method D dihydroxycyclohexane carboxylic acid and3,4-trans- dihydroxycyclohexane carboxylic acid Cyclohexaneacetic acidAldrich C10,450-7 Cyclohexanepropionic acid Aldrich 16,1474-cis/trans-tert-butylcyclohexane Aldrich 37,493-8 carboxylic acid

Synthesis of 3-cis,4-trans-dihydroxycyclohexane carboxylic acid

Racemic 3-cis,4-trans-dihydroxycyclohexane carboxylic acid was readilyattainable from commercially available racemic 3-cyclohexene carboxylicacid. This acid was epoxidised through treatment withmeta-chloroperbenzoic acid and converted to the lactone in situ by theaddition of base (triethylamine), thus setting up the relativestereochemistries. This lactone was then hydrolysed by the action ofaqueous potassium hydroxide, and the final product purified over ionexchange resin, (see PAS Lowden Thesis 1997, Corey, E. J. and Huang, H.,1989).

Method A:

Epoxides A and B were synthesised by standard steps. Cyclohex-3-enecarboxylic acid was protected with 2-trimethylsilylethanol followingactivation with isobutylchloroformate and triethylamine. The resultantester was treated with meta-chloroperbenzoic acid and the resultantracemic mix of diastereomers separated on normal phase silica. Theepoxides were either reacted on (see below) or deprotected directly bythe treatment of trifluoroacetic acid, to liberate the respective freeacids.

Method B:

A protected epoxide was treated with anhydrous HF-pyridine to effect thering opening to produce a pair of racemic regiomers, containing F and OHin a trans arrangement (as previously demonstrated for cyclohexeneoxide). The esters were then deprotected with trifluoroacetic acid toliberate the free acids, (see Welch, J. T. and Seper, K., W., 1988)

Method C

A protected epoxide was treated with concentrated hydrochloric acidsuspended organic solvent to affect the ring opening to produce a pairof racemic regiomers, containing Cl and OH in a trans arrangement (aspreviously demonstrated for cyclohexene oxide). The esters were thendeprotected with trifluoroacetic acid to liberate the free acids, (seeChini, M., Crotti, P., et al., 1992)

Method D

cis-dihydroxylcyclocarboxylic acids were generated by treating protectedepoxides with a catalytic amount of osmium tetraoxide together with aco-oxidant. The esters were then deprotected with trifluoroacetic acidto liberate the free acids.

Bacterial Strains and Growth Conditions

Escherichia coli DH10B (GibcoBRL) was grown in 2xTY medium as describedby Sambrook at al. (1989) and E. coli ET12567 (pUB307) as described inMacNeil et al. (1992) and E. coli ET12567 (pUZ8002) as described inPaget et al. (1999) in 2xTY medium with kanamycin (25 μg/ml). Thevectors pUC18 and Litmus28 were obtained from New England Biolabs.Vector pSET152 is described in Bierman at al., (1992a). E. colitransformants were selected for with 100 μg/ml ampicillin or 50 μg/mlapramycin.

The rapamycin producer S. hygroscopicus ATCC29253 and its derivativeswere maintained on medium 1 agar plates (see below) at 26° C., andcultivated in TSBGM (Tryptic Soy Broth with 1.0% glucose and 100 mM MES,pH 6.0) as described in (Khaw et al., 1998), supplemented with 100 μg/mlapramycin when required.

Liquid cultures were grown at 25° C. in side-baffled Erlenmeyer flaskswith shaking at 300 rpm.

The streptomycin resistant mutant S. hygroscopicus MG1C was selectedusing standard procedures and maintained on medium 1 with streptomycin(50 μg/ml).

Feeding Methods:

Spore stocks of all strains were prepared after growth on medium 1,preserved in 20% w/v glycerol:10% w/v lactose in distilled water andstored at −80° C. Vegetative cultures were prepared by inoculating 100μl of frozen stock into 50 ml medium 6 in 250 ml flask. The culture wasincubated for 36 to 48 hours at 28° C., 250 rpm.

Feeding procedure: Vegetative cultures were inoculated at 0.5 ml into 7ml medium 7 in 50 ml tubes. Cultivation was carried out for 7 days, 26°C., 250 rpm. The feeding/addition of the selected carboxylic acids(“non-natural starters” or “natural starters”) were carried out at 24and 48 hours after inoculation and were fed at 1 mM or 3 mM.

Medium 1: Modified A-Medium

component Source Catalogue # g/l Corn steep powder Sigma C-8160 2.5 gYeast extract Difoc 0127-17 3 g Calcium carbonate Sigma C5929 3 g Ironsulphate Sigma F8633 0.3 g BACTO agar 20 g Wheat starch Sigma S2760 10 gWater to 1 L The media was then sterilised by autoclaving 121° C., 15min.

Medium 2 (Box et al., 1995)

component g/L Soy peptone-SL (Marcor) 10 Glucose (Sigma G-7021) 20Baker's Yeast 5 NaCl (Sigma) 2 Trace Elements ZnSO₄•7H₂O 0.05 MgSO₄•7H₂O0.125 MnSO₄•4H₂O 0.01 FeSO₄•7H₂O 0.02 Adjust pH to 7.0

Medium 3 (Wilkinson et al., 2000)

component g/L Dextrose (Sigma) 15 Glycerol•(BDH-Merck) 15 Soypeptone(Marcor-SL) 15 NaCl (Fisher) 3 CaCO₃ (Sigma) 1Medium 4 (U.S. Pat. No. 3,993,749)

Component g/L Soybean flour (Arkasoy 50) 30 Glucose (Sigma G-7021) 20Ammonium sulphate 15 KH₂PO₄ (Sigma) 5 Trace Elements ZnSO₄•7H₂O 0.05MgSO₄•7H₂O 0.125 MnSO₄•4H₂O 0.01 FeSO₄•7H₂O 0.02 Adjust pH to 6.0

Medium 5 (Box et al., 1995)

Component g/L Soybean flour (Arkasoy 50) 20 Glucose (Sigma G-7021) 20Baker's Yeast 6 K₂HPO₄ (Sigma) 2.5 KH₂PO₄ (Sigma) 2.5 NaCl (Sigma) 5Glycerol (BDH) 30 Soybean oil 10 Trace Elements ZnSO₄•7H₂O 0.05MgSO₄•7H₂O 0.125 MnSO₄•4H₂O 0.01 FeSO₄•7H₂O 0.02 Adjust pH to 6.4

Medium 6: RapV7 Seed Medium

Component Per L Soy bean flour (Nutrisoy) 5 g Dextrin (White, Prolab) 35g Corn Steep Solids (Sigma) 4 g Glucose 10 g (NH₄)₂SO₄ 2 g Lactic acid(80%) 1.6 ml CaCO₃(Sigma) 7 g Adjust pH to 7.5 with 1M NaOH.

Medium 7: MD6 Medium (Fermentation Medium)

Component Per L Soy bean flour (Nutrisoy) 30 g Corn starch (Sigma) 30 gDextrin (White, Prolab) 19 g Fructose 20 g Yeast (Allinson) 3 g CornSteep Solids (Sigma) 1 g L-Lysine 2.5 g KH₂PO₄ 2.5 g K₂HPO₄ 2.5 g(NH₄)₂SO₄ 10 g NaCl 5 g CaCO₃ (Caltec) 10 g MnCL₂ ^(×)4H₂O 10 mg MgSO₄^(×)7H₂O 2.5 mg FeSO₄ ^(×)7H₂O 120 mg ZnSO₄ ^(×)7H₂O 50 mg MES(2-morpholinoethane sulphuric acid monohydrate) 21.2 g pH is correctedto 6.0 with 1M NaOH Before sterilization 0.4 ml of Sigma α-amylase (BAN250) is added to 1 L of medium.

Medium is sterilised for 20 min at 121° C.

Medium 8: MD3 Medium (Fermentation Medium)

Component Per L Soy flour (Nutrisoy) 31.25 g White Dextrin (Prolab)18.75 g KH₂PO₄ 5 g (NH₄)₂SO₄ 1.25 g MnCl₂•4H₂O 10 mg MgSO₄•7H₂O 2.5 mgFeSO₄•7H₂O 120 mg ZnSO₄•7H₂O 50 mg SAG 417 1.2 mL pH to 6.4 with NaOHL-lysine 0.625 g Glucose (40% w/v) 50 mL

Description of Strains

All strains shared the wild type morphology, with cream vegetativemycelia, white aerial hyphae, developing grey spores turning black andcharacteristically hygroscopic.

Preferably spores for use in the generation of the recombinant strainsas described herein were dark grey in colour, as defined in Fan 4, 202 Cto B, more preferably they are as defined in Fan 4, 202 B (RoyalHorticultural Society Colour Chart 2001, available from The RoyalHorticultural Society, 80 Vincent Square, London, SW1P 2PE).

DNA Manipulation and Sequencing

DNA manipulations, PCR and electroporation procedures were carried outas described in Sambrook et al. (1989). Southern hybridisations werecarried out with probes labelled with digoxigenin using the DIG DNAlabelling kit as described by the manufacturer (Boehringer Mannheim).DNA sequencing was performed as described previously (Gaisser et al.,2000).

Fermentation of Streptomyces hygroscopicus Strains.

Streptomyces hygroscopicus strains were cultured from a frozen sporestock in cryopreservative (20% glycerol, 10% lactose w/v in distilledwater) on Medium 1 (see Materials and Methods) and spores were harvestedafter 10-20 days growth at 29° C. Alternatively, spores from frozenworking stocks were inoculated directly into pre-culture medium. Aprimary pre-culture was inoculated with the harvested spores andcultured in 250 ml Erlenmeyer flasks containing 50 ml Medium 6 (seeMaterials and Methods), shaken at 250 rpm with a two-inch throw, at 30°C., for two days. The primary pre-culture was used to inoculatesecondary pre-cultures of Medium 6 (see Materials and Methods), at 10%v/v, which was shaken at 300 rpm with a one-inch throw, at 28° C., for afurther 24 h. Secondary pre-cultures were used to inoculate, at 10% v/v,production Medium 8 (see Materials and Methods) containing 0.01% v/v SAG417 antifoam and allowed to ferment in a stirred bioreactor for five toseven days at 26° C. Airflow was set to 0.75 vvm, over pressure at 0.5bar and the impeller tip speed was controlled between 0.98 ms⁻¹ and 2.67ms⁻¹. Additional SAG 417 was added on demand. pH was controlled at 6-7with ammonium (10% v/v) or sulphuric acid (1 M) and glucose solution(40% w/v) was drip fed on initiation of ammonium demand.

Extraction and High Performance Liquid Chromatography (HPLC) AnalysisMethod (A).

Centrifugation was carried out on 50 ml of the fermentation broth andthe supernatant and the mycelium were extracted separately as follows.The mycelia were washed with H₂O and extracted with 50 ml of methanolfor 16 hours at 4° C. The cell debris was removed by centrifugation, themethanol evaporated to dryness then dissolved in 200 μl methanol. Thesupernatant of the fermentation broth was extracted twice with an equalvolume of ethyl acetate. The organic layer was dried over Na₂SO₄,evaporated to dryness and then dissolved in 200 μl methanol. HPLCanalysis was performed on a Hewlett Packard HP1100 liquid chromatographwith variable wavelength detector or a Finnigan MAT LCQ (Finnigan,Calif.) instrument. High-resolution spectra were obtained on a BrukerBioApex II 4.7 T Fourier Transform-Ion Cyclotron Resonance (FT-ICR) massspectrometer (Bruker, Bremen, FRG).

For NMR analysis, the bacterial broth was centrifuged, the supernatantextracted with three equal volumes of ethylacetate and the myceliaextracted with methanol as described above. The extracts were combined,dried (Na₂SO₄) and evaporated under reduced pressure to yield a whitesolid.

Proton detected NMR spectra (¹H, DQF-COSY, TOCSY, HMQC, HMBC, NOESY)were recorded on a Bruker Advance DRX500 spectrometer which operated at500 MHz at 27° C., with the exception of example 6, where the BrukerAdvance DRX500 spectrometer was operated at 500 MHz at 10° C. Chemicalshifts are described in parts per million (ppm) on the 8 scale and arereferenced to CHCl₃ at δ_(H) 7.26 (¹H) and CHCl₃ at δ_(C) 77.0 (¹³C). Jvalues are given in Hertz (Hz).

Extraction, Isolation and Analysis Protocols (B). Extraction andPurification Protocol:

The fermentation broth was clarified by centrifugation to providesupernatant and cells. The supernatant was applied to a column (16×15cm) of Diaion® HP20 resin (Supelco), washed with water followed by 75%MeOH/H₂O and then eluted with MeOH. The cells were mixed to homogeneitywith an equal volume of acetone. After at least 30 minutes the acetoneslurry was clarified by centrifugation and the supernatant decanted. Thepelleted cells were similarly extracted twice more with acetone. Theacetone extract was combined with the MeOH from the HP20 column and thesolvent was removed in vacuo to give an aqueous concentrate. The aqueous(typically 1-2 L) was extracted with EtOAc (3×1-2 L) and the solventremoved in vacuo to give an oily crude extract (typically 20 g). Theoily residue was dissolved in a minimal volume of EtOAc and dried ontosilica. The coated silica was applied to a silica column (400 g, 36×6cm) that was eluted sequentially with acetone/hexane mixtures rangingfrom 25% acetone initially to 100% acetone. The fractions containingrapamycin analogues were identified by HPLC (280 nm) using conditionsdescribed within.

The rapamycin analogue-containing fractions were combined and thesolvent was removed in vacuo. The residue was further chromatographedover Sephadex LH20, eluting with 10:10:1 chloroform/heptane/ethanol. Thesemipurified rapamycin analogues were purified by reverse phase (C18)high performance liquid chromatography using a Gilson HPLC, eluting aPhenomenex 21.2×250 mm Luna 5 μm C18 BDS column at 21 mL/min, isocraticelution with 50% to 70% CH₃CN/H₂O mixtures depending on the polarity ofthe rapamycin analogue.

Analysis of Culture Broths

An aliquot of whole broth (1 mL) was shaken with CH₃CN (1 mL) for 30minutes. The mixture was clarified by centrifugation and the supernatantanalysed by HPLC with diode array detection. The HPLC system comprisedan Agilent HP1100 equipped with a BDS HYPERSIL C18 3 μm 4.6×150 mmcolumn (ThermoHypersil-Keystone) heated to 40° C. The gradient elutionwas from 55% mobile phase B to 95% mobile phase B over 10 minutesfollowed by an isocratic hold at 95% mobile phase B for 2 minutes with aflow rate of 1 mL/min. Mobile phase A was 10% acetonitrile:90% water,containing 10 mM ammonium acetate and 0.1% trifluoroacetic acid, mobilephase B was 90% acetonitrile:10% water, containing 10 mM ammoniumacetate and 0.1% trifluoroacetic acid. Rapamycin analogues wereidentified by the presence of the characteristic rapamycin triene,centred on 278 nm. FK506 and FK520 analogues are identified by LC-MSanalysis.

Analysis by LCMS

The HPLC system described above was coupled to a Bruker DaltonicsEsquire3000 electrospray mass spectrometer. The same column and gradientelution scheme were used as described above. Mobile phase A was water,mobile phase B was acetonitrile. Positive negative switching was usedover a scan range of 500 to 1000 Dalton.

Example 1 Conjugation of S. hygroscopicus

The plasmid to be conjugated into S. hygroscopicus was transformed byelectroporation into the dam⁻ dcm⁻ ET12567 E. coli strain containingeither pUB307 as described in MacNeil at al. (1992) or pUZ8002 asdescribed in Paget et al. (1999). A preculture was used (over nightculture, 30° C.) to inoculate fresh 2xTY (with 50 μg/ml apramycin and 25μg/ml kanamycin) at a dilution of 1/25 and grown with shaking at 37° C.to an optical density at 595 nm of 0.25-0.6. The cells from this brothwere washed twice with 2xTY, then resuspended with 0.5 ml of 2xTY per 25ml original culture. The quality of the spore stock used is critical forthe success of this method. In this context the age of the spores whenharvested and the use of medium 1 are crucial for the isolation ofhigh-quality spore suspension. To isolate high-quality spore suspensionsof S. hygroscopicus, pre-dried plates of medium 1 agar (see Materialsand Methods section) were spread with S. hygroscopicus spores or myceliausing standard microbiological techniques followed by incubation at26°-28° C. for 14-21 days. Spores were harvested by addition of 1-2 mlof sterile 20% w/v glycerol or water by standard techniques. An aliquotof 200 μl of the S. hygroscopicus spore suspension was washed in 500 μlof 2xTY, resuspended in 500 μl of 2xTY, subjected to heat shock at 50°C. for 10 minutes then cooled on ice. An aliquot of 0.5 ml of the E.coil suspension was mixed with the heat-shocked spores and this mixtureplated on medium 1 agar plates. These plates were incubated at 26°-28°C. for 16 hours before overlaying with 1 mg of nalidixic acid and 1 mgof apramycin per plate. Exconjugant colonies usually appeared after 3-7days.

Use in S. hygroscopicus MG2-10 of an Alternative Integrating Vector,pRT801

Conjugation was also carried out using the φBT1-based integrating vectorpRT801 into S. hygroscopicus MG2-10 as described above. Exconjugantswere patched on to medium 0.1 containing 50 μg/ml apramycin and 50 μg/mlnalidixic acid, and shown to be apramycin resistant.

Example 2 Isolation of the S. hygroscopicus Mutant MG2-10 Carrying theChromosomal Deletion of rapQONMLKJI (FIG. 4)

An S. hygroscopicus mutant (MG2-10) in which the rapamycin modifyinggenes rapQ, rapO/N, rapM, rapL, rapK, rapJ and rapI were deleted wasconstructed as described below.

Isolation of the Streptomycin Resistant Mutant MG1C:

S. hygroscopicus NRRL5491 mycelia were spread onto plates of medium 1containing 50 mg/ml streptomycin. Three colonies were isolated andlabelled MG1A, MG1B and MG1C. These were conjugated as in example 1 withthe plasmid pMG49, a derivative of pSET152 containing the rpsL gene fromalividans TK24. Exconjugants from each of these conjugations werepatched onto a plate if medium 1 containing 50 mg/ml apramycin and 50mg/ml nalidixic acid, to confirm the presence of the plasmid pMG49. Theywere then streaked, along with the original strains MG1A, MG1B and MG1C,onto a both a plate of medium 1 containing no antibiotic and a plate ofmedium 1 containing 50 mg/ml streptomycin. Growth was seen in all casesexcept the streaks of MG1A [pMG49], MG1B [pMG49] and MG1C [pMG49] onstreptomycin, indicating that the w.t. rpsL gene from S. lividans TK24conferred dominant streptomycin sensitivity on these strains. Theproduction of pre-rapamycin was measured in MG1A, MG1B and MG1C and thebest producer, MG1C, was kept for further work.

Conjugation of S. hygroscopicus MG1C

Conjugations were carried out as described in example 1 using thestreptomycin resistant S. hygroscopicus MG1C and vector pMG55 derivedconstructs.

Construction of Conjugative Double Recombination Vector pMG55 (FIG. 3)

The primers MAG47 5′-GCAAGCTTGGTACCGACACGCTCGCCGAACAGG-(SEQ ID NO: 29)and MAG48 5′-GCGCATGCCCTAGGGTGTACATTACTTCTCC-3′ (SEQ ID NO: 30) wereused to amplify the S. lividans rpsL gene using the plasmid pRPSL21(Shima et al., 1996) as a template. The PCR fragment was digested withSphI and HindIII, isolated and ligated with the 3.2 kb fragment ofpSET152 (Bierman et al., 1992b), which had been digested with SphI andHindIII. After transformation into E. coli DH10B, plasmid pMG55 wasisolated. This plasmid was confirmed by sequencing. Plasmid pMG55contains the rpsL gene to allow selection for double recombinants(Hosted and Baltz, 1997).

Isolation of the S. hygroscopicus Mutant MG2-10 Carrying the ChromosomalDeletion of rapQONMLKJI (FIG. 4)

The primers MAG23 5′-TATCTAGACTTCGCACGTGCCTGGGACA-3′ (SEQ ID NO: 31) andMAG24 5′-AGAAGCTTACCCAATTCCAACATCACCT-3′ (SEQ ID NO: 32) were used toamplify the left region of homology (from nt 89298 to nt 90798 in therapamycin cluster as described in Schwecke et al. (Schwecke et al.,1995) using genomic DNA prepared from S. hygroscopicus NRRL5491 as atemplate. The 1.5 kb PCR product was digested with XbaI and HindIII andligated into pUC18 cut with XbaI and HindIII. After transformation intoE. coli DH10B, the plasmid pMAG127-8 was isolated. The primers MAG255′-GGAAGCTTTGACCACACGCCGCCCGTTC-3′ (SEQ ID NO: 33) and MAG265′-ATGCATGCCCGCCGCAACCCGCTGGCCT-3′ (SEQ ID NO: 34) were used to amplifythe right region of homology (from nt 98404 to nt 99904 in the rapamycincluster as described in Schwecke et al. (1995)) using genomic DNAprepared from S. hygroscopicus NRRL5491 as a template. The 1.5 kbproduct of PCR was digested with HindIII and SphI and ligated into pUC18cut with HindIII and SphI. After transformation into E. coli DH10B, theplasmid pMAG128-2 was isolated (FIG. 4). Both plasmids were checked bysequence analysis. The plasmid pMAG127-8 was digested with SphI andHindIII, the plasmid pMAG128-2 was digested with XbaI and HindIII andthe 1.5 kb fragments were isolated from both plasmids. These fragmentswere ligated into pUC18 cut with SphI and XbaI and used to transform E.coli DH10B. The plasmid pMAG131-1 was isolated. This plasmid wasdigested with SphI and XbaI, the 3 kb fragment was isolated and ligatedinto pMG55 cut with SphI and AvrII and the DNA was used to transform E.coli DH10B. The plasmid pMAG144-16 was isolated and used to conjugate S.hygroscopicus MG1C. An apramycin resistant S. hygroscopicus colony wasisolated, grown for 24 hours in TSBGM with shaking at 26° C., and spreadonto medium 1 agar plates containing 50 μg/l streptomycin. Streptomycinresistant colonies were isolated and shown to be apramycin sensitive.The 7606 nt chromosomal deletion of the rapQONMLKJI region of therapamycin cluster was verified in the mutant MG2-10 by using the 1.5 kbPCR product of MAG23 and MAG24 to probe EcoRI- and BamHI-digestedchromosomal DNA. Analysis of the wild type S. hygroscopicus showed theexpected 5.8 kb EcoRI and 5.9 kb BamHI band after hybridisation. Whenchromosomal DNA of MG2-10 was treated similarly, 9.6 kb EcoRI and 7.6 kbBamHI bands were detected, indicating that rapQONMLKJI had been removed.

Example 3 Expression of rapK in the S. hygroscopicus Mutant MG2-10Carrying the Chromosomal Deletion of rapQONMLKJI (FIG. 4)

Construction of Expression Vector pSGset1

The pSET152 (Bierman et at, 1992a) derived vector pCJR336 (kindlyprovided by Christine Martin and Corinne Squire) was created by cloningthe primer dimer of CR3475′-TAAACTAGTCCATCTGAGAGTTTCATATGGCCCTATTCTGCCCAGCCGCTCTAGAAAT-3′ (SEQ IDNO: 35) and CR3485′-ATTTCTAGAGCGGCTGGGCAGAATAGGGCCATATGAAACTCTCAGATGGACTAGTTTA-3′ (SEQ IDNO: 36) into PvuII digested pSET152 using standard molecular biologicaltechniques, thus introducing sites for the restriction enzymes SpeI,NdeI, and XbaI into pSET152. The orientation of the insert was confirmedby sequencing. Plasmid pCJR336 was digested using the restrictionenzymes NdeI/SpeI and vector pSG142 (Gaisser et at, 2000) was digestedidentically. The resulting DNA bands of about 5.4 kb for pCJR336 and 1.2kb for pSG142 were isolated followed by a ligation which was used totransform E. coli DH10B. The vector construct containing the actII-ORF4regulator region was isolated and digested using the restriction enzymeXbaI followed by an alkaline phosphatase treatment according to standardprotocols. The isolated DNA was ligated with a fragment of about 200 bpfrom plasmid pEXoleG2cas (pSG142 derivative containing the ca. 1.2 kbNdeI/BgIII fragment of pSGcasOleG2 (WO01/79520) digested with therestriction enzymes XbaI and NheI. Vector pSGset1 was isolated and thecorrect orientation of the insert was verified using restriction digestsand sequence analysis. Plasmid pSGset1 contains the actII-ORF4regulator, the P_(actl) promoter and the 6×His-tag coding sequence aswell as the lambda to transcriptional termination region (originatingfrom plasmid pQE-16) and it can integrate site-specifically at the φC31attachment site.

Cloning of rapK

The gene rapK was amplified by PCR using the primers BIOSG85′-GGGCATATGAGGCAATTGACTCCGCCGGTCACGGCACCGTACTGCC-3′ (SEQ ID NO: 37) andBIOSG9 5′-GGGGTCTAGAGGTCACGCCACCACACCCTCGATCTCGACC-3′ (SEQ ID NO: 38),which introduce a NdeI site at the 5′ end and a XbaI site at the 3′ endof rapK. Plasmid pR19 (Schwecke et al., 1995) was used as a template.After treatment with T4 polynucleotide kinase using standard techniquesthe PCR product was ligated with SmaI-cut pUC18 and used to transform E.coli DH10B. The DNA sequence of rapK in the isolated plasmid pUCrapK wasverified by sequence analysis. The differences in the DNA sequencecompared to the published sequence (acc. no. X86780) are shown in FIG.27. The resulting changes in RapK are shown in FIG. 28.

Isolation of pSGsetrapK

Plasmid pUCrapK was digested with NdeI and XbaI and the insert fragmentswere isolated and ligated into identically digested pSGset1. Theligation was used to transform E. coli DH10B using standard proceduresand the transformants were analysed. Plasmid pSGsetrapK, was isolatedand the construct was verified using restriction digests and sequenceanalysis.

Example 4 Identification of9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin, FIG. 6)

9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin) was obtained by conjugating the S. hygroscopicus strainMG2-10 as described in Example 1 with pSGsetrapK and isolating theproducts produced on fermentation. This demonstrates that it is possibleto complement the deletion of rapK in the MG2-10 strain and that, if thestrain is fed with pipecolic acid, pre-rapamycin is produced, ananalogue which is lacking the post-PKS modifications.

The plasmid pSGsetrapK was conjugated into S. hygroscopicus MG2-10 andthe strain grown in TSBGM fed with 2 mg/l pipecolic acid at 25° C. withshaking. The mycelia were extracted with methanol and the culture brothwas extracted with ethyl acetate as described previously.

Analysis of the culture broth of the pipecolic acid-fed S. hygroscopicusmutant MG2-10[pSGsetrapK] by HPLC with UV detection at 280 nm revealedthe presence of two major new peaks with retention times of 4.0 and 5.1minutes. Electrospray mass spectroscopy of these peaks revealed thatboth contained ions corresponding to a compound with a MW of 841.5.Neither of these peaks was seen in the culture extractions of the S.hygroscopicus NRRL 5491 strain or the mutant strain MG2-10 without therapK expression plasmid pSGsetrapK. MS/MS analysis of the ion with m/zof 864 (corresponding to the sodium adduct of pre-rapamycin) revealedthat it fragmented into an ion with m/z of 735 corresponding to the lossof m/z 129 (pipecolic acid), or an ion with m/z of 556 corresponding tothe loss of m/z 308 (C28-C42 of pre-rapamycin). This ion itselffragmented further to an ion with m/z 306, corresponding to the loss ofm/z 250 (C14 to C27 of pre-rapamycin). This fragmentation pattern wasidentical to the pattern seen for rapamycin but with the second loss ofm/z (−308) reduced by 14, corresponding to the absence of the C39O-methyl group, the third loss of m/z (−250) reduced by 44,corresponding to the absence of the C27 methoxy and C16 O-methyl groupsand the final ion (306) having a mass reduced by 14 corresponding to theabsence of the C9 ketone group. This was evidence that the compound withMW 841.5 represents9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin).

Example 5 Preparation of Gene Cassettes for Expression in S.hygroscopicus MG2-10

Gene cassettes able to direct the expression of a variety of rapamycinmodifying genes and combinations of modifying genes were constructed asdescribed below.

Cloning of rapN/O

The contiguous genes rapN and rapO, hereafter designated rapN/O wereamplified by PCR using the primers BIOSG25′-GGGCATATGTCGACGACCGATCAGGGTGAGACCGGAAAGGCCTG-3′ (SEQ ID NO: 39) andBIOSG3 5′-GGGGTCTAGAGGTCAGTCCTGGGGTTCGAGAAGCTCGCCGGTCTCCTT-3′ (SEQ IDNO: 40), which introduce a NdeI site at the 5′ end and a XbaI site atthe 3′ end of rapN/O. Plasmid pR19 (Schwecke et al., 1995) was used as atemplate. After treatment with T4 polynucleotide kinase using standardtechniques the PCR product was ligated into SmaI-cut pUC18 and used totransform E. coil DH10B. The DNA sequence of rapN/O in the isolatedplasmid pUCrapN/O was verified by sequence analysis. The differences inthe DNA sequence compared to the published sequence (acc. no. X86780)are shown in FIG. 21. The resulting changes in RapN are shown in FIG.22.

Cloning of rapM

The gene rapM was amplified by PCR using the primers BIOSG45′-GGGCATATGATCCAACCCGACGTCGTGACCGCCTTCACAGCGG-3′ (SEQ ID NO: 41) andBIOSG5 5′-GGGGTCTAGAGGTCACACGCGGACGGCGATCTGGTGCCGATAGG-3′ (SEQ ID NO:42), which introduce a NdeI site at the 5′ end and a XbaI site at the 3′end of rapM. Plasmid pR19 (Schwecke et al., 1995) was used as atemplate. After treatment with T4 polynucleotide kinase using standardtechniques the PCR product was ligated into SmaI-cut pUC18 and used totransform E. coli DH10B. The DNA sequence of rapM in the isolatedplasmid pUCrapM was verified by sequence analysis. The differences inthe DNA sequence compared to the published sequence (acc. no. X86780)are shown in FIG. 23. The resulting changes in RapM are shown in FIG.24.

Cloning of rapL

The gene rapL was amplified by PCR using the primers BIOSG65′-GGGCATATGCAGACCAAGGTTCTGTGCCAGCGTGACATCAAG-3′ (SEQ ID NO: 43) andBIOSG7 5′-GGGGTCTAGAGGTCACTACAGCGAGTACGGATCGAGGACGTCCTCGGGCG-3′ (SEQ IDNO: 44), which introduce a NdeI site at the 5′ end and a XbaI site atthe 3′ end of rapL. Plasmid pR19 (Schwecke et al., 1995) was used as atemplate. After treatment with T4 polynucleotide kinase using standardtechniques the PCR product was ligated into SmaI-cut pUC18 and used totransform E. coli DH10B. The DNA sequence of rapL in the isolatedplasmid pUCrapL was verified by sequence analysis. The differences inthe DNA sequence compared to the published sequence (acc. no. X86780)are shown in FIG. 25. The resulting changes in RapL are shown in FIG.26.

Cloning of rapL_(his)

The gene rapL was amplified by PCR using the primers BIOSG65′-GGGCATATGCAGACCAAGGTTCTGTGCCAGCGTGACATCAAG-3′ (SEQ ID NO: 43) andBIOSG45 5′-GGAGATCTCAGCGAGTACGGATCGAGGACGTCCTCGGGCG-3′ (SEQ ID NO: 45),which introduce a NdeI site at the 5′ end and a BgIII site at the 3′ endof rapL. Plasmid pR19 (Schwecke et al., 1995) was used as a template.After treatment with T4 polynucleotide kinase using standard techniquesthe PCR product was ligated into SmaI-cut pUC19 and used to transform E.coli DH10B. The DNA sequence of rapL in the isolated plasmidpUC19rapL_(his) was verified by sequence analysis.

Cloning of rapK

The gene rapK was amplified by PCR using the primers BIOSG85′-GGGCATATGAGGCAATTGACTCCGCCGGTCACGGCACCGTACTGCC-3′ (SEQ ID NO: 37) andBIOSG9 5′-GGGGTCTAGAGGTCACGCCACCACACCCTCGATCTCGACC-3′ (SEQ ID NO: 38),which introduce a NdeI site at the 5′ end and a XbaI site at the 3′ endof rapK. Plasmid-pR19 (Schwecke et al., 1995) was used as a template.After treatment with T4 polynucleotide kinase using standard techniquesthe PCR product was ligated with SmaI-cut pUC18 and used to transform E.coli DH10B. The DNA sequence of rapK in the isolated plasmid pUCrapK wasverified by sequence analysis. The differences in the DNA sequencecompared to the published sequence (acc. no. X86780) are shown in FIG.27. The resulting changes in RapK are shown FIG. 28.

Isolation of pSGsetrpaN/O, pSGsetrapJ, pSGsetrapM, pSGsetrapQ,pSGsetrapI, pSGsetrapK, and pSGsetrapL

Plasmids pUCrapN/O, pUCrapJ, pUCrapM, pUCrapI, pUCrapL, pUCrapK andpAHL42 were digested with NdeI and XbaI and the insert fragments,ranging in size from about 1.3 kb to 0.7 kb, were isolated and ligatedinto identically digested pSGset1. The ligations were used to transformE. coli DH10B using standard procedures and the transformants wereanalysed. Plasmids pSGsetrapN/O, pSGsetrapJ, pSGsetrapM, pSGsetrapQ,pSGsetrapI, pSGsetrapK, and pSGsetrapL were isolated and the constructswere verified using restriction digests and sequence analysis.

Cloning of rapJ

The gene rapJ was amplified by PCR using the primers BIOSG105′-GGGCATATGAGCACCGAAGCTCAGCAAGAGAGCACGCCCACCGCACGCT-3′ (SEQ ID NO: 46)and BIOSG11 5′-GGGGTCTAGAGGTCACTCCGCTCCCCAGGTGACCCGGAGCTCGGC-3′ (SEQ IDNO: 47), which introduce a NdeI site at the 5′ end and a XbaI site atthe 3′ end of rapJ. Plasmid pR19 (Schwecke et al., 1995) was used as atemplate. After treatment with T4 polynucleotide kinase using standardtechniques the PCR product was ligated with SmaI-cut pUC18 and used totransform E. coli DH10B. The DNA sequence of rapJ in the isolatedplasmid pUCrapJ was verified by sequence analysis. The differences inthe DNA sequence compared to the published sequence (acc. no. X86780)are shown in FIG. 29. The resulting changes in RapJ are shown in FIG.30.

Cloning of rapI

The gene rapI was amplified by PCR using the primers BIOSG125′-GGGCATATGAGCGCGTCCGTGCAGACCATCAAGCTGCC-3′ (SEQ ID NO: 48) and BIOSG135′-GGGGTCTAGAGGTCAGGCGTCCCCGCGGCGGGCGACGACCT-3′ (SEQ ID NO: 49), whichintroduce a NdeI site at the 5′ end and a XbaI site at the 3′ end ofrapI. Plasmid pAHL2 (kindly provided by Huai-Lo Lee) is derived frompUC18 containing the rapI gene and was used as a template. Aftertreatment with T4 polynucleotide kinase using standard techniques thePCR product was ligated with SmaI-cut pUC18 and used to transform E.coli DH10B. The DNA sequence of rapt in the isolated plasmid pUCrapI wasverified by sequence analysis. The differences in the DNA sequencecompared to the published sequence (acc. no. X86780) are shown in FIG.31. The resulting changes in RapI are shown in FIG. 32.

Cloning of rapQ

The gene rapQ was amplified by PCR using the primers AHL215′-CATATGTTGGAATTGGGTACCCGCCTG-3′ (SEQ ID NO: 50) and AHL225′-TCTAGACGCTCACGCCTCCAGGGTG-3′ (SEQ ID NO: 51), which introduce a NdeIsite at the 5′ end and a XbaI site at the 3′ end of rapQ. Plasmid pR19(Schwecke et al., 1995) was used as a template. After treatment with T4polynucleotide kinase using standard techniques the PCR product wasligated with SmaI-cut pUC18 and used to transform E. coli DH10B. The DNAsequence of rapQ in the isolated plasmid pAHL42 was verified by sequenceanalysis. The differences in the DNA sequence compared to the publishedsequence (acc. no. X86780) are shown in FIG. 33. The resulting changesin RapQ are shown in FIG. 34.

Isolation of pUC18eryBVcas

The gene eryBV was amplified by PCR using the primers casOleG21(WO01/79520) and 7966 5′-GGGGAATTCAGATCTGGTCTAGAGGTCAGCCGGCGTGGCGGCGCGTGAGTTCCTCCAGTCGCGGGACGATCT-3′ (SEQ ID NO: 52) and pSG142 (Gaisser et al.,2000) as template. The PCR fragment was cloned using standard proceduresand plasmid pUC18eryBVcas was isolated with an NdeI site overlapping thestart codon of eryBV and an XbaI and BgIII site following the stopcodon. The construct was verified by sequence analysis.

Isolation of vector pSGLit1

The gene eryBV was amplified by PCR using the primers BIOSG15′-GGGTCTAGATCCGGACGMCGCATCGATTAATTAAGGAGGACACATA-3′ (SEQ ID NO: 53) and7966 5′-GGGGAATTCAGATCTGGTCTAGAGGTCAGCCGGCGTGGCGGCGCGTGAGTTCCTCCAGTCGCGGGACGATCT-3′ (SEQ ID NO: 52), which introduce a XbaI sitesensitive to Dam methylation at the 5′ end and a XbaI site and a BgIIIsite at 3′ end of eryBV. Plasmid pUC18eryBVcas was used as a template.After treatment with T4 polynudeotide kinase using standard techniquesthe PCR product was ligated with SmaI-cut pUC18 and used to transform E.coli DH10B. The construct was then digested using BamHI/BgIII and anabout 1.3 kb DNA band was isolated from an agarose gel followed by theligation with BamHI/BgIII digested Litmus 28 vector DNA using standardprocedures. The vector pSGLit1 was isolated and the DNA sequence of theinsert was verified by sequence analysis.

Isolation of pSGsetrpaN/O, pSGsetrapJ, pSGsetrapM, pSGsetrapQ,pSGsetrapI, pSGsetrapK, and pSGsetrapL

Plasmids pUCrapN/O, pUCrapJ, pUCrapM, pUCrapI, pUCrapL, pUCrapK andpAHL42 were digested with NdeI and XbaI and the insert fragments rangingin size from about 1.3 kb to 0.7 kb were isolated and ligated intoidentically digested pSGset1. The ligations were used to transform E.coli DH10B using standard procedures and the transformants wereanalysed. Plasmids pSGsetrapN/O, pSGsetrapJ, pSGsetrapM, pSGsetrapQ,pSGsetrapI, pSGsetrapK, and pSGsetrapL were isolated and the constructswere verified using restriction digests and sequence analysis.

Isolation of pSGLitrapN/O, pSGLitrapJ, pSGLitrapM, pSGLitrapQ,pSGLitrapI, pSGLitrapK, pSGLitrapL and pSGLitrapL_(his)

Plasmids pSGsetrpaN/O, pSGsetrapJ, pSGsetrapM, pSGsetrapQ, pSGsetrapI,pSGsetrapK, pSGsetrapL, and pUC19rapL_(his) were digested usingNdeI/BglII restriction enzymes and the bands ranging from about 0.7 to1.3 kb were isolated followed by ligations with pSGLit1 digested withNdeI/BgIII. The ligations were used to transform E. coli ET12567 and thetransformants were analysed. Plasmids pSGLitrapN/O, pSGLitrapJ,pSGLitrapM, pSGLitrapQ, pSGLitrapI, pSGLitrapK, pSGLitrapL andpSGLitrapL_(his) were isolated.

Isolation of plasmids pSGsetrapKI, pSGsetrapKM, pSGsetrapKN/O,pSGsetrapKL, pSGsetrapKQ and pSGrapKJ

The plasmids pSGLitrapN/O, pSGLitrapJ, pSGLitrapM, pSGLitrapQ,pSGLitrapI, and pSGLitrapL were digested using XbaI and the fragmentsranging from about 0.8 to 1.3 kb were isolated followed by ligationswith pSGsetrapK digested with XbaI and treated with alkaline phosphataseusing standard molecular biological techniques. The ligations were usedto transform E. coli DH10B and the transformants were analysed. PlasmidspSGsetrapKI, pSGsetrapKM, pSGsetrapKN/O, pSGsetrapKL, pSGsetrapKQ andpSGrapKJ were isolated and the orientation of the insert was verified byrestriction digest analysis. For the addition of rapL_(his) theseconstructs were either digested with BgIII/XbaI followed by partialdigest with BgIII as appropriate and the isolated vector fragments wereligated with the ˜1 kb XbaI/BgIII fragment of pSGLitrapL_(his).

Isolation of plasmids pSGsetrapKIJ, pSGsetrapKIM and pSGsetrapKIQ

The plasmids pSGLitrapJ, pSGLitrapM, and pSGLitrapQ were digested usingXbaI and the fragments ranging from about 0.8 to 1.3 were isolatedfollowed by ligations with pSGsetrapKI digested with XbaI and treatedwith alkaline phosphatase using standard molecular biologicaltechniques. The ligations were used to transform E. coif DH10B and thetransformants were analysed. Plasmids pSGsetrapKIJ, pSGsetrapKIM, andpSGrapKIQ were isolated and the orientation of the insert was verifiedby restriction digest analysis. For the addition of rapL_(his) theseconstructs were either digested with BgIII/XbaI followed by partialdigest with BgIII as appropriate and the isolated vector fragments wereligated with the ˜1 kb XbaI/BgIII fragment of pSGLitrapL_(his).

Isolation of plasmids pSGsetrapKN/OI, pSGsetrapKN/OQ, pSGsetrapKN/OM andpSGsetrapKN/OJ

The plasmids pSGLitrapI, pSGLitrapM, pSGLitrapJ, and pSGLitrapQ weredigested using XbaI and the fragments ranging from about 0.8 to 1.3 wereisolated followed by ligations with pSGsetrapKN/O digested with XbaI andtreated with alkaline phosphatase using standard molecular biologicaltechniques. The ligations were used to transform E. coli DH10B and thetransformants were analysed. Plasmids pSGsetrapKN/OI, pSGsetrapKN/OQ,pSGsetrapKN/OM and pSGrapKN/OJ were isolated and the orientation of theinsert was verified by restriction digest analysis. For the addition ofrapL_(his) these constructs were either digested with BgIII/XbaIfollowed by partial digest with BgIII as appropriate and the isolatedvector fragments were ligated with the ˜1 kb XbaI/BgIII fragment ofpSGLitrapL_(his).

Isolation of plasmids pSGsetrapKIM and pSGsetrapKJQ

The plasmids pSGLitrapM and pSGLitrapQ were digested using XbaI and thefragments ranging from about 0.8 to 1.1 were isolated followed by aligation with pSGsetrapKJ digested with XbaI and treated with alkalinephosphatase using standard molecular biological techniques. Theligations were used to transform E. coli DH10B and the transformantswere analysed. Plasmids pSGsetrapKJM and pSGrapKJQ were isolated and theorientation of the insert was verified by restriction digest analysis.For the addition of rapL_(his) these constructs were either digestedwith BgIII/XbaI followed by partial digest with BgIII as appropriate andthe isolated vector fragments were ligated with the ˜1 kb XbaI/BgIIIfragment of pSGLitrapL_(his).

Using the same strategy outlined above, the following gene cassetteswere isolated:

pSGsetrapKIJM pSGsetrapKN/OJI pSGsetrapKIQN/OM pSGsetrapKIJQpSGsetrapKJMN/O pSGsetrapKJMN/OQ pSGsetrapKIJN/O pSGsetrapKJQN/OpSGsetrapKIJN/OMQ pSGsetrapKIMN/O pSGsetrapKIJN/OM pSGsetrapN/OQpSGsetrapKIQN/O pSGsetrapKIJN/OQ pSGsetrapKIJMN/OQ pSGsetrapKN/OMQpSGsetrapKIMN/OQ

An overview is given in FIG. 5.

For the addition of rapL_(his) these cassette constructs were eitherdigested with BgIII/XbaI or with XbaI followed by partial digest withBgIII as appropriate and the isolated vector fragments were ligated withthe about 1 kb XbaI/BgIII fragment of pSGLitrapL_(his).

Example 6 isolation of9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin, FIG. 6)

9-Deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin) was obtained by conjugating the S. hygroscopicus strainMG2-10 with pSGsetrapKL and isolating the products generated asdescribed below. This demonstrates that it is possible to complement thedeletion of rapK and rapL in the MG2-10 strain and that pre-rapamycin isproduced, an analogue which is lacking post-PKS modification. Thefeeding of pipecolic acid is not required when rapL is complementedconfirming that rapL plays a role in the provision of pipecolic acid inthe production of rapamycin.

S. hygroscopicus MG2-10[pSGsetrapKL] was cultured from a frozen workingspore stock in cryopreservative (20% glycerol, 10% lactose w/v indistilled water) on Medium 1 (see Materials and Methods) and spores wereharvested after 14 days growth at 29° C. A primary pre-culture wasinoculated with the harvested spores and cultured in two 250 mlErlenmeyer flasks containing 50 ml Medium 3 (see Materials and Methods),shaken at 250 rpm with a two-inch throw, at 30° C., for two days. Theprimary pre-culture was used to inoculate two secondary pre-cultures ofMedium 2 (see Materials and Methods) and Medium 3, at 10% v/v, which wasshaken at 300 rpm with a one-inch throw, at 25° C., for a further 24 h.Four litres of Medium 4 (see Materials and Methods) and Medium 5 (seeMaterials and Methods) were prepared containing 0.01% v/v Pluronic L101antifoam (BASF). Production Medium 4 was inoculated with the secondarypre-culture in Medium 2 and Production Medium 5 was inoculated with thesecondary pre-culture in Medium 3 at 10% v/v and allowed to ferment in a7 L stirred bioreactor for five to seven days at 25° C. Airflow was setto 0.75 vvm and the impeller tip speed was controlled between 0.98 meand 2.67 me. Additional Pluronic L101 was added on demand.

To confirm the structure of9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin(pre-rapamycin), broths from Medium 4 and Medium 5 were extracted withethyl acetate and reduced to a crude extract by evaporation. Theextracts were defatted on partition with hexane:methanol:water andflashed through a 70 g silica cartridge starting with hexane andfinishing with acetone. Pre-rapamycin fractions from each fermentationwere pooled and flashed through a C18 cartridge starting with water andfinishing with methanol. Pre-rapamycin (8.5 mg) was isolated afterchromatography on Sephadex LH₂₀ using heptane:chloroform:ethanol as themobile phase. This compound was analysed and the structure fullyconfirmed by NMR (FIG. 18-20). The ¹H and ¹³C NMR data are given inTable V below.

TABLE V ¹H and ¹³C NMR data for pre-rapamycin Position δ_(H)multiplicity coupling δ_(C)  1 171.8  2 5.49 52.7  3a 1.76 25.9  3b 2.21 4a 1.21 20.9  4b 1.75  5a 1.47 25.0  5b 1.74  6a 3.27 45.1  6b 3.87 br.d 12.8  8 171.6  9a 2.46 d 12.8 41.4  9b 3.23 d 12.8 10 98.9 11 1.6038.1 12a 1.52 27.6 12b 1.65^(†) 13a 1.38 31.6 13b 1.53 14 4.00 71.5 15a1.48 40.6 15b 1.70 16 3.95 br. d 8.1 75.5 17 139.2 18 6.39 122.6 19 6.33128.1 20 6.17 dd 14.3, 10.7 131.4 21 6.04 130.9 22 5.26 138.1 23 2.2137.2 24a 1.26 39.8 24b 1.64 25 2.30 45.8 26 215.3 27a 2.42 dd 15.1, 4.744.8 27b 2.89 dd 15.1, 5.8 28 4.32 dd 5.5, 4.9 71.4 29 138.6 30 5.26123.7 31 3.20 45.5 32 208.2 33a 2.58 dd 18.1, 4.3 41.5 33b 2.78 dd 18.1,9.6 34 5.18 76.0 35 1.72 31.9 36a 1.00 37.3 36b 1.07 37 1.30 33.1 38aAx. 0.62 ddd 11.9, 11.9, 38.2 11.9 38b eq. 1.83 39 3.24 74.9 40 3.2575.9 41a 1.28 31.5 41b 1.94 42a 0.98 32.2 42b 1.61 43 0.98 d 6.6 16.5 441.61 s 14.1 45 1.04 d 6.8 21.3 46 0.95 d 6.8 15.2 47 1.66 d 0.9 14.1 480.99 d 6.8 15.7 49 0.89 d 6.6 17.4 ^(†) Assignment tentative

Example 7 Isolation of8-deoxo-15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin(pre-prolylrapamycin, FIG. 7)

Feeding of S. hygroscopicus MG2-10[pSEGrapK] with proline acid resultedin the production pre-prolylrapamycin as described below. Thisdemonstrated that in the absence of rapL alternative pipecolic acidanalogues are incorporated.

S. hygroscopicus MG2-10[pSGsetrapK] was grown in TSBGM fed with 1 mg/lproline at 25° C. with shaking. The mycelia were extracted with methanoland the culture broth was extracted with ethyl acetate as describedpreviously.

Analysis of the culture broth of the proline-fed S. hygroscopicus mutantMG2-10[pSGsetrapK] by HPLC with UV detection at 280 nm revealed thepresence of two major new peaks with retention times of 4.5 and 4.6minutes. Electrospray mass spectroscopy of these peaks revealed thatboth contained ions corresponding to a compound with a MW of 827.5.Neither of these peaks were seen in the cultures of S. hygroscopicusNRRL 5491, S. hygroscopicus MG1C or S. hygroscopicus MG2-10 without therapK expression plasmid pSGsetrapK. MS/MS analysis of the ion with m/zof 850 (corresponding to the sodium adduct of pre-prolylrapamycin)revealed that it fragmented into an ion with m/z of 735 corresponding tothe loss of m/z 115 (proline), or an ion with m/z of 542 correspondingto the loss of m/z 308 (C27-C41 of pre-prolylrapamycin). This ion itselffragmented further to an ion with m/z 292, corresponding to the loss ofm/z 250 (C13 to C26 of pre-prolylrapamycin). This fragmentation patternwas identical to the pattern seen for rapamycin but with the first lossof m/z (−115) reduced by 14 corresponding to the change from pipecolicacid to proline for the amino acid, the second loss of m/z (−308)reduced by 14, corresponding to the absence of the C38 O-methyl group,the third loss of m/z (−250) reduced by 44, corresponding to the absenceof the C26 methoxy and C15 O-methyl groups and the final ion (306)having a mass reduced by 14 corresponding to the absence of the C8ketone group and the change from pipecolic acid to proline. This wasevidence that the compound with MW of 827.5 represents8-deoxo-15-O-desmethyl-26-desmethoxy-38-O-desmethyl-prolylrapamycin(pre-prolylrapamycin).

Example 8 Isolation of9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin(39-dehydroxy pre-rapamycin, FIG. 8)

Feeding of S. hygroscopicus MG2-10[pSGsetrapK] with pipecolic acid andcyclohexane carboxylic acid resulted in the production of two majorcompounds, pre-rapamycin which corresponds to the incorporation of thenatural starter unit and 39-dehydroxy pre-rapamycin, which correspondsto the incorporation of the fed starter unit.

S. hygroscopicus MG2-10[pSGsetrapK] was grown in TSBGM fed with 2 mg/lpipecolic acid and 1 mM cyclohexane carboxylic acid at 25° C. withshaking. The culture broth was extracted with ethyl acetate as describedpreviously.

Analysis of the culture broth of the cyclohexane carboxylic acid-fed S.hygroscopicus mutant MG2-10[pSGsetrapK] by HPLC with UV detection at 280nm revealed the presence of one major new peak with a retention time of5.8 minutes. Electrospray mass spectroscopy of this peak revealed thatit contained ions corresponding to a compound with a MW of 825.5. Thispeak was not seen in the cultures of S. hygroscopicus NRRL5491, S.hygroscopicus MG1C or S. hygroscopicus MG2-10 without the rapKexpression plasmid pSGsetrapK. MS/MS analysis of the ion with m/z of 848(corresponding to the sodium adduct of 39-dehydroxy pre-rapamycin)revealed that it fragmented into an ion with m/z of 719 corresponding tothe loss of m/z 129 (pipecolic acid), or an ion with m/z of 556corresponding to the loss of m/z 292 (C28-C42 of 39-dehydroxypre-rapamycin). This ion itself fragmented further to an ion with m/z306, corresponding to the loss of m/z 250 (C14 to C27 of 39-dehydroxypre-rapamycin). This fragmentation pattern was identical to the patternseen for pre-rapamycin but with the second loss of m/z (−292) reduced by16, corresponding to the absence of the C39 hydroxy group. This wasevidence that the compound with MW 825.5 represents9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin(39-dehydroxy-pre-rapamycin).

Example 9 Isolation of 16-O-desmethyl-27-desmethoxy-rapamycin (FIG. 9)

The S. hygroscopicus strain MG2-10 was conjugated with pSGsetrapKIJ asdescribed in Example 1. Feeding of this strain with pipecolic acid andisolation of the products produced on fermentation resulted in theproduction of 16-O-desmethyl-27-desmethoxy-rapamycin.

The plasmid pSGsetrapKIJ (FIG. 5) was conjugated into S. hygroscopicusMG2-10 and the strain grown in TSB GM fed with 2 mg/l pipecolic acid at25° C. with shaking. The mycelia were extracted with methanol and theculture broth extracted with ethyl acetate as described previously.

Analysis of the extracts of the S. hygroscopicus mutantMG2-10[pSGsetrapKIJ] by electrospray mass spectroscopy revealed onemajor new peak of retention time 4.3 minutes which contained ionscorresponding to a compound with a MW of 869. This peak was not seen inthe cultures of S. hygroscopicus NRRL 5491, S. hygroscopicus MG1C S.hygroscopicus MG2-10 with or without the rapK expression plasmidpSGsetrapK. MS/MS analysis of the ion with m/z of 892 (corresponding tothe sodium adduct of 16-O-desmethyl-27-desmethoxy-rapamycin) revealedthat it fragmented into an ion with m/z of 763 corresponding to the lossof m/z 129 (pipecolic acid), or an ion with m/z of 570 corresponding tothe loss of m/z 322 (C28-C42 of 16-O-desmethyl-27-desmethoxy-rapamycin).This ion itself fragmented further to an ion with m/z 320, correspondingto the loss of m/z 250 (C14 to C27 of16-O-desmethyl-27-desmethoxy-rapamycin). This fragmentation pattern wasidentical to the pattern seen for rapamycin but with the third loss ofm/z (−250) reduced by 44, corresponding to the absence of the C16 methyland C27 methoxy groups. This was evidence that the compound with MW 869was 16-O-desmethyl-27-desmethoxy-rapamycin.

Example 10 Array Feeding

S. hygroscopicus MG2-10[pSGsetrapKI] was used to carry out an arrayfeeding. Primary vegetative cultures were prepared by innocculatingmedium with spore stock as described in the Materials and Methods. TSBGM medium was inoculated at 10% v/v using methods described in thematerials and methods section. The following compounds were added asindicated in Table VI below

TABLE VI cyclohexane cyclohex-1-ene cycloheptane carboxylic acidcarboxylic acid carboxylic acid (1 mM) (1 mM) (1 mM) L-lysine (25.3 mM)X X X L-proline (44.7 mM) X X X DL-pipecolinic acid X X X (39.8 mM)trans-4-hydroxy X X X proline (13 mM) cis-4-hydroxy proline X X X (0.2mM)

The cultures were incubated, extracted and measured using techniquesdescribed in the Material and Method section. Table VII shows theresults of the analysis showing the ion (m/z) observed for eachcombination of starter carboxylic acid and amino acid:

TABLE VII cyclohexane cyclohex-1-ene cycloheptane carboxylic acidcarboxylic acid carboxylic acid L-lysine 848.5 848.5 862.4 L-proline834.5 834.5 848.5 DL-pipecolinic acid 848.5 848.5 862.4 trans-4-hydroxy850.5 850.5 864.5 proline cis-4-hydroxy proline 850.5 n.a. 864.5

These data demonstrate incorporation of the fed compounds.

Example 11 Complementation of S. hygroscopicus MG2-10 with fkbO

To assess whether rapK homologous genes such as fkbO in S. hygroscopicusvar. ascomyceticus and S. tsukubaensis, and orf5 in the partiallysequenced ‘hyg’ cluster (Ruan et al., 1997) fulfil similar functions,complementation assays were carried out using fkbO as described below.

Isolation of pMG169-1

The gene fkbO from Strepomyces hygroscopicus var. ascomyceticus (ATCC14891), an FK520 producer, was amplified by PCR using the primers fkbof5′-GGGCATATGACCGATGCCGGACGCCA 3′ (SEQ ID NO: 54) and fkbor 5′GGGGTCTAGATCACGCCACCATGCCTTCGA 3′ (SEQ ID NO: 55), introducing a NdeIsite at the 5′ end and a XbaI site at the 3′ end of fkbO. Genomic DNAisolated from S. hygroscopicus var. ascomyceticus (ATCC 14891) was usedas a template. The amplified PCR product was subjected to digestion withNdeI and XbaI and ligated with NdeI XbaI cut pSGsetI. The ligation wasused to transform E. coli DH10B and the transformants were analysedusing methods described in the Materials and Methods section. PlasmidpMG169-1 was isolated and verified by restriction digestion and S.hygroscopicus MG2-10 was transformed using methods described in theMaterials and Methods section.

Heterologous Complementation of rapK by fkbO

S. hygroscopicus MG2-10[pMG169-1] was grown in TSBGM fed with 2 mg/lpipecolic acid at 25° C. with shaking. The culture broth and myceliawere extracted using methods described in the Materials and Methodssection (Method A). Analysis of the extract with UV detection at 280 nmrevealed the presence of two major new peaks with retention times of 4.5and 4.6 minutes. Electrospray mass spectroscopy of these peaks revealedthat both contained ions with a MW of 827.5 corresponding to two isomersof pre-rapamycin (Example 7).

Example 12 Efficient Production of9-Deoxo-16-O-Desmethyl-27-Desmethoxy-39-Desmethoxy-Rapamycin(39-Dehyroxy Pre-Rapamycin, FIG. 8) in the Absence of Competition byEndogenous Starter Unit by Feeding to a rapK Knockout Mutant

The ability of S. hygroscopicus strains MG2-10 and MG2-10[pSGsetrapK] toincorporate a different starter unit, cyclohexane carboxylic acid, wascompared as described below. When fed cyclohexane carboxylic acid andpipecolic acid MG2:10 produced only one compound (39-dehydroxypre-rapamycin) corresponding to incorporation of the fed starter unitonly, whereas MG2-10[pSGsetrapK] produced two compounds in a 1:1 ratio,39-dehydroxy pre-rapamycin and pre-rapamycin. This demonstrated thatrapK is required for the incorporation of the natural endogenous starterunit and a rapK knock-out strain had no competition of the endogenousstarter unit with the fed starter unit.

S. hygroscopicus MG2-10 was grown on TSBGM fed with 2 mg/L pipecolicacid and 1 mM cyclohexane carboxylic acid at 25° C. with shaking. Theculture broth was extracted with ethyl acetate as described previously.Analysis of the extracts by HPLC with UV detection at 280 nm revealedthe presence of one new major peak with a retention time of 5.8 min.However, S. hygroscopicus MG2-10[pSGsetrapK] (Example 4), producedpre-rapamycin (FIG. 6) in addition to 39-dehydroxy pre-rapamycin in aratio of ˜1:1 when fed with cyclohexane carboxylic acid (Example 8, FIG.8). Surprisingly, feeding of cyclohexane carboxylic acid to S.hygroscopicus MG2-10 resulted in a single product, 39-dehydroxypre-rapamycin. The endogenous starter, 4,5-dihydroxycyclohex-1-enecarboxylic acid, was not incorporated in the absence of rapK. There wastherefore no competition between the incorporation of the fed carboxylicacid and the endogenous starter.

Example 13 Elucidation of the Function of RapM

Cultures of Streptomyces lividans TK24, S. lividans TK24[pSGsetrapM] andS. lividans TK24[pSGsetrapQ] were grown in TSBGM with shaking at 30° C.and fed with 20 μg/ml of pre-rapamycin. Controls remained unfed. After afurther 5 days incubation, the cultures were extracted with ethylacetateand brought to dryness. Reconstitution and analysis by LC-MS identifiedno production of rapamycin analogues in the unfed controls. Two majornew peaks were identified in the extract of S. lividans TK24[pSGsetrapM]fed pre-rapamycin, one at 2.5 min and one at 7.9 min. Electrospray massspectroscopy of these peaks revealed that both contained ionscorresponding to a compound with a MW of 855.6, consistent with9-deoxo-16-O-methyl-27-desmethoxy-39-O-desmethyl-rapamycin(16-O-methyl-pre-rapamycin). Two isomers were commonly observed whenextracts were analysed by LC-MS in the absence of TFA. No new peaks wereidentified in the extracts of S. lividans TK24 or S. lividansTK24[pSGsetrapQ]. Unmodified pre-rapamycin was clearly evident. RapM wasclearly responsible for methylation at the C16 hydroxyl, RapQ was notspecific for this site.

Example 14 Elucidation of the Function of RapJ

Cultures of S. lividans TK24, S. lividans TK24[pSGsetrapK], S. lividansTK24[pSGsetrapJ] and S. lividans TK24[pSGsetrapKJ] were grown in TSBGMwith shaking at 30° C. and fed with 40 μg/ml of pre-rapamycin. Controlsremained unfed. After a further 5 days incubation, the cultures wereextracted with ethylacetate and brought to dryness. Reconstitution andanalysis by LC-MS identified no production of rapamycin analogues in theunfed controls. One major new peak at 4.9 min was identified in theextracts of S. lividans TK24[pSGsetrapKJ] and S. lividansTK24[pSGsetrapJ] fed pre-rapamycin. Electrospray mass spectroscopy ofthis peak revealed that it contained ions corresponding to a compoundwith a MW of 855.5, consistent with16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin (C9oxo-pre-rapamycin). in extracts of S. lividans TK24 and S. lividansTK24[pSGsetrapK] fed with pre-rapamycin, no new peaks were identified.Unmodified pre-rapamycin was clearly evident.

Due to the homology of RapJ with FkbD of the FK506 and FK520 cluster,RapJ has been postulated to oxidise pre-rapamycin at C9 to9-hydroxy-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin (C9OH-pre-rapamycin). RapK has been postulated to be responsible for thefurther conversion to the ketone. Surprisingly, in the presence of RapJ,but in the absence of RapK,16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin (C9keto-pre-rapamycin) was formed. RapJ clearly has an oxidative functionat C9, complete conversion to the ketone was observed. RapK does nothave an oxidative function at C9.

Example 15

Plasmids containing the following combinations of rapamycin modifyinggenes were constructed as described below: pMG260 (rapI, rapJ, rapN,rapO, and rapL), pMG261 (rapI, rapJ, rapN, rapO, rapM and rapL), pMG262(rapI, rapJ, rapN, rapO, rapM, rapQ and rapL) pMG236 (rapN, rapO, rapQand rapL) and pMG238 (rapJ and rapL).

Isolation of Plasmids pMG236 and pMG238

The plasmids pSGsetrapNOQ and pSGsetrapJ were digested using BgIII/XbaIand the isolated vector fragments were ligated with the 1 kb XbaI/BgIIIfragment of pSGLitrapL_(his). Plasmids pMG236 (expressing rapN, rapO,rapQ and rapL) and pMG238 (expressing rapJ and rapL) respectively, wereisolated.

Isolation of plasmids pMG260, pMG261 and pMG262

The plasmids pSGSetrapKIJNOL, pSGSetrapKIJMNOL, and pSGSetrapKIJMNOQLwere digested using BgIII and the isolated insert fragments (containingthe rapamycin cluster genes from the BgIII site in rapI to the BgIIIsite after rapL) were ligated with the vector-containing fragment frompSGSetrapI digested with BgIII. Plasmids pMG260 (expressing rapI, rapJ,rapN, rapO, and rapL), pMG261 (expressing rapI, rapJ, rapN, rapO, rapMand rapL), and pMG262 (expressing rapI, rapJ, rapN, rapO, rapM, rapQ andrapL) were isolated.

Example 16

An S. hygroscopicus mutant (MG3) carrying the chromosomal deletion ofrapK was constructed as described below. Heterologous complementation ofrapK with fkbO can then be performed as described and will result in therestoration of rapamycin production demonstrating that fkbO is able tocomplement the function of rapK in S. hygroscopicus.

Isolation of the S. hygroscopicus Mutant MG3 Carrying the ChromosomalDeletion of rapK

The primers RAPKF1 5′-CAAAGCTTCCTGGCGCGGTTCGGCCGGCA-3′ (SEQ ID NO: 56)and RAPKF2 5′-TGGCATGCCCTTCCCCGCCGTTCCCTGGC-3′ (SEQ ID NO: 57) were usedto amplify the left region of homology outside the gene rapK (fromnt94403 to nt95429 in the rapamycin cluster as described in Schwecke etal., 1995) using genomic DNA prepared from S. hygroscopicus NRRL5491 asa template. The 1 kb PCR product was phosphorylated using T4polynucleotide kinase and ligated into dephosphorylated SmaI cut pUC18.After transformation into E. coli DH10B, the plasmid pMG233-7 wasisolated. The primers RAPKR1 5′-TGGCATGCCCCCGCCGAGCTGACCTGGAA-3′ (SEQ IDNO: 58) and RAPKR2 5′-GTTCTAGAGCTTACGCGTGATGTCGAACG-3′ (SEQ ID NO: 59)were used to amplify the right region of homology outside the gene rapK(from nt96435 to nt97428 in the rapamycin cluster as described inSchwecke et al., 1995) using genomic DNA prepared from S. hygroscopicusNRRL5491 as a template: The 1 kb PCR product was phosphorylated using T4polynucleotide kinase and ligated into dephosphorylated SmaI cut pUC18.After transformation into E. coli DH10B, the plasmid pMG257-7 wasisolated. Both plasmids were checked by sequence analysis. The plasmidpMG233-7 was digested with SphI/XbaI and the 3.7 kb fragment wasisolated, pMG257-7 was digested with SphI/XbaI and the 1 kb fragmentisolated. These fragments were ligated and used to transform E. coliDH10B. The plasmid pMG268-12 was isolated. This plasmid was digestedwith HindIII/XbaI and the 2 kb fragment isolated and ligated into pMG55cut with HindIII/XbaI and the DNA was used to transform E. coli DH10B.The plasmid pMG278-1 was isolated and used to conjugate S. hygroscopicusMG1C.

An apramycin resistant colony is isolated, and is grown for 24 hours inTSBGM with shaking at 30° C. and spread onto medium 1 agar platescontaining 50 ug/l streptomycin. Streptomycin resistant colonies areisolated and shown to be apramycin sensitive. The 1004nt chromosomaldeletion of rapK can be verified in the mutant MG3 by Southern blotting.An overview is given in FIG. 35.

S. hygroscopicus MG3 is grown in TSBGM at 26° C. with shaking. Theculture broth and mycelia are extracted. using methods as described inthe Materials and Methods section. Analysis of the extract with UVdetection reveals the presence of no peaks with the characteristicrapamycin triene.

Expression of fkbO in the S. hygroscopicus Mutant MG3 Carrying theChromosomal Deletion of rapK

Plasmid pMG169-1 (described in example 11) is transformed into S.hygroscopicus mutant MG3 using methods as described in the Materials andMethods section.

Heterologous Complementation of rapK by fkbO

S. hygroscopicus MG3pMG169-1 is grown in TSBGM at 26° C. with shaking.The culture broth and mycelia are extracted using methods as describedin the Materials and Methods section. Analysis of the extract with UVdetection at 280 nm reveals the presence of two major new peaks.Electrospray mass spectroscopy of these peaks reveals that these containions with a MW of 913 corresponding to rapamycin.

Example 17 Isolation and Heterologous Complementation of the S.hygroscopicus Var Ascomyceticus Mutant MG4 Carrying the ChromosomalDeletion of fkbO

Isolation of the S. hygroscopicus var ascomyceticus mutant MG4 carryingthe chromosomal deletion of fkbO

The primers FKOF1 5′-GCTCTAGAGCCCGCGGCTCGCCGGACACG-3′ (SEQ ID NO: 60)and FKOF2 5′-CCCCTGCAGGCGTCCGGCATCGGTCATCAG-3′ (SEQ ID NO: 61) were usedto amplify the left region of homology (from nt45750 to nt46751 in theascomycin cluster as described in Wu et al., 2000) using genomic DNAprepared from S. hygroscopicus var ascomyceticus ATCC14891 as atemplate. The 1 kb PCR product was phosphorylated using T4polynucleotide kinase and ligated into dephosphorylated SmaI cut pUC18.After transformation into E. coli. DH10B, the plasmid pMG258-4 wasisolated. The primers FKOR1 5′-CGCCTGCAGGGATACGGTCCGCCGGGTCTGC-3′ (SEQID NO: 62) and FKOR2 5′-CCAAGCTTGTACGGTTCGCCACGGGCGTGC-3′ (SEQ ID NO:63) were used to amplify the right region of homology. (from nt47785 tont48781 in the rapamycin cluster as described in Wu et al., 2000) usinggenomic DNA prepared from S. hygroscopicus var ascomyceticus ATCC14891as a template. The 1 kb PCR product was phosphorylated using T4polynucleotide kinase and ligated into dephosphorylated SmaI cut pUC18.After transformation into E. coli DH10B, the plasmid pMG259-5 wasisolated. Both plasmids were checked by sequence analysis. The plasmidpMG258-4 was digested with SbfI/HindIII and the 3.7 kb fragment wasisolated, pMG259-5 was digested with SbfI/HindIII and the 1 kb fragmentisolated. These fragments were ligated and used to transform E. coliDH10B. The plasmid pMG265-1 was isolated. This plasmid was digested withHindIII/EcoRI and the 2 kb fragment isolated and ligated into pMG55 cutwith HindIII/EcoRI and the DNA was used to transform E. coli DH10B. Theplasmid pMG267-1 was isolated and used to conjugate S. hygroscopicus varascomyceticus ATCC14891.

An apramycin resistant colony is isolated and is grown for 24 hours inTSBGM with shaking at 30° C. and spread onto medium 1 agar platescontaining 50 ug/l streptomycin. Streptomycin resistant colonies areisolated and shown to be apramycin sensitive. The 1034nt chromosomaldeletion of fkbO can be verified in the mutant MG4 b Southern blotting.An overview is given in FIG. 36.

Expression of RapK in the S. hygroscopicus Var Ascomyceticus Mutant MG4Carrying the Chromosomal Deletion of fkbO

Plasmid pSGsetRapK is transformed into S. hygroscopicus mutant MG4 asdescribed in the Materials and Methods section.

Heterologous Complementation of fkbO by rapK

S. hygroscopicus var ascomyceticus MG4 pSGSetRapK is grown in TSBGM at26° C. with shaking. The culture broth and mycelia are extracted usingmethods as described in the Materials and Methods section. The extractis analysed by LC-MS to reveal the presence of a major new peak and toreveal that this contains ions that correspond to FK520 (ascomycin).

Example 18

It is obvious to those skilled in the art that other biosyntheticclusters that encode FKBP-ligands for example, FK506, can be modifiedsuch that the rapK homologue is deleted or inactivated using the methodsas described herein. In FK506, for example; this could be done byamplifying PCR products against the regions either side of the fkbO gene(sequence accession number AF082099, AF082100), ligating these togetherin a vector such as pMG55, transforming the FK506-producing strain,selecting for the double crossover and confirming the removal of thefkbO gene by southern blotting.

Example 19 Incorporation of Non-Natural Starter Units by the rapKDeletion Strain, S. hygroscopicus MG2-10, into Rapamycin Analogues inthe Absence of Competition by Endogenous Natural Starter Unit

As demonstrated in examples 10 and 12, the rapamycin PKS has a highdegree of flexibility for non-natural starter units and in the absenceof rapK, the system is free of competition from the natural starter. Inthis example, the degree of flexibility is further demonstrated.

S. hygroscopicus MG2-10 was grown, fed and extracted according to thefeeding, extraction and analysis methods outlined in Materials andMethods (Method B). The range of carboxylic acids fed along with thecompounds generated are listed below. Surprisingly, all of thecarboxylic acids listed were incorporated as determined by observing thecharacteristic UV chromophore at 278 nm and electrospray massspectrometry and resulted in the production of rapamycin analogues.

The rapamycin analogues generated corresponded to the formula below asdescribed in Table VIII:

-   -   R₁₆=OH    -   R₁₇=H, OH, halo, thiol, alkyl    -   y=bond, CH₂

R15=

TABLE VIII Carboxylic acid starter unit fed. M − H [M + K] Compoundgenerated cyclohexane carboxylic 824.7 864.6 R₁₅ = E, R₁₆ = 4-OH, y =bond, in acid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H,R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-cis,4-trans- 840.5 880.4 R₁₅ = C, R₁₆= 3-cis-OH, R₁₇ = 4-trans-OH, in dihydroxycyclohexane combination withR₁ = OH, R₂ = H, R₅ = H, carboxylic acid R₆ = H, R₇ = H, R₈ = H, R₉ = H,R₁₀ = H, x = CH₂ 1-cyclohexene 824.4 864.3 R₁₅ = E, R₁₆ = 3-OH, y =bond, in carboxylic acid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ =H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-cyclohexene 840.5 880.4R₁₅ = C, R₁₆ = OH, R₁₇ = OH, in combination carboxylic acid with R₁ =OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂822.4 862.3 R₁₅ = A, R₁₆ = OH, R₁₇ = H, in combination with R₁ = OH, R₂= H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂cycloheptane 838.4 878.3 R₁₅ = E, R₁₆ = OH, y = CH₂, in combinationcarboxylic acid with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉= H, R₁₀ = H, x = CH₂ Methyl 2-norbornane 836.2 876.2 R15 = B, R16 = OH,R17 = H, in carboxylate combination with R₁ = OH, R₂ = H, R₅ = H, R₆ =H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-hydroxycyclohexane 824.7864.6 R₁₅ = E, R₁₆ = 3-OH, y = bond, in carboxylic acid combination withR₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x =CH₂ 4-hydroxycyclohexane 824.6 864.6 R₁₅ = E, R₁₆ = 4-OH, y = bond, incarboxylic acid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ =H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-methylcyclohexane 838.4 878.3 R₁₅= F, R₁₇ = OH, in combination with R₁ = carboxylic acid OH, R₂ = H, R₅ =H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 4-methylcyclohexane838.4 878.3 R₁₅ = D, R₁₇ = OH, in combination with R₁ = carboxylic acidOH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-824.3 864.2 R₁₅ = E, R₁₆ = 3-OH, y = bond, in(cis/trans)methoxycyclohexane combination with R₁ = OH, R₂ = H, R₅ = H,carboxylic acid R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 4-824.2 864.2 R₁₅ = E, R₁₆ = 4-OH, y = bond, in(cis/trans)methoxycyclohexane combination with R₁ = OH, R₂ = H, R₅ = H,carboxylic acid R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ ethyl4-cyclohexanone 824.3 864.2 R₁₅ = E, R₁₆ = 4-OH, y = bond, incarboxylate combination with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈= H, R₉ = H, R₁₀ = H, x = CH₂ 3-fluoro-4-hydroxy 843.0 882.0 R₁₅ = C,R₁₆ = OH, R₁₇ = F, in combination cyclohexane carboxylic with R₁ = OH,R₂ = H, R₅ = H, R₆ = H, R₇ = acid and 4-fluoro-3- H, R₈ = H, R₉ = H, R₁₀= H, x = CH₂ hydrox cyclohexane ycarboxylic acid 3-cyclohexane oxide841.0 880.8 R₁₅ = C, R₁₆ = 3-cis-OH, R₁₇ = 4-trans-OH, in carboxylicacid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H,R₉ = H, R₁₀ = H, x = CH₂ 3,4-cis- 841.2 881.1 R₁₅ = C, R₁₆ = 3-cis-OH,R₁₇ = 4-cis-OH, in dihydroxycyclohexane combination with R₁ = OH, R₂ =H, R₅ = H, carboxylic acid R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x =CH₂ 841.2 881.1 R₁₅ = C, R₁₆ = 3-trans-OH, R₁₇ = 4-trans-OH, incombination with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ =H, R₁₀ = H, x = CH₂ 3-chloro-4-hydroxy 858.8 898.8 R₁₅ = C, R₁₆ = OH,R₁₇ = Cl, in combination cyclohexane carboxylic with R₁ = OH, R₂ = H, R₅= H, R₆ = H, R₇ = acid and 4-chloro-3- H, R₈ = H, R₉ = H, R₁₀ = H, x =CH₂ hydroxy cyclohexane carboxylic acid (and the pair of oppositediastereomers) cyclohexylpropionic 825.0 864.9 R₁₅ = C, R₁₆ = 3-cis-OH,R₁₇ = 4-trans-OH, in acid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ =H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ TBC

Example 20 Incorporation of Non-Natural Starter Units by the rapKDeletion Strain, S. hygroscopicus MG2-10[pSGsetrapN/OQL_(his)], intoRapamycin Analogues in the Absence of Competition by Endogenous NaturalStarter Unit

As demonstrated in examples 10, 12 and 19, the rapamycin PKS has a highdegree of flexibility for non-natural starter units and in the absenceof rapK, the to system is free of competition from the natural starter.In this example, the degree of flexibility is further demonstrated.

S. hygroscopicus MG2-10[pSGsetrapN/OQL_(his)] was grown, fed andextracted according to the feeding, extraction and analysis methodsoutlined in Materials and Methods (Method B). The range of carboxylicacids fed along with the compounds generated are listed below.Surprisingly, all of the carboxylic acids listed were incorporated asdetermined by observing the characteristic UV chromophore at 278 nm andelectrospray mass spectrometry and resulted in the production ofrapamycin analogues.

The rapamycin analogues generated corresponded to the formula below asdescribed in Table IX:

-   -   R₁₆=OH    -   R₁₇=H, OH, halo, thiol, alkyl    -   y=bond, CH₂

R15=

TABLE IX Carboxylic acid starter unit fed. M − H [M + K] Compoundgenerated cyclohexane carboxylic 840.4 880.4 R₁₅ = E, R₁₆ = 4-OH, y =bond, in acid combination with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇ = H,R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-cis,4-trans- 840.4 880.4 R₁₅ = C, R₁₆= 3-cis-OH, R₁₇ = 4-trans-OH, dihydroxycyclohexane in combination withR₁ = OH, R₂ = H, R₅ = carboxylic acid H, R₆ = H, R₇ = H, R₈ = H, R₉ = H,R₁₀ = H, x = CH₂ 856.4 896.4 R₁₅ = C, R₁₆ = 3-cis-OH, R₁₇ = 4-trans-OH,in combination with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉= H, R₁₀ = H, x = CH₂ 1-cyclohexene 824.4 864.4 R₁₅ = E, R₁₆ = 3-OH, y =bond, in carboxylic acid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ =H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 840.4 880.4 R₁₅ = E, R₁₆ =3-OH, y = bond, in combination with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇= H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-cyclohexene 840.4 880.4 R₁₅ = C,R₁₆ = OH, R₁₇ = OH, in carboxylic acid combination with R₁ = OH, R₂ = H,R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 822.4 862.4 R₁₅= A, R₁₆ = OH, R₁₇ = H, in combination with R₁ = OH, R₂ = H, R₅ = H, R₆= H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 840.4 880.4 R₁₅ = A, R₁₆ =OH, R₁₇ = H, in combination with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇ =H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ cycloheptane 854.4 894.4 R₁₅ = E,R₁₆ = OH, y = CH₂, in combination carboxylic acid with R₁ = OH, R₂ = OH,R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂methyl-2-norbornane 852.4 892.4 R₁₅ = B, R₁₆ = OH, R₁₇ = H, incombination carboxylic acid with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇ =H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 3-hydroxycyclohexane 824.4 864.4 R₁₅= E, R₁₆ = 3-OH, y = bond, in carboxylic acid combination with R₁ = OH,R₂ = H, R₅ = H, R₆ = H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂4-hydroxycyclohexane 840.4 880.4 R₁₅ = E, R₁₆ = 4-OH, y = bond, incarboxylic acid combination with R₁ = OH, R₂ = H, R₅ = H, R₆ = H, R₇ =H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 824.4 864.4 R₁₅ = E, R₁₆ = 4-OH, y =bond, in combination with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇ = H, R₈ =H, R₉ = H, R₁₀ = H, x = CH₂ 4-methylcyclohexane 838.4 878.4 R₁₅ = D, R₁₇= OH, in combination with R₁ = carboxylic acid OH, R₂ = H, R₅ = H, R₆ =H, R₇ = H, R₈ = H, R₉ = H, R₁₀ = H, x = CH₂ 854.4 894.4 R₁₅ = D, R₁₇ =OH, in combination with R₁ = OH, R₂ = OH, R₅ = H, R₆ = H, R₇ = H, R₈ =H, R₉ = H, R₁₀ = H, x = CH₂

Example 20 Incorporation of Non-Natural Starter Units by the rapKDeletion Strain, S. hygroscopicus MG3, into Rapamycin Analogues in theAbsence of Competition by Endogenous Natural Starter Unit

As demonstrated in examples 10, 12 and 19, the rapamycin PKS has a highdegree of flexibility for non-natural starter units and in the absenceof rapK, the system is free of competition from the natural starter. Inthis example, the degree of flexibility is further demonstrated.

S. hygroscopicus MG3 is grown, fed and extracted according to thefeeding, extraction and analysis methods outlined in Materials andMethods (Method B). The range of carboxylic acids fed that can be fed islisted below. Incorporation of the carboxylic acids listed andproduction of rapamycin analogues is determined by observing thecharacteristic UV chromophore at 278 nm and electrospray massspectrometry.

Carboxylic acid starter units that can be fed include. cyclohexanecarboxylic acid, 3-cis,4-trans-dihydroxycyclohexane carboxylic acid,1-cyclohexene carboxylic acid, 3-cyclohexene carboxylic acid,cycloheptane carboxylic acid, methyl 2-norbornane carboxylate,3-hydroxycyclohexane carboxylic acid, 4-hydroxycyclohexane carboxylicacid, 3-methylcyclohexane carboxylic acid, 4-methylcyclohexanecarboxylic acid, 3-(cis/trans)methoxycyclohexane carboxylic acid,4-(cis/trans)methoxycyclohexane carboxylic acid, ethyl 4-cyclohexanonecarboxylate, 3-fluoro-4-hydroxycarboxylic acid and4-fluoro-3-hydroxycarboxylic acid, 3-cyclohexane oxide carboxylic acid,3,4-cis-dihydroxycyclohexane carboxylic acid,3-chloro-4-hydroxycarboxylic acid and 4-chloro-3-hydroxycarboxylic acid(and the pair of opposite diastereomers), cyclohexylpropionic acid and4-tert-Butylcyclohexane carboxylic acid

Example 21 Incorporation of Non-Natural Starter Units by the fkbODeletion Strain, S. hygroscopicus Var. Ascomyceticus MG4, into FK520Analogues in the Absence of Competition by Endogenous Natural StarterUnit

As demonstrated in examples 10, 12, 19 and 20, the rapamycin PKS has ahigh degree of flexibility for non-natural starter units. In the absenceof fkbO, the FK520 system is free of competition from the naturalstarter. In this example, the degree of flexibility of the FK520 PKS isinvestigated, free of competition from the natural starter.

S. hygroscopicus var. ascomyceticus MG4 is grown, fed and extractedaccording to the feeding, extraction and analysis methods outlined inMaterials and Methods (Method B). Examples of the range of carboxylicacids that can be fed are given in Table IV. Incorporation of thecarboxylic acids listed and production of FK520 analogues is determinedby electrospray mass spectrometry.

Example 22 Incorporation of Non-Natural Starter Acids into FK506Analogues by an fkbO Deletion Mutant of S. tsukubaensis in Absence ofCompetition from the Natural Starter

An fkbO deletion mutant of S. tsukubaensis is grown and fed according tothe feeding methods outlined in Materials and Methods. A sub-set of thecarboxylic acids listed in Table IV in Materials and Methods is fed.Analysis is performed as described in Method (B) of Materials andMethods.

Example 23 Isolation of Product from Fermentation of S. hygroscopicusMG2-10[pSGsetrapKIL_(h)]

9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin was obtained byconjugating the S. hygroscopicus strain MG2-10 with pSGsetrapKIL_(h) andisolating the fermentation products generated as described below. Thisdemonstrates that it is possible to complement the deletion of rapK,rapI and rapL in the MG2-10 strain and that9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin is produced, an analoguewhich is lacking the post-PKS modifications. The feeding of pipecolicacid is not required when rapL is complemented confirming that rapLplays a role in the provision of pipecolic acid in the production ofrapamycin.

S. hygroscopicus MG2-10 [pSGsetKIL_(his)] was fermented (see Materialsand Methods), extracted and isolated using the method (B) as outlined inMaterials and Methods. The isocratic solvent system used for preparativeHPLC was 60% CH₃CN/H₂O.

9-Deoxo-16-O-desmethyl-27-desmethoxy rapamycin (Compound 6) has thefollowing characteristics:

-   -   Isolated yield: 22 mg    -   Molecular weight: 856    -   Molecular formula: C₄₉H₇₇NO₁₁    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=878, m/z for M-H=854        Table X below summarises the ¹H and ¹³C NMR data for        9-deoxo-16-O-desmethyl-27-desmethoxy rapamycin in CDCl₃.

TABLE X Proton δ_(H) multiplicity coupling δ_(C)  1 169.0 171.5  2 4.375.40 55.6 52.5  3a 1.51 1.75^(a) 26.5 26.3  3b 2.40 2.19  4a 20.9  4b 5a 1.30 1.48 25.1  5b 1.68 1.72  6a 4.45 3.26 39.0 44.4  6b 2.16 3.83 8 171.7 172.4  9a 2.41 2.54 38.7 40.2  9b 2.67 2.89 10 98.4 99.7 10-OH6.62 5.34 br. s 11 1.37 1.51 38.7 38.7 12a 1.67 1.62 27.3 27.6 12b 1.481.48 13a 1.29 1.32 13b 14 4.21 3.87 71.3 69.6 15a 1.47^(b) 1.50 15b 1.661.65 16 4.21 4.06 dd 6.1, 6.1 76.0 75.6 17 141.6 138.4 18 6.08 6.22 d d11.2 11.2 122.5 125.0 19 6.38 6.31 dd dd 14.0, 11.2 14.7, 128.6 127.711.2 20 6.01 6.17 dd 14.5, 131.1 132.2 10.5 21 6.04 6.04 130.3 130.3 225.18 5.30 dd dd 14.1, 9.1 14.9, 139.4 139.1 9.3 23 2.11 2.15 39.5 37.324a 1.34 1.35 40.3 40.3 24b 1.68 1.67 25 2.43 2.44 45.5 46.3 26 215.2216.1 27a 2.53 2.60 46.7 47.9 27b 2.65 2.43 28 4.33 4.39 dd 7.9, 3.271.7 71.9 29 139.6 139.6 30 5.36 5.45 d 9.9 123.7 125.4 31 3.24 3.3746.4 45.6 32 209.0 209.1 33a 2.63 2.63 39.4 39.4 33b 2.95 2.95 34 5.135.38 76.0 74.2 35 1.93 1.98^(b) 32.7 32.7 36a 1.04 1.03 37.8 39.8 36b1.17 1.16 37 1.34 1.38 33.2 33.2 38a ax. 0.61 0.73 ddd ddd 11.9, 11.9,11.9, 33.9 34.5 11.9 11.9, 11.9 38b eq. 2.04 2.09 39 2.90 2.91 84.5 84.440 3.37 3.37 73.8 73.8 41a 1.31 1.31 31.2 31.2 41b 1.97 1.97 42a 0.970.97 31.7 31.7 42b 43 0.93 0.93 d d 6.5 6.5 16.8^(c) 16.9^(c) 44 1.781.63 s s 15.6 12.7 45 0.98 1.00 21.7 21.7 46 1.00 1.02 16.7 19.1 47 1.581.48 s s 13.1 11.7 48 1.07 1.00 d 6.9 16.2 14.6 49 0.89 0.89 d d 6.8 6.814.6^(d) 15.2^(d) 50 3.37 3.37 s s 56.5 56.5 ^(a)may be assigned insteadto H4a ^(b)tentative assignment ^(c)the assignment may be interchanged^(d)the assignment may be interchanged

Compound 6 exists as a 1:1 mixture of conformers in CDCl₃. The dataabove is for both conformers. Where a dotted line has been drawn acrossthe table it was not possible to determine connectivity between spinsystems, hence the assignment of data to a particular conformer is notpossible.

Example 24 Isolation of product from fermentation of S. hygroscopicusMG2-10[pSGsetrapKIMLh]

9-Deoxo-27-desmethoxy-rapamycin was obtained by conjugating S.hygroscopicus MG2-10 strain with pSGsetKIML_(his) as described inexample 1 and isolating the products produced on fermentation. Thisdemonstrated that it was possible to complement the deletion of rapK,rapI, rapM and rapL in the MG2-10 strain with the production of arapamycin analogue lacking some post-PKS modification.

S. hygroscopicus MG2-10 [pSGsetKIML_(his)] was fermented (see Materialsand Methods), extracted and isolated using the method (B) as outlined inMaterials and Methods.

The isocratic solvent system used for preparative HPLC was 75%CH₃CN/H₂O. 9-Deoxo-27-desmethoxy rapamycin (Compound 16) has thefollowing characteristics:

-   -   Isolated yield: 24 mg    -   Molecular weight: 870    -   Molecular formula: C₅₀H₇₉NO₁₁    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=892, m/z for M-H=868

Table XI below summarises the ¹H and ¹³C NMR data for9-deoxo-27-desmethoxy rapamycin in CDCl₃.

TABLE XI Position δ_(H) multiplicity coupling δ_(C)  1 171.0  2 5.37 m52.0  3a 1.73 m 26.8  3b 2.22 m  4a 1.39 m 20.5  4b 1.73 m  5a 1.56 m25.1  5b 1.77 m  6a 3.34 m 43.5  6b 3.85 br. d 12.9  8 173.4  9a 2.43 d14.4 38.8  9b 2.74 d 14.4 10 98.0 10-OH 6.02 s 11 1.43 m 39.1 12a 1.44 m27.5 12b 1.58 m 13a 1.28 m 32.2 13b 1.45 m 14 3.61 m 65.8 15a 1.55 m38.6 15b 1.64 m 16 3.70 dd 10.8, 4.7 84.5 17 134.8 18 5.98 d 9.2 130.819 6.34 m 126.9 20 6.32 m 133.1 21 6.11 dd 15.3, 9.0 130.6 22 5.46 dd15.2, 8.6 139.3 23 2.22 m 35.7 24a 1.28 m 40.2 24b 1.49 m 25 2.58 m 44.826 215.0 27a 2.65 m 46.2 27b 2.65 m 28 4.37 m 73.1 29 139.8 30 5.32 d9.9 124.5 31 3.38 m 46.3 32 208.9 33a 2.59 m 41.4 33b 2.59 m 34 5.04 ddd5.2, 5.2, 5.2 75.7 35 1.97 m 33.4 36a 1.11 m 38.6 36b 1.26 m 37 1.41 m33.1 38a ax. 0.69 ddd 12.3, 12.3, 12.3 34.1 38b eq. 2.11 m 39 2.93 m84.4 40 3.37 m 73.9 41a 1.32 m 31.2 41b 1.97 m 42a 1.00 m 31.6 42b 1.68m 43 0.88 d 6.4 16.9 44 3.10 s 55.6 45 1.59 s 9.9 46 1.02 d 7.2 20.5 471.03 d 7.1 15.7 48 1.67 s 12.2 49 1.12 d 6.8 16.3 50 0.92 d 6.8 15.8 513.39 s 56.5

Example 25 Isolation of Product from Fermentation of S. hygroscopicusMG2-10[pSGsetKIN/OLh]

9-Deoxo-16-O-desmethyl-27-O-desmethyl-rapamycin was obtained byconjugating S. hygroscopicus MG2-10 strain with pSGsetKIN/OL_(his) asdescribed in Example 1 and isolating the products produced onfermentation. This demonstrated that it was possible to complement thedeletion of rapK, rapI, rapN/O and rapL in the MG2-10 strain with theproduction of a rapamycin analogue lacking some post-PKS modification.

S. hygroscopicus MG2-10 [pSGsetKIN/OL_(his)] was fermented (seeMaterials and Methods), extracted and isolated using the method (B) asoutlined in Materials and Methods.

The isocratic solvent system used for preparative HPLC was 60%CH₃CN/H₂O. 9-Deoxo-16-O-desmethyl-27-O-desmethylrapamycin (Compound 9)has the following characteristics:

-   -   Isolated yield: 77 mg    -   Molecular weight: 872    -   Molecular formula: C₄₉H₇₇NO₁₂    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=894, m/z for M-H=870        Table XII below summarises the ¹H and ¹³C NMR data for        9-deoxo-16-O-desmethyl-27-O-desmethylrapamycin in CDCl₃.

TABLE XII Position δ_(H) multiplicity coupling δ_(C)  1 172.1  2 5.55 m52.8  3a 1.74 m 26.0  3b 2.21 m  4a 1.18 m 21.1  4b 1.73 m  5a 1.44 m25.2  5b 1.73 m  6a 3.28 m 45.7  6b 3.87 m  8 171.6  9a 2.41 d 12.5 42.3 9b 3.34 d 12.5 10 99.2 10-OH 4.15 m 11 1.61 m 38.3 12a 1.50 m 27.9 12b1.61 m 13a 1.36 m 31.5 13b 1.52 m 14 3.99 m 72.5 15a 1.45 m 40.9 15b1.70 m 16 3.86 m 75.3 17 140.0 18 6.44 d 11.4 121.9 19 6.33 dd 14.4,11.4 128.6 20 6.20 dd 14.8, 10.6 131.2 21 6.02 dd 14.9, 10.6 131.2 225.25 m 137.4 23 2.26 m 35.3 24a 1.21 m 41.1 24b 1.21 m 25 2.37 m 40.9 26212.8 27 4.55 d 2.3 74.9 28 4.20 77.3 29 135.8 30 5.25 m 124.9 31 3.29 m44.9 32 208.0 33a 2.53 dd 18.2, 4.0 42.2 33b 2.81 dd 18.2, 10.6, 34 5.28ddd 4.0, 4.0 75.8 35 1.71 m 31.2 36a 0.92 m 36.9 36b 1.04 m 37 1.23 m32.6 38a ax. 0.28 ddd 11.9, 11.9, 34.2 11.9 38b eq. 1.88 m 39 2.85 84.840 3.29 m 74.1 41a 1.26 m 31.3 41b 1.92 m 42a 0.88 m 32.3 42b 1.57 m 430.98 d 6.2 16.6 44 1.59 s 14.6 45 1.01 d 6.4 21.4 46 0.89 d 6.4 12.0 471.90 s 15.7 48 0.92 d 6.4 15.6 49 0.84 d 6.8 17.6 50 3.37 s 57.5

Example 26 Isolation of Product from Fermentation of S. hygroscopicusMG2-10[pSGsetKJLh]

16-O-Desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin was obtained byconjugating S. hygroscopicus MG2-10 strain with pSGsetKJL_(his) asdescribed in Example 1 and isolating the products produced onfermentation. This demonstrated that it was possible to complement thedeletion of rapK, rapJ and rapL in the MG2-10 strain with the productionof a rapamycin analogue lacking some post-PKS modification.

S. hygroscopicus MG2-10 [pSGsetKJL_(his)] was fermented (see Materialsand Methods), extracted and isolated using the method (B) as outlined inMaterials and Methods.

The isocratic solvent system used for preparative HPLC was 55%CH₃CN/H₂O. 16-O-Desmethyl-27-desmethoxy-39-O-desmethyl rapamycin(Compound 3) has the following characteristics:

-   -   Isolated yield: 176 mg (mixture of 2 interconverting isomers)    -   Molecular weight: 856    -   Molecular formula: C₄₅H₇₃NO₁₂    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=878, m/z for M-H=854

MS fragmentation: The sodiated adduct (m/z 878) was fragmented toprovide three fragments: C8-C42, m/z MNa⁺749; C1-C27, m/z MNa⁺570;C28-C42+C1-C14, m/z MNa⁺628. The fragment ions 628 and 570 werefragmented further to give the same fragment: C1-C14, m/z MNa⁺320. Themass of this C1-C14 fragment is 14 mass units greater than theequivalent fragment from the fragmentation of the sodiated adduct of9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin(Compound 1) consistent with oxidation at C9.

Example 27 Isolation of product from fermentation of S. hygroscopicusMG2-10[pSGsetKMNOLh]

9-Deoxo-27-O-desmethyl-39-O-desmethyl-rapamycin was obtained byconjugating S. hygroscopicus MG2-10 strain with pSGsetKMN/OL_(his) asdescribed in example 1 and isolating the products produced onfermentation. This demonstrated that it was possible to complement thedeletion of rapK, rapM, rapN/O and rapL in the MG2-10 strain with theproduction of a rapamycin analogue lacking some post-PKS modification.

S. hygroscopicus MG2-10 [pSGsetKMN/OL_(his)] was fermented (seeMaterials and Methods), extracted and isolated using the method (B) asoutlined in Materials and Methods.

The isocratic solvent system used for preparative HPLC was 60%CH₃CN/H₂O. 9-Deoxo-27-O-desmethyl-39-O-desmethyl rapamycin (Compound 8)has the following characteristics:

-   -   Isolated yield: 6 mg    -   Molecular weight: 872    -   Molecular formula: C₄₉H₇₇NO₁₂    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=894, m/z for M-H=870

MS fragmentation: The sodiated adduct (m/z 894) was fragmented toprovide three fragments: C8-C42, m/z MNa⁺765; C1-C27, m/z MNa⁺586;C28-C42+C1-C14, m/z MNa⁺614. The fragment ions 614 and 586 werefragmented further to give the same fragment: C1-C14, m/z MNa⁺306. TheC1-C14 is identical to that obtained from fragmentation of the sodiatedadduct of 9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin;the compound is 9-deoxo. The C1-C27 fragment is 30 mass units greaterthan the equivalent fragment from9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin,consistent with one hydroxylation and one methylation. RapM methylatesthe hydroxy group at C-16 (see Example 22 for pSGsetKIL_(his) togetherwith Example 23 pSGsetKIML_(his)) and RapN in combination with RapOhydroxylates C27 so the data is consistent with the compound being9-deoxo-27-O-desmethyl-39-O-desmethyl rapamycin (Compound 8).

Example 28 Isolation of Product from Fermentation of S. hygroscopicusMG2-10[pSGsetKIJLh]

16-O-desmethyl-27-desmethoxy-rapamycin was obtained by conjugating S.hygroscopicus MG2-10 strain with pSGsetKIJL_(his) as described inExample 1 and isolating the products produced on fermentation. Thisdemonstrated that it was possible to complement the deletion of rapK,rapI, rapJ and rapL in the MG2-10 strain with the production of arapamycin analogue lacking some post-PKS modification.

S. hygroscopicus MG2-10 [pSGsetKIJL_(his)] was fermented (see Materialsand Methods), extracted and isolated using the method (B) as outlined inMaterials and Methods.

The isocratic solvent system used for preparative HPLC was 60%CH₃CN/H₂O. 16-O-Desmethyl-27-desmethoxy rapamycin (Compound 12) has thefollowing characteristics:

-   -   Isolated yield: 11 mg    -   Molecular weight: 870    -   Molecular formula: C₄₉H₇₅NO₁₂    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm

Electrospray MS: m/z for MNa⁺=892, m/z for M-H=868

Example 29 Isolation of product from fermentation of S. hygroscopicusMG2-10[pGsetKL_(his)]

9-Deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin wasobtained by conjugating S. hygroscopicus MG2-10 strain withpSGsetKL_(his) as described in example 1 and isolating the productsproduced on fermentation. This demonstrated that it was possible tocomplement the deletion of rapK and rapI in the MG2-10 strain with theproduction of a rapamycin analogue lacking post-PKS modification(pre-rapamycin).

S. hygroscopicus MG2-10 [pSGsetKL_(his)] was fermented, extracted andisolated using the methods outlined in Materials and Methods.

The isocratic solvent system used for preparative HPLC was 60%CH₃CN/H₂O.

9-Deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin(Compound 1) has the following characteristics:

-   -   Isolated yield: 24 mg    -   Molecular weight: 842    -   Molecular formula: C₄₈H₇₅NO₁₁    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=864, m/z for M-H=840

MS fragmentation: The sodiated adduct (m/z 864.5) was fragmented toprovide four fragments: C8-C42, m/z MNa⁺735; C1-C27, m/z MNa⁺556;C28-C42+C1-C14, m/z MNa⁺614, C1-C14, m/z MNa⁺306. The expected m/z forthese fragments were determined by comparison to the reportedfragmentation of rapamycin (J. A. Reather, Ph.D. Dissertation,University of Cambridge, 2000). These fragments have the same m/z as thepredicted m/z for the fragmentation of9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin.

Example 30 Isolation of Product from Fermentation of S. hygroscopicusMG2-10 Fed with Cyclohexane Carboxylic Acid

9-Deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy-rapamycin wasobtained on feeding cyclohexane carboxylic acid to S. hygroscopicusMG2-10 and isolating the products produced on fermentation. Theresulting mutasynthesis demonstrated that it was possible to chemicallycomplement the deletion of rapK in the MG2-10 strain, in the absence ofnatural endogenous starter, with the resulting production of a rapamycinanalogue lacking post-PKS modification.

S. hygroscopicus MG2-10 was fermented (see Materials and Methods), fed(see Materials and Methods), extracted and isolated using the method (B)as outlined in Materials and Methods.

The isocratic solvent system used for preparative HPLC was 60%CH₃CN/H₂O.

9-Deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy rapamycin (Compound47) has the following characteristics:

-   -   Isolated yield: 12 mg    -   Molecular weight: 826.    -   Molecular formula: C₄₈H₇₅NO₁₀    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa^(÷)=848.5, m/z for M-H=825

MS fragmentation: The sodiated adduct (m/z 848.5) was fragmented toprovide four fragments: C8-C42, m/z MNa⁺719; C1-C27, m/z MNa⁺556;C28-C42+C1-014, m/z MNa⁺598, C1-C14, m/z MNa⁺306. These data illustratethat the difference between Compound 47 and9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin(Compound 1) is located in the region of 028-042. This fragment is 16mass units less for Compound 47 than it is for Compound 1, consistentwith Compound 47 being9-deoxo-16-O-desmethyl-27-desmethoxy-39-desmethoxy rapamycin.

Example 31 Isolation of Product from Fermentation of S. hygroscopicusMG2-10[pSGsetKNOLh]

9-Deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin isobtained by conjugating S. hygroscopicus MG2-10 strain withpSGsetKN/OL_(his) as described in Example 1 and isolating the productsproduced on fermentation. This demonstrates that it is possible tocomplement the deletion of rapK, rapN/O and rapL in the MG2-10 strainwith the production of a rapamycin analogue lacking some post-PKSmodification.

S. hygroscopicus MG2-10 [pSGsetKN/OL_(his)] is fermented (see Materialsand Methods), extracted and isolated using the method (B) as outlined inMaterials and Methods.

The isocratic solvent system used for preparative HPLC is 60% CH₃CN/H₂O.

9-Deoxo-16-O-desmethyl-27-O-desmethyl-39-O-desmethyl rapamycin (Compound2) has the following characteristics:

-   -   Molecular weight: 858    -   Molecular formula: C₄₈H₇₅NO₁₂    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MK⁺=896, m/z for M-H=856

Example 32 Identification of Product from Fermentation of S.hygroscopicus MG2-10[pSGsetKJNOLh]

16-O-Desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin was obtained byconjugating S. hygroscopicus MG2-10 strain with pSGsetKJN/OL_(his) asdescribed in example 1 and analysing the products produced onfermentation. This demonstrated that it was possible to complement thedeletion of rapK, rapJ, rapN/O and rapL in the MG2-10 strain with theproduction of a rapamycin analogue lacking some post-PKS modification.

The fermentation broth (1 mL) was treated as described in theextraction, isolation and analysis Method (B) described in Materials andMethods. The HPLC chromatogram (280 nm) contained a peak that had thecharacteristic rapamycin triene (268 nm, 278 nm, 288 nm). This peak wasnot observed in the chromatogram of the control sample extracted from S.hygroscopicus MG2-10 in the absence of the cassette. LCMS (see Materialsand Methods, Method B) of the novel rapamycin analogue peak gave ionsm/z 895 (MNa⁺) and 871 (M-H). These ions confirm that the molecularweight of the novel rapamycin analogue is 872, 30 mass units greaterthan 9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl rapamycin(Compound 1), consistent with oxidation at C9 (rapJ) and hydroxylationat C27 (rapN/O). These data are consistent with the compound being16-O-desmethyl-27-O-desmethyl-39-O-desmethyl rapamycin (Compound 7).

Example 33 Isolation of Product from Fermentation of S. hygroscopicusMG2-10[pSGsetKJNOLh]

16-O-Desmethyl-27-O-desmethyl-39-O-desmethyl-rapamycin is obtained byconjugating S. hygroscopicus MG2-10 strain with pSGsetKJN/OL_(his) asdescribed in Example 1 and isolating the products produced onfermentation. This demonstrates that it is possible to complement thedeletion of rapK, rapJ, rapN/0 and rapL in the MG2-10 strain with theproduction of a rapamycin analogue lacking some post-PKS modification.

S. hygroscopicus MG2-10 [pSGsetKJN/OL_(his)] is fermented (see Materialsand Methods), extracted and isolated using the method (B) as outlined inMaterials and Methods.

The isocratic solvent system used for preparative HPLC is 60% CH₃CN/H₂O.

16-O-Desmethyl-27-O-desmethyl-39-O-desmethyl rapamycin (Compound 7) hasthe following characteristics:

-   -   Molecular weight: 872    -   Molecular formula: C₄₈H₇₃NO₁₃    -   UV (by diode array detection during HPLC analysis): 268 nm, 278        nm, 288 nm    -   Electrospray MS: m/z for MNa⁺=895, m/z for M-H=871

Example 34 Identification of Product from Fermentation of S.hygroscopicus MG2-10 [pSGsetKIJNOQLh]

16-O-Desmethyl-rapamycin was obtained by conjugating S. hygroscopicusMG2-10 strain with pSGsetKIJN/OQL_(his) as described in example 1 andanalysing the products produced on fermentation. This demonstrated thatit was possible to complement the deletion of rapK, rapI, rapJ, rapN/O,rapQ and rapL in the MG2-10 strain with the production of a rapamycinanalogue lacking methylation at C16-OH. In addition, it clearlyidentified RapQ as the SAM-dependent O-methyltransferase responsible formethylation of C27-OH.

S. hygroscopicus MG2-10 [pSGsetKIJN/OQL_(his)] was fermented (seeMaterials and Methods), extracted and analysed using the method (B) asoutlined in Materials and Methods.

The fermentation broth (1 mL) was treated as described in Materials andMethods. The HPLC chromatogram (280 nm) contained a peak that had thecharacteristic rapamycin triene (268 nm, 278 nm, 288 nm). This peak wasnot observed in the chromatogram of the control sample extracted from S.hygroscopicus MG2-10 in the absence of the cassette. LCMS (see Materialsand Methods) of the novel rapamycin analogue peak gave ions m/z 923(MNa⁺) and 899 (M-H). These ions confirm that the molecular weight ofthe novel rapamycin analogue is 900, 14 mass units less than rapamycin.It has already been established that the only post-PKS gene not includedin the cassette, rapM, acts to methylate the C16-OH, hence the novelrapamycin analogue is 16-O-desmethyl rapamycin (Compound 20) and rapQ isshown to be functional and acting to O-methylate at C27.

Example 35 Bioassay of Rapamycin Analogues

-   -   (1)=9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin        (pre-rapamycin)    -   (6)=9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin    -   (16)=9-deoxo-27-desmethoxy-rapamycin,    -   (3)=16-O-desmethyl-27-desmethoxy-39-O-desmethyl-rapamycin    -   (9)=9-deoxo-16-Odesmethyl-27-O-desmethyl-rapamycin    -   (8)=9-deoxo-27-O-desmethyl-39-O-desmethyl-rapamycin.

Cancer Cell Lines:

Growth inhibition of adherent human tumour cell lines of solidmalignancies HT29 (colon) and MCF-7 (breast) was tested in vitro usingan MTT (344,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)assay using micro-titre plates (Sieuwerts, A. M., et al., 1995). Allcell lines were obtained from either the ATCC (American Type CultureCollection) or ECACC (European Collection of Cell Cultures). All celllines were grown from frozen stocks and passaged at least once prior touse in RPMI 1640. Cells were harvested from sub-confluent cultures usingminimal trypsinization. Cells were diluted to the appropriate densityfor each cell line (dependent on cell doubling time) in RPMI 1640, andseeded in 60 wells of a 96 well plate in a volume of 100 μl per well(i.e. outside wells of the plate were not used). Plates were incubatedat 37° C. overnight. Following this incubation, log scale dilutions ofreference and test substances were added in 100 μl per well, 6replicates were used to test all test compounds, reference compounds andmedium controls. Plates were incubated for a further 72 h prior toanalysis. MTT (5 mg/ml) was added to each well and plates werere-incubated for 3-4 h. Unreacted MTT was removed from the wells andformazan crystals formed from the MTT were dissolved in DMSO andcharacteristic absorbance read at 570 nm. The concentration (nM) of eachtest compound and reference compound, which resulted in 50% of maximuminhibition (IC₅₀), was calculated for each cell line and quoted alongwith the maximum percentage of inhibition observed (I_(m)), see TableXIII. For reference, rapamycin has an IC₅₀ of 200 nM and an I_(m) of 40%in the HT-29 cell line and an IC₅₀ of 0.03 nM and an I_(m) of 56% in theMCF-7 cell line.

TABLE XIII Assay 1 6 16 3 9 8 IC₅₀ I_(m) IC₅₀ I_(m) IC₅₀ I_(m) IC₅₀I_(m) IC₅₀ I_(m) IC₅₀ I_(m) HT29 50.1 38 25 38 15.8 25 63.1 37 12.6 3563 30 rIC₅₀ MCF-7 3.2 38 126 48 2 32 20 38 17.8 40 20 38 rIC₅₀

Mixed Lymphocyte Reaction (MLR):

Originally developed to assess tissue compatibility prior to allografts,MLR offers an established model for immune reaction in vitro (SOULILLOU,J. P., et al. (1975); T. Meo. “Immunological Methods”, L. Lefkovits andB. Pernis, Eds., Academic Press, N.Y. pp. 227-239 (1979). MLR wasperformed by mixing splenic lymphocytes isolated from C57BL/6 mice(5×10⁵ cells) with inhibited splenic lymphocytes from CBA mice (2.5×10⁵cells). The inhibited CBA lymphocytes induced a proliferative responsein C57BL/6 lymphoctes and this was determined by [³H] thymidineincorporation into DNA as a measure of proliferation of spleniclymphocytes isolated from C57BL/6 mice. The anti-proliferative effectwas assayed for in the presence of log scale dilutions of referencecompounds, test compounds and media controls over a 72 h period at 37°C. The concentration of each test compound and reference compound, whichinhibited lymphocyte proliferation by 50% (IC₅₀), compared to controlproliferation, was calculated for each cell line and quoted as a ratioof the concentration of rapamycin required to inhibit lymphocyteproliferation by 50% (rIC₅₀), see Table XIV.

TABLE XIV Assay 1 6 16 3 9 8 MLR 9.4 8.8 >14.7 7.9 6.5 4.1 rIC₅₀

Anti-Fungal Assay:

The comparative anti-fungal activities of reference and test compoundswere determined against pathogenic fungi Candida albicans DSM 5816,Candida albicans DSM 1386 and Candida glabrata DSM 11226. This wasachieved using a microtitre plate adaption of the NCCLS Reference Methodfor Broth Dilution Antifungal Susceptibility Testing for Yeasts:Approved Standard (M27-A, vol. 17 No. 9. (1997)). Yeast strains wereinoculated (10⁴ cfu/ml) to RPMI 1640 media containing 0.165 mM MOPS, pH7. Growth was determined in the presence of log scale dilutions ofreference compounds, test compounds and media controls after incubationwith shaking at 37° C., 24 h. Minimum inhibitory concentration (MIC) andminimum fungicidal activity (MFC) were determined for test compounds andexpressed as a ratio of the rapamycin minimum inhibitory concentration(rMIC respectively), see Table XV.

TABLE XV Assay 1 6 16 3 9 8 C. albicans DSM 1 1 1 1 1 1 5816 rMIC C.albicans DSM 5 5 5 1 1 1 1386 rMIC C. glabrata DSM 5 5 5 1 1 1 11226rMIC

REFERENCES

-   Alarcon, C. M., Heitman, J., and Cardenas, M. E. (1999) Protein    kinase activity and identification of a toxic effector domain of the    target of rapamycin TOR proteins in yeast. Molecular Biology of the    Cell 10: 2531-2546.-   Aparicio, J. F., Molnar, I., Schwecke, T., Konig, A., Haydock, S.    F., Khaw, L. E., Staunton, J., and Leadlay, P. F. (1996)    Organization of the biosynthetic gene cluster for rapamycin in    Streptomyces hygroscopicus: analysis of the enzymatic domains in the    modular polyketide synthase. Gene 169: 9-16.-   Baker, H., Sidorowicz, A., Sehgal, S. N., and Vézina, C. (1978)    Rapamycin (AY-22, 989), a new antifungal antibiotic. III. In vitro    and in vivo evaluation. Journal of Antibiotics 31: 539-545.-   Bierman, M., Logan, R., O'Brien, K., Seno, E. T., Nagaraja Rao, R.,    and Schoner, B. E. (1992) Plasmid cloning vectors for the conjugal    transfer of DNA from Escherichia coli to Streptomyces spp. Gene 116:    43-49.-   Blanc, V., Lagneaux, D., Didier, P., Gil, P., Lacroix, P., and    Crouzet, J. (1995) Cloning and analysis of structural genes from    Streptomyces pristinaespiralis encoding enzymes involved in the    conversion of pristinamycin II_(B) to pristinamycin II_(A)    (PIT_(A)): PII_(A) synthase and NADH:riboflavin 5′-phosphate    oxidoreductase. Journal of Bacteriology 177: 5206-5214.-   Blanc, V., Gil, P., Bamas-Jacques, N., Lorenzon, S., Zagorec, M.,    Schleuniger, J., Bisch, D., Blanche, F., Debussche, L., Crouzet, J.,    and Thibaut, D. (1997) Identification and analysis of genes from    Streptomyces pristinaespiralis encoding enzymes involved in the    biosynthesis of the 4-dimethylamino-L-phenylalanine precursor of    pristinamycin I. Molecular Microbiology 23: 191-202.-   Box, S. J., Shelley, P. R., Tyler, J. W., Verrall, M. S.,    Warr, S. R. C., Badger, A. M., Levy, M. A., and Banks, R. M. (1995)    27-O-Demethylrapamycin, an immunosuppressant compound produced by a    new strain of Streptomyces hygmscopicus. Journal of Antibiotics 48:    1347-1349.-   Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C.    T., Lane, W. S., and Schreiber, S. L. (1994) A mammalian protein    targeted by G1-arresting rapamycin-receptor complex. Nature 369:    756-758.-   Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G.,    Lawrence, J. C., and Abraham, R. T. (1996) Direct inhibition of the    signaling functions of the mammalian target of rapamycin by the    phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO    Journal 15: 5256-5267.-   Cao, W., Mohacsi, P., Shorthouse, R., Pratt, R. and Morris, R. E.    (1995). Effects of rapamycin on growth factor-stimulated vascular    smooth muscle cell DNA synthesis. Inhibition of basic fibroblast    growth factor and platelet-derived growth factor action and    antagonism of rapamycin by FK506. Transplantation 59(3): 390-395.-   Carlson, R. P., Hartman, D. A., Tomchek, L. A., Walter, T. L.,    Lugay, J. R., Calhoun, W., Sehgal, S. N., Chang, J. Y. (1993).    Rapamycin, a potential disease-modifying antiarthritic drug. J.    Pharmacol. Exp. Ther. 266(2):1125-38.-   Chambraud, B., Radanyi, C., Camonis, J. H., Shazand, K., Rajkowski,    K., and Baulieu, E. E. (1996) FAP48, a new protein that forms    specific complexes both immunophilins FKBP59 and FKBP12. Prevention    by the immunosuppressant drugs FK506 and rapamycin. Journal of    Biological Chemistry 271: 32923-32929.-   Chang, J. Y., Sehgal, S. N., and Bansbach, C. C. (1991) FK506 and    rapamycin: novel pharmacological probes of the immune response.    Trends in Pharmacological Sciences 12: 218-223.-   Chen, J., Zheng, X. F., Brown, E. J., and Schreiber, S. L. (1995)    Identification of an 11-kDa FKBP12-rapamycin-binding domain within    the 289-kDa FKBP12-rapamycin-associated protein and characterization    of a critical serine residue. Proceedings of the National Academy of    Sciences of the United States of America 92: 4947-4951.-   Chini, M., Crotti, P., Gardelli, C., and Macchia, F., (1992),    Tetrahedron, 48, 3805-3812-   Choi, J. W., Chen, J., Schreiber, S. L., and Clardy, J. (1996)    Structure of the FKBP12-rapamycin complex interacting with the    binding domain of human FRAP. Science 273: 239-242.-   Chung, L., Liu, L, Patel, S., Carney, J. R., and    Reeves, C. D. (2001) Deletion of rapQNML from the rapamycin gene    cluster of Streptomyces hygroscopicus gives production of the    16-O-desmethyl-27-desmethoxy analog. Journal of Antibiotics 54:    250-256.-   Corey, E. J. and Huang, H., (1989) Tetrahedron Lett., 30, 5235-5238    DiLella, A. G., and Craig, R. J. (1991) Exon organization of the    human FKBP-12 gene: correlation with structural and functional    protein domains. Biochemistry 30: 8512-8517.-   Du, L. C., Sánchez, C., Chen, M., Edwards, D. J., and    Shen, B. (2000) The biosynthetic gene cluster for the antitumor drug    bleomycin from Streptomyces verticillus ATCC15003 supporting    functional interactions between nonribosomal peptide synthetases and    a polyketide synthase. Chemistry & Biology 7: 623-642.-   Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C.,    Hollingshead, M., Arbuck, S. G., Travis, R., Sausville, E. A.,    Houghton, P. J. (2001). Biochemical correlates of mTOR inhibition by    the rapamycin ester CCI-779 and tumor growth inhibition. Clin.    Cancer Res. 7(6):1758-64-   Fehr, T., Sanglier, J-J., Schuler, W., Gschwind, L., Ponelle, M.,    Schilling, W., Wioland, C. (1996). Antascomicinc A, B, C, D and E:    Novel FKBP12 binding compounds from a Micromonospora strain. J.    Antibiot. 49(3): 230-233.-   Ferrari, S., Pearson, R. B., Siegmann, M., Kozma, S. C., and    Thomas, G. (1993) The immunosuppressant rapamycin induces    inactivation of P70^(s6k) through dephosphorylation of a novel set    of sites. Journal of Biological Chemistry 268: 16091-16094.-   Findlay J. A, and Radics, L. (1980) Canadian Journal of Chemistry    58:579.-   Fishbein, T. M., Florman, S., Gondolesi, G., Schiano, T., LeLeiko,    N., Tschernia, A., Kaufman, S. (2002). Intestinal transplantation    before and after the introduction of sirolimus. Transplantation.    73(10):1538-42.-   Foey, A., Green, P., Foxwell, B., Feldmann, M., Brennan, F. (2002).    Cytokine-stimulated T cells induce macrophage IL-10 production    dependent on phosphatidylinositol 3-kinase and p70S6K: implications    for rheumatoid arthritis. Arthritis Res. 4(1):64-70. Epub 2001 Oct.    10.-   Gaisser, S., Reather, J., Wirtz, G., Kellenberger, L., Staunton, J.,    and Leadlay, P. F. (2000) A defined system for hybrid macrolide    biosynthesis in Saccharopolyspora erythraea. Molecular Microbiology    36: 391-401.-   Gaisser, S., Lill, R., Staunton, J., Mendez, C., Salas, J., Leadlay,    P F. (2002) Parallel pathways for oxidation of 14-membered    polyketide macrolactones in Saccharopolyspora erythraea. Mol    Microbiol 44:771-81.-   Galat, A. (2000) Sequence diversification of the FK506-binding    proteins in several different genomes. European Journal of    Biochemistry 267: 4945-4959.-   Gregory, C. R., Huie, P., Billingham, M. E. and Morris, R. E.    (1993). Rapamycin inhibits arterial intimal thickening caused by    both alloimmune and mechanical injury. Its effect on cellular,    growth factor and cytokine response in injured vessels.    Transplantation 55(6):1409-1418.-   Gregory M A, Till R, Smith, M C M. (in Press) Integration site for    Streptomyces phage φBT1 and the development of site-specific    integrating vectors. J Bacteriol.-   Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel,    S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M.,    Jauch, K. W., and Geissler, E. K. (2002) Rapamycin inhibits primary    and metastatic tumor growth by antiangiogenesis: involvement of    vascular endothelial growth factor. Nature Medicine 8: 128-135.-   Hamilton, G. S., and Steiner, J. P. (1998) Immunophilins: Beyond    immunosuppression. Journal of Medicinal Chemistry 41: 5119-5143.-   Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K.,    Weng, Q. P., Kasuga, M., Nishimoto, I., and Avruch, J. (1997)    Regulation of eIF-4E BP1 phosphorylation by mTOR. Journal of    Biological Chemistry 272: 26457-26463.-   Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and    Schreiber, S. L. (1999) Rapamycin-modulated transcription defines    the subset of nutrient-sensitive signaling pathways directly    controlled by the Tor proteins. Proceedings of the National Academy    of Sciences of the United States of America 96: 14866-14870.-   Hatanaka, H., Kino, T., Miyata, S., Inamura, N., Kuroda, A., Goto,    T., Tanaka, H.,-   Okuhara, M. (1988). FR-900520 and FR-900523, novel    immunosuppressants isolated from a Streptomyces. II. Fermentation,    isolation and physico-chemical and biological characteristics. J.    Antibiot (Tokyo). 41(11):1592-601.-   Hatanaka H, Kino T, Asano M, Goto T, Tanaka H, Okuhara M. (1989).    FK-506 related compounds produced by Streptomyces tsukubaensis No.    9993. J. Antibiot (Tokyo). 42(4):620-2.-   Hendrickson, B. A., Zhang, W., Craig, R. J., Jin, Y. J., Bierer, B.    E., Burakoff, S., and DiLella, A. G. (1993) Structural organization    of the genes encoding human and murine FK506-binding protein    (FKBP)13 and comparison to FKBP1. Gene 134: 271-275.-   Hentges, K. E., Sirry, B., Gingeras, A. C., Sarbassov, D.,    Sonenberg, N., Sabatini, D., and Peterson, A. S. (2001) FRAP/mTOR is    required for proliferation and patterning during embryonic    development in the mouse. Proceedings of the National Academy of    Sciences of the United States of America 98: 13796-13801.-   Hopwood, D. A. (1997) Genetic contributions to understanding    polyketide synthases. Chemical Reviews 97: 2465-2497.-   Hosted, T. J., and Balt, R. H. (1997) Use of rpsL for dominance    selection and gene replacement in Streptomyces roseosporus. Journal    of Bacteriology 179: 180-186.-   Hung, D. T., and Schreiber, S. L. (1992) cDNA cloning of a human 25    kDa FK506 and rapamycin binding protein. Biochemical and Biophysical    Research Communications 184: 733-738.-   Hung, D. T., Jamison, T. F., and Schreiber, S. L. (1996)    Understanding and controlling the cell cycle with natural products.    Chemistry & Biology 3: 623-639.-   Jain, S., Bicknell, G. R., Whiting, P. H., Nicholson, M. L. (2001).    Rapamycin reduces expression of fibrosis-associated genes in an    experimental model of renal ischaemia reperfusion injury. Transplant    Proc. 33 (1-2):556-8.-   Jin, Y. J., Burakoff, S. J., and Bierer, B. E. (1992) Molecular    cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25.    Journal of Biological Chemistry 267: 10942-10945.-   Kahan, B. D., Chang, J. Y., and Sehgal, S. N. (1991) Preclinical    evaluation of a new potent immunosuppressive agent, rapamycin.    Transplantation 52: 185-191.-   Kahan, B. D., and Camardo, J. S. (2001) Rapamycin: Clinical results    and future opportunities. Transplantation 72:1181-1193.-   Kallen, J. A., Sedrani, R., and Cotter's S. (1996) X-ray crystal    structure of 28-O-methylrapamycin complexed with FKBP12. Is the    cyclohexyl moiety part of the effector domain of rapamycin? Journal    of the American Chemical Society 118: 5857-5861.-   Kawasome, H., Papst, P., Webb, S., Keller, G. M., Johnson, G. L.,    Gelfand, E. W., and Terada, N. (1998) Targeted disruption of    p70^(s6k) defines its role in protein synthesis and rapamycin    sensitivity. Proceedings of the National Academy of Sciences of the    United States of America 95: 5033-5038.-   Khaw, L. E., Bohm, G. A., Metcalfe, S., Staunton, J., and    Leadlay, P. F. (1998) Mutational biosynthesis of novel rapamycins by    a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL,    encoding a putative lysine cyclodeaminase. Journal of Bacteriology    180: 809-814.-   Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F., and    Hopwood, D. A. (2000) Practical Streptomyces Genetics, John Innes    Foundation, Norwich. Kirby, B., and Griffiths, C. E. M. (2001)    Psoriasis: the future. British Journal of Dermatology 144:37-43.-   Kirchner, G. I., Winkler, M., Mueller L., Vidal, C., Jacobsen, W.,    Franzke, A., Wagner, S., Buick, S., Manns M. P., and Sewing    K.-F. (2000) Pharmacokinetics of SDZ RAD and cyclosporin including    their metabolites in seven kidney graft patients after the first    dose of SDZ RAD. British Journal of Clinical Pharmacology    50:449-454.-   König, A., Schwecke, T., Molnár, I., Bohm, G., Lowden, P. A. S.,    Staunton, J., and Leadlay, P. F. (1997) The pipecolate-incorporating    enzyme for the biosynthesis of the immunosuppressant rapamycin.    Nucleotide sequence analysis, disruption and heterologus expression    of rapP from Streptomyces hygroscopicus. European Journal of    Biochemistry 247: 526-534.-   Kunz, J., Loeschmann, A., Deuter-Reinhard, M., and    Hall, M. N. (2000) FAP1, a homologue of human transcription factor    NF-X1, competes with rapamycin for binding to FKBP12 in yeast.    Molecular Microbiology 37: 1480-1493.-   Kuo, C. J., Chung, J. K., Fiorentino, D. F., Flanagan, W. M.,    Blenis, J., and Crabtree, G. R. (1992) Rapamycin selectively    inhibits interleukin-2 activation of p70 S6 kinase. Nature 358:    70-73.-   Lee, M. H. Pascopella, L, Jacobs, W. R., Jr and Hatfull, G. F    (1991). Site specific integration of mycobacteriophage L5:    integration-proficient vectors for Mycobacterium smegmatis,    Mycobacterium tuberculosis and Bacille Calmette-Guerin. Proc. Natl.    Acad. Sci. USA, 88:3111-3115.-   Lee M H, Pascopella L, Jacobs W R Jr, Hatfull G F. (1991),    Site-specific integration of mycobacteriophage L5:    integration-proficient vectors for Mycobacterium smegmatis,    Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl    Acad Sci USA; 88:3111-5.-   Liang, J., Choi, J., and Clardy, J. (1999) Refined structure of the    FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution. Acta    Crystallographica Section D-Biological Crystallography 55: 736-744.-   Lomovikaya, N., Fonstein, L, Ruan, X., Stassi, D., Katz, L., and    Hutchinson, C. R. (1997.) Gene disruption and replacement in the    rapamycin-producing Streptomyces hygroscopicus strain ATCC 29253.    Microbiology-Uk 143: 875-883.-   Lowden, P. A. S., Böhm, G., Staunton, J., and Leadlay, P. F. (1996)    The nature of the starter unit for the rapamycin polyketide    synthase. Angewandte Chemie 35: 2249-2251.-   Lowden, P. A. S., (1997) Ph.D. Dissertation, University of    Cambridge. “Studies on the biosynthesis of rapamycin”.-   Lowden, P. A. S., Wilkinson, B., Bohm, G. A., Handa, S., Floss, H.    G., Leadlay, P. F., and Staunton, J. (2001) Origin and true nature    of the starter unit for the rapamycin polyketide synthase.    Angewandte Chemie-International Edition 40: 777-779.-   Luengo, J. I., Yamashita, D. S., Dunnington, D., Beck, A. K.,    Rozamus, L. W., Yen, H. K, Bossard, M. J., Levy, M. A., Hand, A.,    Newmantarr, T., Badger, A., Faucette, L., Johnson, R. K., Dalessio,    K., Porter, T., Shu, A. Y. L., Heys, R., Choi, J. W., Kongsaeree,    P., Clardy, J., and Holt, D. A. (1995) Structure-Activity Studies of    Rapamycin Analogs—Evidence That the C-7 Methoxy Group Is Part of the    Effector Domain and Positioned at the Fkbp12-Frap Interface.    Chemistry & Biology 2: 471-481.-   Lyons, W. E., George, E. B., Dawson, T. M., Steiner, J. P., and    Snyder, S. H. (1994) Immunosuppressant FK506 promotes neurite    outgrowth in cultures of PC12 cells and sensory ganglia. Proceedings    of the National Academy of Sciences of the United States of America    91:3191-3195.-   MacNeil, D. J., Gewain, K. M., Ruby, C. L., Dezeny, G., Gibbons, P.    H., and MacNeil, T. (1992) Analysis of Streptomyces avermitilis    genes required for avermectin biosynthesis utilizing a novel    integration vector. Gene 111: 61-68.-   Marahiel, M. A., Stacheihaus, T., and Mootz, H. D. (1997) Modular    peptide synthetases involved in nonribosomal peptide synthesis.    Chemical Reviews 97: 2651-2673.-   Matsuura, M., Noguchi, T., Yamaguchi, D., Aida, T., Asayama, M.,    Takahashi, H. and Shirai, M. (1996). The sre gene (ORF469) encodes a    site-specific recombinase responsible for integration of the R4    phage genome. J Bact. 178(11):3374-3376.-   McAlpine, J. B, Swanson S. J., Jackson, M., Whittern, D. N. (1991).    Revised NMR assignments for rapamycin. Journal of Antibiotics 44:    688-690.-   Meo, T. in “Immunological Methods”, L. Lefkovits and B. Pernis,    Eds., Academic Press, N.Y. pp. 227-239 (1979).-   Molnár, I., Aparicio, J. F., Haydock, S. F., Khaw, L. E., Schwecke,    T., Konig, A., Staunton, J., and Leadlay, P. F. (1996) Organisation    of the biosynthetic gene cluster for rapamycin in Streptomyces    hygroscopicus: analysis of genes flanking the polyketide synthase.    Gene 169: 1-7.-   Morice, M. C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban    Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P.,    Guagliumi, G., Molnar, F., Falotico, R. (2002). RAVEL Study Group.    Randomized Study with the Sirolimus-Coated Bx Velocity    Balloon-Expandable Stent in the Treatment of Patients with de Novo    Native Coronary Artery Lesions. A randomized comparison of a    sirolimus-eluting stent with a standard stent for coronary    revascularization. N. Engl. J. Med. 346(23):1773-80.-   Motamedi, H., Shafiee, A., Cai, S. J., Streicher, S. L., Arison, B.    H., and Miller, R. R. (1996) Characterization of methyltransferase    and hydroxylase genes involved in the biosynthesis of the    immunosuppressants FK506 and FK520. Journal of Bacteriology 178:    5243-5248.-   Motamedi, H., Cai, S. J., Shafiee, A., and Elliston, K. O. (1997)    Structural organization of a multifunctional polyketide synthase    involved in the biosynthesis of the macrolide immunosuppressant    FK506. European Journal of Biochemistry 244: 74-80.-   Motamedi, H., and Shafiee, A. (1998) The biosynthetic gene cluster    for the macrolactone ring of the immunosuppressant FK506. European    Journal of Biochemistry 256: 528-534.-   Myckatyn, T. M., Ellis, R. A., Grand, A. G., Sen, S. K., Lowe, J. B.    3rd, Hunter, D. A., Mackinnon, S. E. (2002). The effects of    rapamycin in murine peripheral nerve isografts and allografts.    Plast. Reconstr. Surg. 109(7):2405-17.-   Navé, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., and    Sheperd, P. R. (1999) Mammalian target of rapamycin is a direct    target for protein kinase B: identification of a convergence point    for opposing effects of insulin and amino-acid deficiency on protein    translation. Biochemical Journal 344:427-431.-   Navia, M. A. (1996) Protein-drug complexes important for    immunoregulation and organ transplantation. Current Opinion in    Structural Biology 6: 838-847.-   NCCLS Reference Method for Broth Dilution Antifungal Susceptibility    Testing for Yeasts: Approved Standard M27-A, vol. 17 No. 9. (1997).-   Nishida, H., Sakakibara, T., Aoki, F., Saito, T., Ichikawa, K.,    Inagaki, T., Kojima, Y., Yamauchi, Y., Huang, L. H., Guadliana, M.    A., Kaneko, T., and Kojima, N. (1995) Generation of novel rapamycin    structures by microbial manipulations. Journal of Antibiotics 48:    657-666.-   Nielsen, J. B., Hsu, M. J., Byrne, K. M., and Kaplan, L. (1991)    Biosynthesis of the immunosuppressant immunomycin: the enzymology of    pipecolate incorporation. Biochemistry 30: 5789-5796.-   Paget, M. S. B., Chamberlin, L., Atrih, A., Foster, S. J., and    Buttner, M. J. (1999) Evidence that the extracytoplasmic function    sigma factor σ^(E) is required for normal cell wall structure in    Streptomyces coelicolorA3(2). Journal of Bacteriology 181: 204-211)-   Paiva, N. L., Demain, A. L., and Roberts, M. F. (1991) Incorporation    of acetate, propionate, and methionine into rapamycin By    Streptomyces hygroscopicus. Journal of Natural Products 54: 167-177.-   Paiva, N. L., Demain, A. L., and Roberts, M. F. (1993) The immediate    precursor of the nitrogen-containing ring of rapamycin is free    pipecolic acid. Enzyme and Microbial Technology 15: 581-585.-   Patterson, C. E., Schaub, T., Coleman, E. J., and    Davies E. C. (2000) Developmental regulation of FKBP65. An    ER-localized extracellular matrix binding-protein. Molecular Biology    of the Cell 11:3925-3935.-   Pfeifer, B. A., Admiraal, S. J., Gramajo, H., Cane, D. E., and    Khosla, C. (2001) Biosynthesis of complex polyketides in a    metabolically engineered strain of E. coli. Science 291: 1790-1792.-   Powell, N., Till, S., Bungre, J., Corrigan, C. (2001). The    immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and    sirolimus (rapamycin) inhibit allergen-induced proliferation and    IL-5 production by PBMCs from atopic asthmatic patients. J. Allergy    Clin. Immunol. 108(6):915-7-   Rabinovitch, A., Suarez-Pinzon, W. L., Shapiro, A. M., Rajotte, R.    V., Power, R. (2002). Combination therapy with sirolimus and    interleukin-2 prevents spontaneous and recurrent autoimmune diabetes    in NOD mice. Diabetes. 51(3):638-45.-   Raught, B., Gingras, A. C., and Sonenberg, N. (2001) The target of    rapamycin (TOR) proteins. Proceedings of the National Academy of    Sciences of the United States of America 98: 7037-7044.-   Rawlings, B. J. (2001) Type I polyketide biosynthesis in bacteria    (Part A). Natural Product Reports 18: 190-227.-   Reather, J. A., (2000), Ph.D. Dissertation, University of Cambridge.    “Late steps in the biosynthesis of macrocyclic lactones”.-   Reitamo, S., Spuls, P., Sassolas, B., Lahfa, M., Claudy, A.,    Griffiths, C. E.; Sirolimus European Psoriasis Study Group. (2001).    Efficacy of sirolimus (rapamycin) administered concomitantly with a    subtherapeutic dose of cyclosporin in the treatment of severe    psoriasis: a randomized controlled trial. Br. J. Dermatol.    145(3):438-45.-   Rosen, M. K., and Schreiber, S. L. (1992) Natural products as probes    of cellular function: studies of immunophilins. Angewandte    Chemie-Intemational Edition in English 31: 384-400.-   Roymans, D., and Slegers, H. (2001) Phosphaditidylinositol 3-kinases    in tumor progression. European Journal of Biochemistry 268:487-498.-   Ruan, X. A., Stass, D., Lax, S. A., and Katz, L. (1997) A second    type-I PKS gene cluster isolated from Streptomyces hygroscopicus    ATCC 29253, a rapamycin-producing strain. Gene 203: 1-9.-   Salituro, G. M., Zink, D. L., Dahl, A., Nielsen, J., Wu, E., Huang,    L., Kastner C., Dumont, F. (1995) Meridamycin: a novel    nonimmunosuppressive FKBP12 ligand from Streptomyces hygroscopicus.    Tetrahydron letters 36: 997-1000.-   Schwarzer, D., and Marahiel, M. A. (2001) Multimodular biocatalysts    for natural product assembly. Naturwissenschaften 88: 93-101.-   Sambrook, J., Fritsch. E. F., and Maniatis, T. (1989) Molecular    cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory    Press, N. Y.-   Schreiber, S. L., and Crabtree, G. R. (1992) The mechanism of action    of cyclosporine A and FK506. Immunology Today 13: 136-142.-   Schwecke, T., Aparicio, J. F., Molnar, I., Konig, A., Khaw, L. E.,    Haydock, S. F., Oliynyk, M., Caffrey, P., Cortes, J., Lester, J. B.,    Böhm, G. A., Staunton, J., and Leadlay, P. F. (1995) The    biosynthetic gene cluster for the polyketide immunosuppressant    rapamycin. Proceedings of the National Academy of Sciences of the    United States of America 92: 7839-7843.-   Sedrani, R., Cottens, S., Kallen, J., and Schuler, W. (1998)    Chemical modifications of rapamycin: the discovery of SDZ RAD.    Transplantation Proceedings 30: 2192-2194.-   Sehgal, S. N., Baker, H., and Vézina, C. (1975) Rapamycin    (AY-22,989), a new antifungal antibiotic II. Fermentation, isolation    and characterization. The Journal of Antibiotics 28: 727-733.-   Shepherd, P. R, Withers, D. J., and Siddle K. (1998)    Phosphoinositide 3-kinase: the key switch mechanism in insulin    signalling. Biochemical Journal 333: 471-490.-   Shima, J., Hesketh, A., Okamoto, S., Kawamoto, S., and    Ochi, K. (1996) Induction of actinorhodin production by rpsL    (encoding ribosomal protein S12) mutations that confer streptomycin    resistance in Streptomyces lividans and Streptomyces coelicolor    A3(2). Journal of Bacteriology 178: 7276-7284.-   Sigal, N. H., and Dumont, F. J. (1992) Cyclosporine A, FK-506, and    rapamycin: pharmacological probes of lymphocyte signal transduction.    Annual Review of Immunology 10: 519-560.-   Sieuwerts, A. M., Klijn, J. G., Peters, H. A., Foekens, J. A.    (1995). The MTT tetrazolium salt assay scrutinized: how to use this    assay reliably to measure metabolic activity of cell cultures in    vitro for the assessment of growth characteristics, IC50-values and    cell survival. Eur. J Clin. Chem. Clin. Biochem. 33(11):813-23.-   Smovkina, T., Mazodier, P., Boccard, F., Thompson, C. J. and    Guerineau, M. (1990) Construction of a series of pSAM2-based    integrative vectors for use in actinomycetes. Gene 94: 53-59.-   SOULILLOU, J. P., CARPENTER, C. B., LUNDIN, A. P. and    STROM, T. B. (1975) Augmentation of proliferation and in vitro    production of cytotoxic cells by 2-ME in the rat. J Immunol.    115(6):1566-71.-   Staunton, J., and Weissman, K. J. (2001) Polyketide biosynthesis: a    millennium review. Natural Product Reports 18: 380-416.-   Steiner, J. P., Hamilton, G. S., Ross, D. T., Valentine, H. L., Guo,    H., Connolly, M. A., Liang, S., Ramsey, C., Li, J.-H. J., Huang, W.,    Howorth, P., Soni, R., Fuller, M., Sauer, H., Nowotnik, A. C., and    Suzdak, P. D. (1997) Neutrophic immunophilin ligands stimulate    structural and functional recovery in neurodegenerative animal    models. Proceedings of the National Academy of Sciences of the    United States of America 94:2019-2024.-   Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., and    Schuman, E. M. (2002) A rapamycin-sensitive signaling pathway    contributes to long-term synaptic plasticity in the hippocampus.    Proceedings of the National Academy of Sciences of the United States    of America 1:467-472.-   Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S.    L., and Clardy, J. (1993) Atomic structures of the human    immunophilin FKBP-12 complexes with FK506 and rapamycin. Journal of    Molecular Biology 229: 105-124.-   Van Mellaert, L., Mei, L., Lammertyn, E., Schacht, S., and    Anné, J. (1998) Site-specific integration of bacteriophage VWB    genome into Streptomyces venezuelae and construction of a VWB-based    integrative vector. Microbiology 144:3351-3358.-   Vézina, C., Kudelski, A., and Sehgal, S. N. (1975) Rapamycin    (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the    producing streptomycete and isolation of the active principle. The    Journal of Antibiotics 28: 721-726.-   Vilella-Bach, M., Nuzzi, P., Fang, Y. M., and Chen, J. (1999) The    FKBP12-rapamycin-binding domain is required for    FKBP12-rapamycin-associated protein kinase activity and G₁    progression. Journal of Biological Chemistry 274: 4266-4272.-   Waller, J. R., and Nicholson, M. L. (2001) Molecular mechanisms of    renal allograft fibrosis. British Journal of Surgery 88:1429-1441.-   Warner, L. M., Adams, L. M., Chang, J. Y., Sehgal, S. N. (1992). A    modification of the in vivo mixed lymphocyte reaction and    rapamycin's effect in this model. Clin. Immunol. Immunopathol.    64(3):242-7.-   Weber, T., and Marahiel, M. A. (2001) Exploring the domain structure    of modular nonribosomal peptide synthetases. Structure 9: R3-R9-   Welch, J. T. and Seper, K., W., (1988), J. Org. Chem., 53, 2991-2999-   Wilkinson, B., Foster, G., Rudd, B. A. M., Taylor, N. L.,    Blackaby, A. P., Sidebottom, P. J., Cooper, D. J., Dawson, M. J.,    Buss, A. D., Gaisser, S., Bohm, I. U., Rowe, C. J., Cortés, J.,    Leadlay, P. F. and Staunton, J. (2000). Novel octaketide macrolides    related to 6-deoxoerythronolide B provide evidence for iterative    operation of the erythromycin polyketide synthase. Chemistry &    Biology 7: 111-117.-   Wong, G. K., Griffith, S., Kojima, I., and Demain, A. L. (1998)    Antifungal activities of rapamycin and its derivatives,    prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin.    Journal of Antibiotics 51: 487-491.-   Wu, K., Chung, L., Revill, W. P., Katz, L., and Reeves, C. D. (2000)    The FK520 gene cluster of Streptomyces hygroscopicus var.    ascomyceticus (ATCC 14891) contains genes for biosynthesis of    unusual polyketide extender units. Gene 251: 81-90.-   Yem, A. W., Tomasselli, A. G., Heinrikson, R. L., Zurcher-Neely, H.,    Ruff, V. A., Johnson, R. A., and Deibel, M. R. (1992) The Hsp56    component of steroid receptor complexes binds to immobilized FK506    and shows homology to FKBP-12 and FKBP-13. Journal of Biological    Chemistry 267: 2868-2871.-   Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J.,    Frost, P., Gibbons, J. J. (2001) mTOR, a novel target in breast    cancer. the effect of CCI-779, an mTOR inhibitor, in preclinical    models of breast cancer. Endocrine-Related Cancer 8:249-258.-   Zhu, J., Wu J., Frizell, E., Liu, S. L., Bashey, R., Rubin, R.,    Norton, P., Zem, M. A. (1999). Rapamycin inhibits hepatic stellate    cell proliferation in vitro and limits fibrogenesis in an in vivo    model of liver fibrosis. Gastroenterology. 117(5):1198-204.

1-66. (canceled)
 67. A compound according to the formula

wherein R₁ is H or CH₃; R₂ is H, OH, or OCH3; and R₃ is OH or OCH₃. 68.The compound of claim 67, wherein said compound has the formula


69. The compound of claim 68, wherein said compound has the formula


70. The compound of claim 68, wherein said compound has the formula


71. The compound of claim 68, wherein R₁ is H; R₂ is H; and R₃ is OH.72. The compound of claim 68, wherein R₁ is H; R₂ is OH; and R₃ is OH.73. The compound of claim 68, wherein R₁ is H; R₂ is OCH₃; and R₃ is OH.74. The compound of claim 68, wherein R₁ is H; R₂ is H; and R₃ is OCH₃.75. The compound of claim 68, wherein R₁ is CH₃; R₂ is OH; and R₃ is OH.76. The compound of claim 68, wherein R₁ is H; R₂ is OCH₃; and R₃ isOCH₃.
 77. The compound of claim 68, wherein R₁ is CH₃; R₂ is H; and R₃is OCH₃.
 78. The compound of claim 68, wherein R₁ is CH₃; R₂ is OH; andR₃ is OCH₃.
 79. The compound of claim 68, wherein R₁ is CH₃; R₂ is OCH₃;and R₃ is OH.
 80. The compound of claim 68, wherein R₁ is CH₃; R₂ isOCH₃; and R₃ is OCH₃.
 81. The compound of claim 67, wherein saidcompound has the formula


82. The compound of claim 81, wherein said compound has the formula


83. The compound of claim 81, wherein R₁ is H; R₂ is H; and R₃ is OH.84. The compound of claim 81, wherein R₁ is H; R₂ is OH; and R₃ is OH.85. The compound of claim 81, wherein R₁ is H; R₂ is OCH₃; and R₃ is OH.86. The compound of claim 81, wherein R₁ is H; R₂ is OH; and R₃ is OCH₃.87. The compound of claim 81, wherein R₁ is CH₃; R₂ is H; and R₃ is OH.88. The compound of claim 81, wherein R₁ is CH₃; R₂ is OH; and R₃ is OH.89. The compound of claim 81, wherein R₁ is H; R₂ is OCH₃; and R₃ isOCH₃.
 90. The compound of claim 81, wherein R₁ is CH₃; R₂ is OH; and R₃is OCH₃.
 91. The compound of claim 81, wherein R₁ is CH₃; R₂ is H; andR₃ is OCH₃.
 92. The compound of claim 81, wherein R₁ is CH₃; R₂ is OCH₃;and R₃ is OH.
 93. A method of treating a pathology selected from thegroup consisting of cancer, a fungal infection, an autoimmune,proliferative and/or hyperproliferative disease, diabetes, acute orchronic rejection of an organ or tissue transplant, asthma, psoriasis,eczema, rheumatoid arthritis, fibrosis, an allergy and a fibroticpathology, said method comprising administering to a subject in needthereof an effective amount of a pharmaceutical composition comprising acompound of claim 67.